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The aim of this project was to identify novel mutations in proteins causing immunodeficiency. This was achieved by confirming 
whole exome sequencing (WES) results of potential mutations and genes of interest through Sanger sequencing and allelic 
orientation of mutations. Functional experiments were then designed and performed on patient samples and stable cell lines 
expressing patient mutants. The experiments examined the known functions of the proteins of interest and cell types that 
appeared to be affected in the patient immunological profile.  
The main topic of this thesis is centered around an index case who presented at age 17 with a life-long history of recurrent 
sinopulmonary infections and established bronchiectasis. Immunological investigations showed severe 
panhypogammaglobulinaema, marginally reduced CD4 count and reduced T cell proliferative responses.  
WES identified potentially damaging mutations in Ca2+-release activated Ca2+ regulator 2A (CRACR2A): c.430 A>G 
(p.144R>G) and c.898 G>T (p.300E>*) which were inherited via the maternal line; c.834 G>T (p.278E>D) in the paternal allele. 
In primary patient samples, T cells had reduced calcium flux, cytokine production and p-JNK.  
The two mutant patient alleles were expressed using retroviral transduction in the CRACR2A knock-out Jurkat cell line. Both 
alleles resulted in reduced calcium flux and IL-2 expression when compared to wild-type CRACR2A. The maternal mutant 
allele expression produced a truncated protein (resulting from the p.300E>* mutation), with abnormal localisation and 
significantly reduced p-JNK. This truncated protein was not seen in the primary cells, and so is not likely to be expressed in 
the patient.  
The data suggests that biallelic mutations in CRACR2A can lead to primary immunodeficiency, which affects T cell related 
function. This is the first time CRACR2A has been linked to disease.  
The identification of novel mutations in patient with primary immunodeficiency and using functional experiments to see their 
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Chapter 1 Introduction 
 
1.1 Immune cell lineage 
The immune system is split into two main categories; the innate and adaptive response. The innate immune system provides 
the initial response to infection and consists of granulocytes and monocytes. The main subtypes of this system can be seen in 
Figure 1.1.1. Adaptive immune response is the focus of this thesis The main cells of this system are lymphoid cells, such as T 
and B cells. Both of these cell types produce memory cells that allow for a rapid secondary response to the same foreign 
invasion. 
 
Figure 1.1.1 Immune cell lineages 











































1.1.1 T cells 
T cells are part of the adaptive immune response. T cells mature in the thymus and express T cell receptor (TCR), and either 
cluster of differentiation (CD)8 or CD4 glycoproteins on their surface. CD8+ cells (Tc) are cytotoxic and are involved in the viral 
and tumour immune responses. CD4+ cells are helper T cells (Th) that differentiate into different subsets as shown in Figure 
1.1.2 and are characterised by different cytokine profiles (Romagnani, 2000; Geginat, Lanzavecchia and Sallusto, 2003; 
Raphael et al., 2015; Golubovskaya and Wu, 2016). Th cells have different functions in the immune system depending on the 
cytokines they express, such as pro-inflammatory or regulatory. All Th cells express interleukin (IL)-2, which induces 
proliferation of all T cell subtypes, which then creates a positive feedback loop during an immune response. Different subsets 
work to balance the immune response, for example Th17 are proinflammatory and when not regulated can cause autoimmunity 
and break immune tolerance. However, regulatory T cells (Tregs) are able to supress and moderate Th17 cells and so maintain 






Figure 1.1.2 T cells subtypes and functions 
Figure taken and adapted with permission from Golubovskaya and Wu, 2016 licenced under CC BY (Janeway CA Jr, 
Travers P, Walport M, 2001; Golubovskaya and Wu, 2016; Kwun et al., 2017). 
 
1.1.1.1  T cell development 
As part of the adaptive immune response T cells need to be able to distinguish between self and non-self, this is controlled by 
positive and negative selection in the thymus. Immature T cells progress through multiple developmental stages and undergo 
somatic recombination to generate individual T cell clones expressing unique TCRs. These TCRs bind and recognize different 
antigens. In general, this antigen recognition process occurs when the TCR binds to antigen being presented by other cells on 
major histocompatibility complex (MHC) proteins. MHC class I interact with CD8+ T cells and MHC class II with CD4+ T cells. 
During positive selection the T cells are selected on their ability to bind to MHC complexes. Apoptosis is induced in cells that 
cannot bind, while positively selected cells receive survival signals, determination of whether the cells will be CD8+ or CD4+ is 
also determined at this stage by which type of MHC complex they bind most effectively. Negative selection allows for the 
removal of T cells that bind too strongly to self-antigens. The autoimmune regulator (AIRE) protein in thymus induces the 
expression of proteins from other tissues and cell types not normally found in the thymus, to allow for selection against most 





1.1.2 B cells 
B cells link the innate and adaptive immune responses. They have the ability to respond rapidly to damage-associated 
molecular patterns and antigenic stimuli, but also form long-lived serologic memory. B cells perform diverse functions, such as 
antibody secretion, cytokine production and antigen presentation. They interact with both innate cells and T cells, and therefore 
shape the outcome of the immune response toward immunity or tolerance (Hoffman, Lakkis and Chalasani, 2016). 
B cells express clonally diverse cell surface immunoglobulin (Ig) receptors recognising specific antigenic epitopes. As shown 
in Figure 1.1.1, B cells  differentiate into plasma cells. Plasma cells are big lymphocytes with large amounts of endoplasmic 
reticulum (ER), which produce antibodies to specific antigens. They respond to signals from T cells (Figure 1.1.2) during 
infection and continue to produce antibodies to the required antigen until the infection is controlled. Plasma cells are often 
found within chronic infection and inflammation (Janeway CA Jr, Travers P, Walport M, 2001). 
 
1.1.2.1 B cell Development 
Once differentiated in the primary lymphoid organ, the bone marrow, the B cells migrate and reside in the follicles of the spleen. 






Figure 1.1.3 B cell subtypes and function 
Republished with permission of American Society of Nephrology, from B Cells, Antibodies, and More., Hoffman, William; 
Lakkis, Fadi G; Chalasani, Geetha, volume 11, issue 1, 2016]; permission conveyed through Copyright Clearance Center, 







1.1.3 T and B cell interaction 
A successful immune system is characterised through interactions between distinct cell types. 
 
1.1.3.1 T cell influence on B cells 
T cells play a role in the maturation of B cells in the follicles of secondary lymphoid organs (SLO), such as the lymph nodes 
and the spleen, this subset of T cells is called follicular helper T cells (Tfh). Tfh , B cells, and IL-21 drive B cells to proliferate 
and differentiate into plasma cells, leading to antibody production. SLO are organised into T and B cell zones. Tfh reside in B 
cells zones and form germinal centres (GCs) during an ongoing immune response. B cells within GCs undergo rapid 
proliferation, differentiation into plasma cells and antibody diversification (Kwun et al., 2017). 
The interaction between Th cells and B cells can occur outside of SLOs and is essential for the production of antibodies and 
the autoimmune response. The T cell dependent response of B cells results in optimal affinity-matured antibody responses that 
are required for host defence, including rapid neutralization of bacterial toxins and blockade of viral cell entry (Petersone et al., 
2018). 
Costimulatory molecules are essential for T and B cell interaction, such as CD28, CD40, cytotoxic T-lymphocyte-associated 
protein (CTLA)-4. CTLA-4-mediated regulation of CD28 signalling controls the engagement of secondary costimulatory 
pathways such as  inducible T-cell costimulatory (ICOS) and OX40, and profoundly influences the capacity of T cells to provide 
B cell help. 
Most B cells require interaction with T cells in order to produce antibodies, except for a small number found within specialised 
sites such as the spleen and peritoneum. They are particularly important for dealing with encapsulated bacteria, which often 
have a polysaccharide outer layer as opposed to proteins, which allows them to evade T cells. T-independent B cells are able 
to recognise these layers and produce antibodies without T cell interaction (Hoffman, Lakkis and Chalasani, 2016). 
 
1.1.3.2 B cell influence on T cells 
B cells have cellular functions that can affect T cells, through presentation of antigens, costimulatory factions or cytokines. T 




surface, through CD40 and CD40L interaction and IL-6 signalling. B cells can also inhibit T cells by expressing IL-10, which 
reduces T cell activation and increases differentiation into Tregs. (Hoffman, Lakkis and Chalasani, 2016) 
 
 
1.1.4 Monocytes and macrophages 
Monocytes and macrophages are a component of innate immunity, through the mononuclear phagocyte system. Monocytes 
are derived in the bone marrow and circulate in the blood and spleen. They are the first line of host defence and can recognize 
danger signals or infection-associated pathogen-associated molecular patterns via pattern recognition receptors (PRRs), such 
as toll-like and nucleotide oligomerization domain (NOD)-like receptors (TLR and NLR) (Takeuchi and Akira, 2010; Varga and 
Foell, 2018). Monocytes can phagocytose, present antigens, secrete chemokines, and proliferate in response to infection and 
injury. Monocytes also differentiate into macrophages and dendritic cells. Macrophages are terminally differentiated cells that 
phagocytose pathogens and toxins, secrete chemokines to recruit other immune cells, and migrate to local lymph nodes (Chiu 
and Bharat, 2016). 
 
1.1.4.1 Interferon response 
Macrophages and dendritic cells produce type 1 interferons (IFNs) after sensing pathogen components via their PRRs. IFNs 
are polypeptides that are secreted by infected cells. They induce antimicrobial states that limit the spread of viral pathogens, 
promote antigen presentation and natural killer (NK   cell function, inhibit cytokine production and activate antigen-specific T 
and B cell responses and immunological memory (Trinchieri, 2010; Ivashkiv and Donlin, 2014). Canonical type I IFN signalling 
activates the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, leading to transcription of 
IFN-stimulated genes (ISGs). 
The expression of IFNs and pro-inflammatory cytokines following the detection of foreign DNA species, such as cyclic 
dinucleotides (CDNs), can be controlled by stimulator of interferon genes (STING). This protein is ubiquitously expressed on 
the membrane of ER, and can be activated by ER stress. Upon activation they can activate the downstream signalling cascades 




1.2 Primary immunodeficiency 
Primary immunodeficiency (PID) and primary immunodeficiency diseases (PIDDs) are a group of disorders which result in a 
compromised immune system. The definition has continued to expand and now encompasses not only susceptibilities to 
infections but also dysregulated inflammation and tolerance toward endogenous and exogenous antigens. Over 340 of the 
recognised 350 PIDDs are associated with a single gene. Monogenetic mutations make up 80% of all rare Mendelian diseases 
(Wright, FitzPatrick and Firth, 2018; Rahit and Tarailo-Graovac, 2020). The disorders are varied resulting in a large range of 
phenotypes and severities. The inborn errors cause part of the immune system to be missing or not function correctly (Bousfiha 
et al., 2018; Picard et al., 2018; Chinn et al., 2020). To help better understand and diagnose patient PIDs are classified into 
categories. It is thought that PIDs are more common than reported and epidemiologic studies would be one of the only ways 
to fully grasp the prevalence of these diseases . PID can present at any age, 1 in 2000 people may have a PID of some form 
though the most severe forms of PID are normally found in the first few months of life (Bousfiha et al., 2013). 
PID covers three distinct but often overlapping types of disease: immunodeficiency, autoimmunity and autoinflammatory. 
Immunodeficiency is characterised by the susceptibilities to infections and will be the main topic of discussion in this project 
(Todoric et al., 2013). 
Autoimmunity is when the immune system attacks self. The susceptibility to autoimmune disease is often influenced by a large 
number of polymorphic genes, rather than a single gene as seen in immunodeficiency. The adaptive immune response targets 
self-antigens and can affect either a specific organ (Grave’s and multiple sclerosis) or lead to a more general inflammatory 
condition (systemic lupus erythematous). Autoimmunity is associated with relapses and flares of disease (Truedsson, 
Bengtsson and Sturfelt, 2007; Todoric et al., 2013). 
Autoinflammatory diseases are defined as self-directed inflammation. These systemic diseases may affect any organ or 
system, are considered rare and encompass a wide variety of diseases and syndromes. Innate immune cells, including 
macrophages and neutrophils, are activated in these diseases. Chronic or recurrent episodes of inflammation occur in the 




Autoimmunity and autoinflammation can manifest in immunodeficiency diseases. Common Variable Immunodeficiency (CVID), 
for example, can result in inflammatory bowel disease, haemolytic anaemia and rheumatoid arthritis as well as the characteristic 
recurrent chronic infections (Goyal et al., 2009). 
 
 
1.2.1 Why study PID 
PIDs are rare diseases, with a reported prevalence of between 1:16 000 and 1:50 000 (O’Shea, 2018). These small numbers 
provide challenges to effective diagnosis, clinical care and research. The number of patients being diagnosed with PID is 
increasing, the United Kingdom Primary Immunodeficiency (UKPID) Registry increased from 2229 patients to 4758 between 
2013 to 2018 (Shillitoe et al., 2018). This expansion has allowed for improved molecular diagnostics, an increased number of 
identified genes and increased collaboration between clinicians/researchers. However, as at 2018 less than 22% of patients 
had a proven genetic defect underlying their PID (Shillitoe et al., 2018). 
Being able to identify the genetic cause of a patient’s disease can improve the diagnosis and treatment options available to the 
patient. More informed and quicker decisions are possible to the clinicians and scientists who contribute to this process, if it is 
a known gene associated with PID. Personalised medicine or gene therapies may be available depending on the genetic cause. 
It can also identify family members at risk. In addition to improving patient care, identifying the genetic cause of disease can 
improve the PID field and immunology in general. As it can lead to broader or more detailed phenotype data and a better 
understanding of the immune system as well as protein function. PID potential can lead to the identification of novel genes 
essential for the normal immune response, which would normally be identified in knock-down (KD) cell culture studies, where 
potential genes of interest are KD and the affect analysed. It allows for understanding of important mechanisms and pathways 
for immune cells. Potential novel genes or mutations could also lead to potential therapeutic targets of interest for other 
diseases, such as cancer. Immunotherapy can improve treatment efficacy in cancer (Robert, 2020). Checkpoint inhibitor 
antibodies are used to block the binding of co-stimulatory molecules on T cells, such as CTLA-4, programmed cell death protein 
1 (PD-1) and programmed death-ligand 1 (PD-L1), from binding to their protein partners. This allows for the activation of 




1.2.2 Types of PID  
PIDs have been categorised into 9 broad sections by the International Union of Immunological Societies (IUIS) Expert 
Committee of PID. However, an important point to remember is that this classification is very general and other considerations 
should be taken into account (Al-Herz and Notarangelo, 2012). Between the 9 sections there are some deficiencies that fall 
into multiple categories and ones that have yet to be identified may require a new section altogether. Casanova et al. 2008 
shows 3 different factors which need to be considered for each new case of PID to gain a better understand of the disease: 
epidemiological (frequency and age of onset), phenotype (clinical and cellular) and genotype (mode of inheritance and 
mutations). Another factor that can complicate classifying a PID is genotype versus phenotype. Mutations can give rise to 
diverse phenotypic presentations in different individuals due to a range of genetic and environmental differences. (Lawrence 





The 9 main categories, shown in Figure 1.2.1 represent the most profound phenotype associated with each identified gene 
(Casanova et al., 2014; Picard et al., 2015; Bousfiha et al., 2020; Tangye et al., 2020). The Online Mendelian Inheritance in 
Man (OMIM) reference is included for each defect as they recognise the wide phenotypic variability associated with each gene, 
due to the different mutations in the same gene, environmental and host factors. The patients discussed in this thesis fall into 
3 of these categories.  
 
Figure 1.2.1 Prevalence of each IUIS category  
Data taken from the ESID for the patient population in 2014. Antibody disorders (III) are the most common making up 
more than half of the population. PIDs affecting cellular and humoral immunity affect (I) 14% of this population and around 
70% of those cases are SCID. Data taken from http://esid.org/Working-Parties/Registry/ESID-Database-Statistics  
 
1.2.2.1.1 Immunodeficiency affecting cellular and humoral immunity (I) 
The two main branches for this category are severe combined immunodeficiency (SCID) and combined immunodeficiency 
(CID), distinguished by lymphopenia and normal white cell count respectively. SCID is a group of different PIDs, where the 
main clinical symptom is severe infection, often more serious than that of a healthy child and possibly life threatening. Infections 
that are not normally harmful to children can cause devastating effects to those with SCID. SCID can be fatal and is normally 
diagnosed in infancy. Along with severe recurrent infection, SCID is also associated with chronic diarrhoea and a failure to 




natural killer (NK) cells and B cells can also be affected. Autoimmune manifestations can occur due to alterations in the central 
and peripheral tolerance which filters out self-reactive lymphocytes (Giardino et al., 2016; Pai, 2019). 
X-linked SCID is the result of a mutation in the IL-2 receptor subunit gamma (IL-2RG) gene critical for lymphocyte development 
and function and accounts for about half of SCID cases. T and NK cells are normally absent while B cells are non-functional. 
Male infants with this disease have chronic diarrhoea, thrush, severe bacterial infections, skin rashes and an absence of tonsils 
and lymph nodes. A bone marrow transplant or gene therapy is required to repair the immune system as the disease can be 
fatal within the first two years of life (Allenspach, Rawlings and Scharenberg, 1993).  
 
1.2.2.1.2 Combined immunodeficiency with associated or syndromic features (II) 
This category contains deficiencies with a well-defined set of signs and symptoms that appear together to define the disease. 
The PIDs are generally associated with T cell immunodeficiency. Many in this category have some form of growth or 
developmental abnormities and reduced function or number of a specific T cell subtype. Wiskott-Aldrich syndrome (WAS) is 
characterised by thrombocytopenia, eczema, and recurrent bacterial infection. Thrombocytopenia is a lack of platelet cells and 
so is associated with abnormal bleeding. It is an X-linked disease associated with WAS protein which is expressed only in the 
hematopoietic cells. The protein functions in the cell cytoskeleton, regulating actin polymerization (Bompard and Caron, 2004; 
Boisson, Quartier and Casanova, 2015; Giardino et al., 2016). 
Calcium release-activated calcium channel protein 1 (Orai1) deficiency is another disease with a unique clinical phenotype and 
the complete loss of function of Orai1 can cause SCID. It is associated with severe infections early in life due to defects in the 
development or activation of T cells, immunodeficiency, anhidrotic ectodermal dysplasia (AED) and congenital myopathy, a 
muscle disorder present at birth. AED is the reduced ability to sweat, reducing the body’s ability to modulate temperature as 
well as sparse scalp and body hair. ORAI1 is involved in calcium transport through the formation of Ca2+-release activated Ca2+ 
(CRAC) channels in the plasma membrane. Calcium influx is essential for T cell activation, proliferation and cytokine production 





1.2.2.1.3 Predominantly antibody deficiencies (III) 
Predominantly antibody deficiencies are the most common type of PID as seen in Figure 1.2.1, with selective IgA deficiency 
and CVID being the most prevalent respectively. Most PIDs in this category are associated with recurrent bacterial infections 
and are categorised according to the specific immunoglobulin deficiency (IgG, IgA, and IgM) and the B cell numbers. CVID is 
a heterogeneous group of disorders which have a serum Ig characterised by low IgG and IgA with or without low IgM. The 
phenotype can vary but most cases present with recurrent infections, cytopenia, enlarged lymph nodes, poor antibody response 




1.2.3 Current Therapies for PID 
The main treatment for SCID or severe disease is allogeneic hematopoietic stem cell transplantation (HSCT). This HSCT 
requires a stem cell match, and may require chemotherapy prior to transplant. It has a good survival rate, but normally antibody 
production is not regained so immunoglobulin therapy is required (Bousfiha et al., 2015; Pai, 2019). Recently, new born 
screening for SCID has allowed for early diagnosis and treatment, which has improved the survival rate of this therapy (Bucciol 
and Meyts, 2020). 
Immunoglobulin replacement therapy allows antibodies to be infused into patients with antibody deficiencies. The infusions are 
given every 3 to 4 weeks and normally continue for the patient’s lifetime. Like Ig infusions more targeted therapies are available 
such as cytokines, cytokine inhibitors and small molecules, to control symptoms. Rituximab (anti-CD20) for examples is used 
to treat autoimmune phenotypes and selective inhibition of IL-6R is used with tocilizumab (Bousfiha et al., 2015; Bucciol and 
Meyts, 2020). 
Gene therapy has been used in the treatment of X linked SCID and WAS. It involves inserting a normal copy of the gene into 






1.2.4 Molecular screening of patients  
In PID 340 genes have been identified, but there are still many cases where the affected gene is unknown. There is a push in 
the research community to discover more of these targets, to add to gene panels for mutation screening, which can ultimately 
lead to better treatment for patients.  
Gene panels screen patients for known mutations that cause disease, these panels can be specified to the patient phenotype. 
For example, a patient with antibody deficiency can be screened for known mutations and genes of interest that have previously 
been shown to be pathogenic, such CD40 ligand which caused immunodeficiency with hyper-IgM (Bousfiha et al., 2015).A next 
generation sequencing (NGS) PID panel of 242 genes has been reported (Rae et al., 2018). It was tested on twenty-seven 
participants, and identified 15 reportable variants in 48% of the participants. The panel results had implications for treatment in 
37% of the patients. In patients with mutations not identified by gene panels, whole exome sequencing is available (WES). 
WES is a powerful technique that allows the sequencing of specific DNA that makes up 2 % of the total genome. The exome 
makes up the coding regions of genes, which accounts for 85 % of known disease related variants. WES has many advantages 
as a genetic platform for identifying novel genes and mutations associated with PID. It is high-yield and more cost-efficient than 
whole genome sequencing (WGS). It is an unbiased technique and it has wide utility due to its use in both commercial and 
research facilities. The main limitations are that 50-70 % of patients do not receive a diagnosis after WES and not all patient 
exomes have 100 % coverage (Choi et al., 2009; Y. Yang et al., 2013; 1000 Genomes Project Consortium et al., 2015; Warr 






1.3 The CRAC channel 
The CRAC channel has an important role in non-excitable cells, due to the more passive nature of the channel. Calcium moves 
into the cell due to the gradient created by low internal calcium concentration maintained in cells. Excitable cells such as nerves 
and muscles, rely more heavily on voltage gated channels (Lewis, 2001; Jairaman and Prakriya, 2013). 
The movement of calcium is essential for many cellular functions, due to this pronounced gradient maintained in cells, as 
calcium spikes are sufficient to deliver non-encoded messages unlike K+ and Na+. Calcium can induce large conformational 
changes in receptors and proteins with EF hand domains, due to its divalent charge. These interactions have a high affinity 
and specificity, making calcium an excellent secondary massager for cellular signalling (Carrasco and Meyer, 2010; Jairaman 
and Prakriya, 2013). 
 
 
1.3.1 CRAC channel  
Calcium release-activated calcium channel protein (Orai1) is a 32.7 kDa glycoprotein comprising of four transmembrane α 
helices anchored in the plasma membrane (PM), which forms the pore of the CRAC channel. Stromal Interaction molecule 1 
(STIM1) STIM1 is a 77 kDa single-pass transmembrane protein located in the ER, a calcium sensor protein which activates 
the formation of CRAC channels when the ER stores are depleted (Srikanth and Gwack, 2012; Joseph, Reicher and Barda-
Saad, 2014). The resting and active states of the channel are shown in Figure 1.3.1. During TCR activation multiple CRAC 
channels form at the immunological synapse (IS) and form puncta, this allow for large effector functional changes to take place 
within the cells (Barr et al., 2008, 2009; Srikanth and Gwack, 2012). 
Regulation of the CRAC channel occurs predominantly through STIM1 (Prakriya, 2009). At low Ca2+ concentrations of the ER, 
CRAC channel activation is initiated through the EF hand domain of STIM1. Regulation can also occur due to Ca2+ 
concentration levels in the cytosol. Cytosolic Ca2+ can inactivate CRAC channels through two spatially and temporally distinct 
mechanisms, called fast and slow inactivation, through Ca2+ dependent inactivation (CDI). Ca2+ −dependent fast inactivation 




seconds and requires a rise in global Ca2+. It is regulated by mitochondria and the ER-resident protein, store-operated calcium 
entry-associated regulatory factor (SARAF) (Srikanth, Ribalet and Gwack, 2013). Additional regulation can occur through 
calmodulin (CaM) which is able to bind the N terminus of Orai1 at elevated Ca2+ concentration and cause CDI. In contrast, 
calcium release activated channel regulator 2A (CRACR2A) is able to stabilise the CRAC channel complex and promotes the 
channel formation (Srikanth, Jung, Kim, et al., 2010; Srikanth, Ribalet and Gwack, 2013; Parekh, 2017). This protein is also 
able to respond to changes in cytosolic Ca2+ through its EF hand domains. More details about the protein CRACR2A are 
provided in Chapter 3.  
In its resting state STIM1 has recently been found to have another role, binding to STING in the ER, which keeps STING 
inactive and unable to play its role in interferon expression. STING plays a key role in the viral immune response in the cGAS 
pathway, which is activated by single stranded DNA. More details about STING are provided in Chapter 5. (Ishikawa, Ma and 
Barber, 2009; Motwani, Pesiridis and Fitzgerald, 2019; Rice et al., 2019; Srikanth et al., 2019)  
 
 
1.3.2 Role in the immune system 
Lymphocytes are electrically non-excitable cells, so the majority of calcium influx is mediated by store-operated calcium entry 
(SOCE). CRAC channels are predominately made up of two proteins; Orai1 and STIM1.  
At rest lymphocytes maintain low levels of calcium. Regulated oscillations in cytosolic and organellar Ca2+ concentrations 
control effector functions such as metabolism, proliferation, differentiation, antibody and cytokine secretion and cytotoxicity. As 
an essential secondary messenger, unregulated Ca2+ changes in lymphocytes can lead to various autoimmune, inflammatory 
and immunodeficiency syndromes (Lewis, 2001; Jairaman and Prakriya, 2013; Christo et al., 2015; Trebak and Kinet, 2019). 





Figure 1.3.1 The CRAC channel  
Key components of the CRAC channel, Orai1 pore complex and STIM1 translocate to ER- PM junctions during store depletion of the ER, the proteins oligermise to form 




1.3.2.1 Calcium in T cells and pathways 
Calcium flux is especially important in T cells for activation, proliferation, cytokine production and NFAT and NFκB signalling. 
Ca2+ influx and efflux across the PM of T cells occurs via several types of Ca2+-permeable channels and transporters, including 
SOCE. SOCE or calcium influx after store depletion is essential for T cell function, such as TCR activation and acute release 
of cytotoxic granules by CD8 + T cells within minutes of stimulation (Oh-hora and Rao, 2008). Different T cell subsets have 
varied sensitivity to calcium flux. Th1 and Th17 cell function is inhibited by moderate suppression of SOCE, whereas Tfh, Treg, 
and CD8 + T cells are relatively unaffected by suppression of the CRAC channel function (Vaeth, Kahlfuss and Feske, 2020). 
T cells also have voltage channels such as the PM Ca2+ ATPases (PMCAs) and sarcoplasmic/ER Ca2+ ATPases (SERCAs) 
which pump Ca2+ from the cytosol to the extracellular space and the ER, respectively. They pump Ca2+ ions against the 
electrochemical gradient, thus requiring energy in the form of ATP (Kozak and Putney, 2017). The function of these channels 
in immune cells is not as profound as in nerves and muscles. 
 
1.3.2.2 T cell receptor activation 
When the TCR is activated, phospholipase C (PLC) ᵧ1 hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to its receptor in the ER and the calcium stores are released. The 
STIM1 molecule can sense the depletion of the calcium stores due to the EF hand domains. When the T cells are in a resting 
state the EF domains are bound by calcium but as the store is depleted, the calcium dissociates from causing a conformational 
change, multimerization and the translocation to areas of the ER membrane in close proximity to the PM. Orai1 interacts with 
the STIM1 forming the CRAC channel which allows calcium to enter into the ER store, by SOCE. When the store is replenished 
calcium binds to STIM1 causing it to dissociate from Orai1. The calcium flux in T cells is heavily controlled which causes 
oscillating calcium concentrations. These oscillations of calcium rhythms are thought to be an additional regulation of 
downstream T cell effector function, as specific rhythms can cause particular gene transcription patterns through the NFAT and 
NFϰB. The oscillations also sensitise the T cells to changes in calcium flux (Barr et al., 2008; Christo et al., 2015; Woo et al., 




Rapid cytoskeletal rearrangements and the increase of intracellular calcium concentration downstream of TCR activation allow 
for T cell effector functions and organisation of an immunological synapse. Formation of the IS facilitates redistribution of 
receptors, signalling molecules and organelles towards the T cell–APC interface. These two systems form a positive feedback 





Figure 1.3.2 Calcium and cytoskeleton response to TCR activation 
Reprinted from The calcium feedback loop and T cell activation: Biochimica et Biophysica Acta (BBA) - Biomembranes, 
1838 edition 2, Noah Joseph,Barak Reicher,Mira Barda-Saad, How cytoskeleton networks control intracellular calcium 
flux, Pages No. 557-568, Copyright (2014), with permission from Elsevier (Joseph, Reicher and Barda-Saad, 2014). 
 
 
1.3.3 CRAC channel deficiencies  
CRAC channel deficiencies were briefly mentioned in Section 1.2.2.1.2, as they fit under the PID category II. Deficiency of 
Orai1 or STIM1 can result in SCID which presents with severe infections, immunodeficiency, AED and congenital myopathy, a 
muscle disorder present at birth. SCID can be fatal and is normally diagnosed in infancy. The syndromic features of these 
deficiencies are shown in Table 1.3.1. The severe infections are a result of impaired T cell activation and development. T cells 
are sensitive to mutations in CRAC channel proteins. There is 4 fold more STIM1 expressed and they do not express the 




Table 1.3.1 Phenotypes associated with Orai1 and STIM1 deficiencies 
 
Autoimmune hemolytic anemia (AIHA), Ectodermal dysplasia (ED), Immune thrombocytopenic purpura (ITP) 
(Feske, 2010; Kim et al., 2011; Eckstein and Lacruz, 2018; Rice et al., 2019) 
Deficiency Orai1 STIM1 
Host Human Mouse Human Mouse 
Survival limited by Immunodeficiency Perinatal lethality Immunodeficiency Perinatal lethality 
Immune dysfunction 
Infections 
T cell activation defect 
Mitochondria-mediated cell 
death pathways ↓ 
T cell defect  
Mast cell defect 
Infections 
T cell activation defect 
Treg numbers ↓ 
T cell defect 













Myopathy - congenital, global 
Respiratory muscle insufficiency 
Atrophy of type II muscle fibres 




ED like phenotype 
Dental enamel defect 
(amelogenesis imperfecta type 
III) 
Anhydrosis 
Dry and exfoliate skin 
Sparse/thin/brittle hair 
Alopecia 





Thrombocyte function No bleeding diathesis 
Platelet activation ↓ 
Thrombus formation ↓ 
No bleeding diathesis 
Thrombocytopenia 
(autoimmune) 
Platelet activation ↓ 




1.3.3.1 Immune cell phenotype 
CRAC channel deficiency can result in T cell dysregulation. As previously mentioned, SOCE is essential for many T cell 
functions. The T cell phenotype often has a normal number of total T cells, but the Treg and Th numbers are reduced. T cells 
have reduced proliferation responses and reduced cytokine production (Feske, 2011; Rice et al., 2019). 
Myeloid lineage cells, such as mast cells, macrophages, and dendritic cells, express Fc receptors (FcRs), which activate 
phospholipase C and subsequently induces Ca2+ depletion from the ER. In mast cells, SOCE and STIM1 have a critical role in 
degranulation. The initial release of Ca2+ from the ER stores and the final fusion step with the plasma membrane of mast cell 
degranulation requires calcium, after the initial granular translocation and docking. STIM1-dependent Ca2+ influx positively 
regulates the activation of both NF-κB and NFAT in mast cells. NF-κB promotes the expression of IL-6 and TNF and NFAT 
enhances the production of IL-13 and TNF. Impaired NF-κB and NFAT activation in STIM1 deficiency may contribute to the 
insufficient production of these cytokines (Blank and Rivera, 2004; Baba et al., 2008).  
In B cells, SOCE also plays an important signalling function. Deficiency in either STIM or Orai proteins show a defect in SOCE 
and proliferation response to BCR activation. B cell development and antibody responses remain normal. B cells from B-dKO 
mice fail to produce an anti-inflammatory cytokine, IL-10. The deficiency of CRAC channel proteins does not seem to have as 
profound an effect in B cells as in T cells (Scharenberg, Humphries and Rawlings, 2007; Gwack et al., 2008; Matsumoto et al., 
2011).  
 
1.3.3.1.1 Nervous system 
In CRAC channel deficiencies, neuronal phenotypes are normally limited to developmental delays and seizures. Neurological 
phenotypes linked to CRAC channel deficiency are rare (Feske, 2010, 2011; Bollimuntha, Pani and Singh, 2017; Kozak and 
Putney, 2017).  
 
1.3.3.2 Muscle phenotype 
SOC is important for the regulation of muscle function, which is highlighted by muscular hypotonia, or decreased muscle tone, 




Bousfiha et al., 2015; Rice et al., 2019). STIM1 was found to be expressed at high levels in skeletal muscle controlling muscle 
function and properties. Calcium drives NFAT-dependent morphogenetic remodeling and sarcoplasmic-reticulum (SR) Ca2+-
store filling. Orai1 loss of function mutations can result in myopathies. SOCE deficient phenotypes include abnormal muscle 
development, differentiation and function due to the reduced NFAT signalling, and reduced expression of SERCA channels 
and MHC proteins (Kiviluoto et al., 2011; Li et al., 2012). 
 
1.3.3.3 Ectodermal dysplasia like phenotype 
Ectodermal dysplasia (ED) are a group of disorders in which two or more of the ectodermally derived structures develop 
abnormally such as the skin, sweat glands, hair, nails, teeth and mucous membranes. 90 % of cases are linked to mutations 
in four genes: EDA1, EDAR, EDARAAD and WNT10A. CRAC channel deficiency is not associated with ED, because even 
though the same tissues are affected and the phenotypes look similar, the underlying mechanisms of disease differ. There is 
no evidence that Orai1 or STIM1 are involved in the development of these tissues, but rather in their function and maintenance. 
The enamel develops normally but has mineralization defects, which is linked to the upregulation of STIM1 and ORAI1 during 
maturation  at the mineralization stage (Eckstein and Lacruz, 2018). 
CRAC proteins have important roles in eccrine sweat glands, ORAI1 allows for  stimulation of  chloride channels necessary for 
fluid secretion and STIM1/2 enables sustainable levels of Ca2+ transport in ameloblasts to cause proper enamel mineralization. 
The enamel defects are present in deciduous and permanent teeth, the teeth can appear discoloured, have increased wear, 
hypoplasia (thinning of enamel) and chipping. ED like symptoms vary and are not always present in patients (Feske, Picard 
and Fischer, 2010; Concepcion et al., 2016; Eckstein and Lacruz, 2018). 
 
1.3.3.4 Neurons phenotype 
Calcium and SOCE are important for neurosecretion, exocytosis, neuronal growth and differentiation, and the maintenance of 
neural circuits. In neurons, the main channel responsible for store-operated calcium entry are transient receptor potential (TRP) 
channels. In general, altered calcium signalling can lead to reactive oxygen species (ROS) production, abnormal protein 




Huntingtons and muscular dystrophy. As stated above neuronal phenotypes are rare in CRAC channel deficiencies. STIM2 is 
thought to compensate during STIM1 deficiency (Feske, 2011; Bollimuntha, Pani and Singh, 2017; Kozak and Putney, 2017).  
 
1.3.3.5 Mice phenotype 
As described in Table 1.3.1, mice phenotypes of Orai1 and STIM1 deficiency are similar to those shown in humans. Complete 
deficiency of these genes can lead to fatality 24 h postpartum. Cytokine production by CD4+ and CD8+ T cells are dramatically 
impaired, including that of IFNγ, TNF, IL-2, IL-4, IL-10 and IL-17 (Trebak and Kinet, 2019). 
 
1.3.3.5.1 Orai1 deficiency 
Orai1 deficient mice are small in size, with eyelid irritation and sporadic hair loss. T and B cells develop normally, but have 
impaired function due to reduced SOCE and cytokine production. B cells have a decreased Ca2+ influx and cell proliferation in 
response to B-cell receptor stimulation (Gwack et al., 2008). 
T cell-specific Orai1-knockout mice show no signs of experimental autoimmune encephalomyelitis (EAE) and have reduced 
Th1 cell-dependent and Th17 cell-dependent cytokine production, including IL-17A and IFNγ (Ma et al., 2010). ORAI1 
deficiency renders T cells resistant to death upon long-term TCR activation, due to the reduction in nuclear import of NFAT. 
This can be restored by expression of either ORAI1 or constitutively active NFAT. The mice have no developmental defects in 
T cells, but have increased memory and effector T cells. The mice have splenomegaly and lymphadenopathy phenotypes 
(Trebak and Kinet, 2019). 
SOCE seems to be involved in neuronal functions, but not development. In Orai1 deficient mice, no abnormal structures in the 
brain were found (Kozak and Putney, 2017). 
 
1.3.3.5.2 STIM1 deficiency 
STIM1 deficient mice have 70 % lethality due to cardiopulmonary defects. The surviving animals have retarded growth, 




Ca2+ store-refilling rate in smooth muscle cells and activation of multiple signal transduction cascades associated with growth 
signalling (calcineurin, AKT, and ERK1/2) are reduced, which results in impaired neonatal muscle growth (Beyersdorf et al., 
2009; Li et al., 2012). 
Mice lacking STIM1/2 in T cells (T-dKO mice) developed sever autoimmune disease (Oh-hora et al., 2008). SOCE is essential 
for the development and function of Tregs, which express Forkhead box P3 (Foxp3) as a master transcription factor. Tregs in 
these mice had a decreased expression of inhibitory surface molecules such as CTLA-4 and TIGIT. B cells were present at 
normal levels, but had increased turnover (ki-67 expression). The B cells were constitutively active, with continuous plasma 
cell differentiation and a 10-fold increase of Igs in sera compared to WT mice (Kozak and Putney, 2017). 
CD4+ T cell-specific STIM1 deficiency have reduced SOCE in response to anti-CD3 stimulation. The cells failed to sustain 
NFAT nuclear translocation and produce IL-2 on TCR activation (Trebak and Kinet, 2019). 
STIM1 and Orai1-knockout mouse embryonic fibroblasts (MEFs) are more susceptible than wildtype cells to oxidative stress.  
STIM1 deficiency in particular was shown to be involved in regulation of mitochondrial shape, bioenergetics and in oxidative 




1.4 Aims  
The overall aim of this thesis tis to investigate potential novel genes or mutations that could be causing the patient’s PID 
phenotype. For each case study there are two main directions used to investigate this where possible which are broken down 
below.  
First, by looking at the genetic and molecular data, to see if the mutations are present and the possible functional effects of 
these mutations using existing research, databases and computational models. This can help rule out mutations unlikely to be 
pathogenic and therefore allow for more in depth functional studies on likely candidates, as seen in the second section.  
 
1. Confirm potential mutations and their segregation in patient with PID. 
o Research genes and mutations identified by WES or gene panels 
o Identify mutations that could be pathogenic by finding potential links between protein function and patient 
phenotype 
o Confirm mutations by Sanger sequencing 
o Identify segregation of mutations by sequencing parental DNA or through cloning 
The second avenue is taking the potential candidate and looking in more detail at the cell types, pathways and functions 
associated, to see the pathogenic affect. This was done both in primary patient cells and in cell line models expressing the 
mutations.  This was done to amass data on whether these mutations are affecting function and therefore causing the patient 
phenotype. 
 
2. Use primary samples and in vitro models to determine if mutations identified are pathogenic and causing of the patient 
phenotype 
o Develop functional assays specific to the mutations confirmed in the patient 
o Perform functional experiments in patient and HC samples 
o Develop cell lines with the genes of interest knocked out 




Chapter 2 Materials and Methods 
 
2.1 Materials 
The oligonucleotides used for this project were purchased from Sigma and are shown in Table 2.1.1. The vectors and antibodies 





Table 2.1.1 Oligonucleotides 
 
Code Name Sequence Tm (°C) Ta  (°C) Application 
A DHSR4_ex4_F GGAACCCACTCTAACTCCTCA 62.1 
65 
PCR and sequencing of gDNA. Amplicon 299 
bp (Chapter 3) B DHSR4_ex4_R TCCATAGCAGCCTTCAGTCC 64.3 
C EFCAB4B_ex6_F ATGATTCCTGGCAGGTGAGA 64.7 PCR and sequencing of gDNA. Amplicon 380 
bp (Chapter 3) D EFCAB4B_ex6_R ATTCCAGTGCAGGGACCAG 65.2 
E EFCAB4B_ex9_F GGCCCTGATGTTGAGTAGGT 62.9 PCR and sequencing of gDNA. Amplicon 279 
bp (Chapter 3) F EFCAB4B_ex9_R GTGAATGGCAGGGAAAGTGG 66.6 
G EFCAB4B_ex10_F AAACAAGGTGAGGCCAGGG 66.3 PCR and sequencing of gDNA. Amplicon 384 
bp (Chapter 3) H EFCAB4B_ex10_R AGCCCAAATCCTCTTTTCACAG 65.3 
I EFCAB4B-var1_F TGTTTGATGCCCTGGATGCT 67.8 
67 
PCR and sequencing of cDNA. Amplicon 234 
bp (Chapter 3) J EFCAB4B-var1_R GGGCTCCAAGTCTGTCCATC 66 
K EFCAB4B-var2/3_F GTTTCAAGCCCGCAGTCAAG 67 PCR and sequencing of cDNA. Amplicon 232 
bp (Chapter 3) L EFCAB4B-var2/3_R GCTTTCCAACTGCTGCTGAG 65.2 
M sR2A_D230A_F GATGGACAGACTTGGAGCCC 66 PCR and sequencing of cDNA. Amplicon  305 
bp (Chapter 3) N sR2A_D230A_R CTTGACTGCGGGCTTGAAAC 67 
O mtR2A_D230A_F GCTGCTTATGCTGAAGAAATCC 63.9 
58 Mutagenesis (Chapter 3) 
P mtR2A_D230A_R AATTTTCCTTTTTAGGGCAC 58.6 
Q mtR2A_Q131*_F TGCAGGTGAATAGGTGGCCCA 71.8 
67 Mutagenesis (Chapter 3) 
R mtR2A_Q131*_R TCTTCCTGACTTGGGTTATTCTGG 66.1 
S Mt_R144G_F AGGTGTATCTGTCCGGAGGGGATGAGGATC 77.1 
72 Mutagenesis (Chapter 4) 
T Mt_R144G_R GATCCTCATCCCCTCCGGACAGATACACCT 77.1 
U Mt_E278D_F AGCAGGAGCTGGATCAGCTCACCCAGAAGC 80 
72 Mutagenesis (Chapter 4) 
V Mt_E278D_R GCTTCTGGGTGAGCTGATCCAGCTCCTGCT 80 
X Mt_E300*_F ATCATGACAAGCATTAGACCAAGGCTGAGA 73 
72 Mutagenesis (Chapter 4) 
Y Mt_E300*_R TCTCAGCCTTGGTCTAATGCTTGTCATGAT 73 
Z STIM1_ex4 F TGTGGTAAATATTAAGGTCAGCATGA 64.1 
63.8 
PCR and sequencing of gDNA. Amplicon 289 
bp (Chapter 5) A1 STIM1_ex4 R TCACTTAACTGGCCAGAGCA 63.4 
B1 CANT1_ex2 F CGGGGTCTAAGGACAGGTG 64.5 
65 
PCR and sequencing of gDNA. Amplicon 379 




Code Name Sequence Tm (°C) Ta  (°C) Application 
D1 TMEM173_ex5F TCCCAGCAAGTTCTCTAGGT 60.5 
63 
PCR and sequencing of gDNA. Amplicon 347 
bp (Chapter 5) E1 TMEM173_ex5R TTCAGCCACTGAAGAGAGCC 64.7 
F1 h36B4 F&R F- CAACGTGGGCTCCAAGCAGAT,  R - GGTCCTCCTTGGTGAACA N/A N/A SYBR green qPCR (Chapter 5) 
G1 hSTIM1 F&R F-  TCCCTTGTCCATGCAGTCCC, R- GGAATGGGTCAAATCCCTCT N/A N/A SYBR green qPCR (Chapter 5) 
H1 hIFNa F&R F- TAGACAAATTCTGCACCGAAC, R- AGATGGAGTCCGCATTACTC N/A N/A SYBR green qPCR (Chapter 5) 
I1 hIFNB F&R F - TGCTCTGGCACAACAGGTAG, R - AGCCTCCCATTCAATTGCCA N/A N/A SYBR green qPCR (Chapter 5) 
 
F- forward, R- reverse, Tm – Melting temperature, Ta - annealing temperature used in experiments, red bases are ones that are mutated from WT. All primers were 





Table 2.1.2 Plasmids 
 
Name Insert Features of interest Application Supplier Vector Map 
pC2.1 - TA cloning site, easy insertion TA cloning 









EGFP in same open reading frame as 
insert (bicistronic), to track expression 
of recombinant proteins 
Electroporation of 
CRACR2A into Jurkat 
cell lines 
Gifted from Gina Doodey Figure 2.2.3 
pMAX GFP N/A Small size, easy to transfect 
Electroporation high 
efficiency plasmids 












Stable and transient expression,  self-
inactivating 3' long terminal repeat 
(LTR) 
Electroporation and 
stable cell lines, 
expression of CRACR2A 
mutants 





High transfection efficiency in HEK293 
cells. Does not express in Jurak cells.- 
High efficiency HEK293 
test 




LentiCRISPR lentiviral CRISPR/Cas9 
and single guide RNA system by 
GeCKO 




Packaging vector Viral transduction  Gifted by Gwack Lab Figure 2.2.10 




Table 2.1.3 Antibodies 
All antibodies are selective to human.  
 
Name Target Host Supplier Application Conditions Other 
hCD3 - E.coli 
 Invitrogen, #16-0037-
81 
Cytokine study, calcium 
flux (Flex Station), 
culturing 
- (All chapters) 
hCD28 - E.coli 
Invitrogen, 14-0289-
80  
Cytokine study, calcium 
flux (Flex Station), 
culturing 
- (All chapters) 
Anti-GAPDH GAPDH Rb Genetex GTX10018 
WB of PBMCs and cell 
lines 
1:10000 in 5 % milk (All chapters) 
Anti-CD4-FITC CD4 ms 
Invitrogen, #11-0042-
82 
FACS (T cells) 5 µL/ sample FITC (Chapter 3) 
Anti-CD8-PE CD8 ms 
Invitrogen, 
MHCD0804 









5 µL/ sample 
eFluor 450 (Chapter 3) 
Recombinant 
Human IL-2 
- E.coli PeproTech, #200-02 T cell expansion - 
Purity ≥ 98 %, specific 
activity of ≥ 1 x 107 














Flow cytometry 5 µL/ sample (Chapter 3) 
Anti-CRACR2A CRACR2A  Rb 
ProteinTech, Cat  
LOT  
WB of PBMCs and cell 
lines 
1:800 in 5 % milk (Chapters 3&4) 
Anti-CRACR2A 
(Gwack) 
CRACR2A  Rb 
Made in house by 
Gwack lab 
WB of PBMCs and cell 
lines 
IF - 1:2000, WB - 1:5000 
5 % milk 




Name Target Host Supplier Application Conditions Other 
Anti-β actin β actin ms 
Santa Cruze, 
SC47778, Lot J1518 
WB of PBMCs and cell 
lines 
1:2000 in 5 % BSA (Chapters 3 & 4) 
Phalloidin F actin - 
Life Tech, Lot 
1246066 
IF 1:40 / sample 
Alexa Fluor 488 (Chapter 
4) 
Anti-Vav1 Vav1     IP   (Chapter 4)  











ms IgG Donkey Invitrogen, A10037 IF secondary 1:500 / sample 





Rb IgG Donkey Invitrogen, IF secondary 1:500 / sample 
Alexa Fluor 568 (Chapter 
4) 
Anti-FLAG FLAG ms Millipore, F7425 WB of cell lines 
IF - 1:500, WB - 1:5000 in 
5 % BSA 
(Chapter 4) 
Anti-Orai1 Orai1 Rb  Sigma, O8264  WB of cell lines 1 in 100 (Chapter 4) 
IFN α 2A - Xeno-Free Merk millipore GF416 Monocyte stimulation EC50 0.1-0.4 ng/mL  
Human Recombinant, 
purity > 95 % (Chapter 5)  
Anti-STIM1  STIM1 Rb Sigma, HA161 
WB of PBMCs and cell 
lines 
1:250 in 5 % milk 
Raised against full length 
protein (Chapter 5) 
Anti-STIM1 
D88E10 
STIM1 Rb CST #5668 WB of PBMCs 1:5000 in 5 % milk 
Raised against C-
terminal (Chapter 5) 
Anti-GOK/STIM1 STIM1 ms BD #610954 WB of PBMCs 1:500 in 5 % milk 
Raised against N-
terminal (Chapter 5) 




2.1.1 Cell lines 
2.1.1.1 Reagents 
Dulbecco's Modified Eagle Medium (DMEM) - Gibco  
Fetal Calf Serum (FCS) – Sigma (St. Louis, USA),  F7524 
Freeze media for all cell lines and PBMCs – FCS and 10 % DMSO (Sigma) 
G418 disulfate salt solution or Geneticin – Sigma, G8168 
Hanks’ Balanced Salt solution (HBSS) – Sigma, 55021C 
L-Glutamine (200 mM) – Thermo, 25030081 
MEM non- essential amino acid (NEAA) (100X) – Sigma, M7145 
Penicillin-Streptomycin (Pen/Strep) - Gibco™ (USA), 15070 
Roswell Park Memorial Institute (RPMI) 1640 Medium - Gibco 
Sodium Pyruvate (100 mM) –Thermo, 11360070 
Trypsin (10 x) - Life Technologies, Carlsbad, (USA), 15400 
X-Gal – Invitrogen, B1690 
LB broth – Sigma  
 
2.1.1.2 Cell lines 
2.1.1.2.1 DH5 cells 
Subcloning efficiency DH5 competent cells (Invitrogen, Cat:18265017) are chemically derived competent cells with a 
transformation efficiency of >1x106 cfu/g plasmid DNA. They contains lacZΔM15 for blue/white screening with X-gal. The cells 
are cultured at 37 °C either on LB agar plates or on an orbital shaker in LB Broth. Both the solid and liquid media were made 






HEK293 (ATCC- CRL-1573) were cultured at 37 °C with 5 % CO2, in complete DMEM medium with 1 % Pen-Strep and 10 % 
FCS. Cell lysates from this line were used as a control in western blots.  
 
2.1.1.4 HEK293T 
HEK293T(ATCC- CRL-11268) are human embryonic kidney cells that were derived from HEK293 cells to contain a SV40 large 
T antigen and have high transfectability. Cells were cultured in the same way as the parent HEK293 line. 
These cells were mainly used for retroviral transduction. They were transfected with a virus and their supernatant was added 
to ‘difficult to transfect cells’, in this case Jurkat cells. They were also used as a control in a range of experiments as they are 
a well-documented cell line that is easy to grow and to transfect. Gifted by the Gwack group (UCLA).  
 
2.1.1.5 HEK293FT 
These cells are a fast growing variant of HEK293T cells, specifically optimised for lentiviral transduction. They require a more 
complex media than other HEK293 cells: DMEM media with 10 % FBS, 0.1 mM NEAA, 6 mM L-glutamine, 1 mM MEM sodium 
pyruvate and 500 µg Geneticin. Gifted by Julie Burns (University of Leeds). 
 
2.1.1.6 Jurkat cell line 
Jurkat cells (ATCC: TIB-152) were derived from peripheral blood of a 14-year-old boy with acute T cell leukaemia. They are 
able to produce IL-2 after stimulation with phorbol esters and lectins or antibodies against the T3 antigen and provide a readout 
on the survival and signalling mechanisms of cells. The cells were cultured at 37 °C with 5 % CO2, in complete RPMI 1640 
medium with 1 % Pen-Strep and 10 % FCS. Gifted by Dr Gina Doody (University of Leeds).  
This cell line was used as a T cell model, serving as a control due to its uniform response, in calcium flux experiments, western 
blots and qPCR. Assay for primary T cells were developed using Jurkat cells. Jurkat cells were also used to make stable cell 






2.1.2 Patients and Healthy controls 
The work in this project is covered by ethical approval granted for a study entitled ‘Molecular genetic investigations of autosomal 
recessive conditions’, which was approved by the South Yorkshire Research Ethics Committee on 18th February 2011 (REC 
ref. number 11/H1310/1). NHS Permission for Research at Leeds Teaching Hospitals NHS Trust was granted on 29th April 
2011 (LTHT R&D number CG11/9764). 
All patients who participated in this study consented to whole exome sequencing (WES) and further research testing with 
ethical approval. Patient samples were made available by Dr Sinisa Savic and the Department of Clinical Immunology and 






During this project multiple methods and reagents were used in similar experiments, as they were performed in different 
laboratories. This is because the same reagents were not available in all locations. During the secondment in LA, the Gwack 
Labs standard protocols and reagents were used rather than ones previously optimised in University of Leeds. The protocol 
used is specified in the legends to all figures and tables. 
 
 
2.2.1 Molecular Biology 
2.2.1.1 Whole exome sequencing (WES) 
Whole blood DNA was prepared for exome sequencing using SureSelectXT with All Exon v5 capture library and sequenced 
on Illumina HiSeq 3000 for 2 × 150-bp paired-end sequencing. Reads were aligned with BWA-MEM to GRCh37/hg19 and 
variant calling was performed according to GATK-best practices.  
 
2.2.1.2 Selection of potentially pathogenic mutations from WES data 
Once the mutations are identified the frequency in the population is located. In general, if it is rare in a population (<0.0001) it 
is likely to cause disease. Next the genes associated with these rare mutations are compared to the patient phenotype to see 
if the gene function is similar or has previously been linked to other disease states. Before any further experiments are run it is 
essential to confirm the mutations of interest by Sanger sequencing. WES is a very powerful technique but artefacts can appear. 
In Sanger sequencing a much smaller and specific section of the genomic DNA are analysed and which provides more 
confidence in the results.  
Filtering and prediction of functional consequences was performed using Variant Effect Predictor (VEP) 
(http://www.ensembl.org/info/docs/tools/vep/index.html), Exome Variant Server (http://evs.gs.washington.edu/EVS/), the 
Single Nucleotide Polymorphism database (https://www.ncbi.nlm.nih.gov/projects/SNP/) and ClinVar  




(http://gnomAD.broadinstitute.org). Filtering of common variations and annotation was performed using vcfhacks 
(https://github.com/gantzgraf/vcfhacks) and in-house scripts. Candidate variants were required to pass the following filtering 
conditions: frequency (count/coverage) between 20-100%, according to VEP-annotation at least one canonical transcript is 
affected with one of the following consequence: variants of the coding sequence, frameshift, missense, protein altering, splice 
acceptor, splice donor, or splice region; an in frame insertion or deletion; a start lost, stop gained, or stop retained, or according 
to VEP an ExAC frequency unknown, <=0.01, or with clinical significance 'path'. 
 
2.2.1.3 Polymerase chain reaction (PCR) 
PCR was used for the amplification of specific regions of single stranded DNA from 5 to 3 using synthetic primers seen Table 
2.1.1. All standard PCRs were performed with 1x PCR Master Mix HotShot Diamond (Clent Life Science HS002) , 20 µM 
Primer (forward and reverse) and genomic DNA at 20-21 ng in a final volume of 10 µL, following the reaction scheme in Figure 
2.2.1.  
 
Figure 2.2.1 Standard PCR reaction scheme  
As a negative control for all PCR experiments, a reaction mix was set up without DNA, to check for contamination of the 
primer stocks and reaction mixes. 
 
2.2.1.4 Sanger sequencing 
PCRs were generated using the standard protocol and primers. Free nucleotides were removed by ExoSAP-IT (Affymetric) 
before a sequencing reaction was performed using the BigDye Terminator v3 Cycle Sequencing Kit (Thermo, 4337455) as per 
manufacturer’s instructions. The reaction used a single primer, normally one of two primers originally used to generate the 
PCR product, or one located within the PCR product. The products generated were ethanol precipitated and the DNA 
1. 95oC 5 minutes 
2. 94oC 30 seconds 
3. 65oC 30 seconds (variable, Tm dependent 
4. 72oC 45 seconds (variable timing, 30 sec/500bp) 
5. Go to step 2 for 44 times 
6. 72oC 5 minutes 




resuspended in Hi-Di Formamide (Thermo, 4311320) for analysis on the ABI3130xl Genetic Analyzer, which used capillary 
electrophoresis to separate DNA by size. 
Sanger sequencing was performed in house, except for sequencing performed at UCLA which was outsourced to Laragen 
(CA, USA). When confirming mutations, two PCRs were generated for each patient and sequenced with the forward and 
reverse primers.  
 
2.2.1.5 Gel electrophoresis 
PCR products were run on 1.5 % agarose gels to check the quality of the PCR product and to ensure that they were the 
expected molecular weight. Initially ethidium bromide (EtBr) was used to visualise the DNA, but later in the project a safer gel 
dye was used in the form of Gel Red.  
 
2.2.1.5.1 Reagents 
1.5 % agarose gel – 1.5 % SeaKem LE Agarose (Lonza), 1 x TAE in water with EtBr (Thermofisher) or GelRed (Biotium)  
6X DNA Loading Dye – Thermofisher, R0611  
100 bp Marker – NEB, N3231L 
50x TAE, pH 8.5 – 0.04 M Tris base, 0.002 M Disodium EDTA, 0.02 M acetic acid (all reagents from Fisher Scientific) 
 
2.2.1.6 cDNA generation 
RNA was isolated from PBMCs using the QIAamp RNA Blood Mini Kit (QIAGEN, 52304), following manufacturer’s instructions. 
Reverse transcription was performed on 1 µg total RNA using GoScript Reverse Transcription System using both random 
primers and Primer dT, or using High capacity RNA kit, which uses Random primers only. The switch to the high capacity kit 
was due to the use of an established protocol for cDNA isolation from monocytes in a 96 well plate for TaqMan qPCR (Srikanth 





2.2.1.7 TA cloning 
To determine the orientation of mutations, on a single allele, cDNA was isolated and amplified as detailed in Section 2.2.1.6. 
TA Cloning Kit with CR2.1 Vector (Invitrogen, K202040, Table 2.1.2) and subcloning efficiency DH5 competent cells were 
used to perform TA cloning of this PCR product. Following transformation, positive cells were selected with Ampicillin (100 
µg/mL final concentration) and identified using X-Gal (20 µg/mL). Colony PCR, which includes an additional 10 minute step at 
95 °C before the standard PCR reaction scheme (Figure 2.2.1), was used to identify colonies with the vector and insert, on an 
agarose gel. GenElute™ Plasmid Miniprep Kit (Sigma) was then used to purify DNA from these positive colonies. Sanger 
sequencing was finally used to confirm the mutations. 
 
2.2.1.8 CRACR2A cloning and site directed mutagenesis   
A variety of cloning protocols were performed on the cDNA sequence of CRACR2A. Figure 2.2.2 shows the sequences of the 






Figure 2.2.2 CRACR2A isoform sequences for cloning 
The two isoforms of CRACR2A share the first 1119 nucleotides. The donor plasmids gifted by Lynn McKeown (University 
of Leeds) contain the cDNA sequences for the long and short isoforms of CRACR2A. The sequence of both isoforms was 
confirmed by Sanger sequencing in-house. ATG – Start codon, TAA and TAG - Stop codons, NNN – codon containing 
main patient mutations described in Chapter 3, the base in red is the point mutation location. 
 
2.2.1.8.1 PCR cloning 
The basic protocol for plasmid cloning by PCR was forced cloning performed by restriction with XhoI+EcoR1. The recipient 
plasmid used in this project was pIRES2-EGFP (Figure 2.2.3) a bicistronic vector designed for the simultaneous expression of 
a green fluorescent protein and a protein of interest (CRACR2A) from the same transcript in transfected mammalian cells. This 




located upstream of the IRES, both the gene of interest and the EGFP coding region are transcribed into, and then translated 
from a single bicistronic mRNA.  
The sequence of the primers used for cloning are in Table 2.2.1 The PCR cloning adds additional bases so predicted sizes of 
the short and long amplicons increased to 1218 bp and 2239 bp respectively.  
 
 
Figure 2.2.3 pIRES2-EGFP plasmid map 
Map taken from BDbioscience, PT3267-5, #6029-1.  
pIRES2-EGFP contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV) between the 






Table 2.2.1 Cloning primer sequences 
Primer Name RE Sequence 
Cloning_F1 XhoI tagatcCTCGAGGCCACCATGGCTGCCCCTGACGGGAGGGT
A 
Cloning_R_short EcoR1 tagatcGAATTCTTAGACTGGTCCTTCCGA 
Cloning_R_long EcoR1 tagatcGAATTCCTATCAGCCACAGCAGGATTT 
 
Primers were made by Sigma. The Tm of all primers was above 70 °C at 90.6, 71.2 and 74.7 °C respectively. All PCR 
reactions used a temperature of 70 °C for annealing. Lower case is the leader sequence, CTCGAG - XhoI at 5’ end, 
GAATTC - EcoRI at 3’ end after stop codon, GCCACC - KOZAK , ATG – Start codon, TTA and CTA - Stop codon in 
reverse orientation.  
The cloning PCR primers contain three key elements. A leader sequence of 3-6 bp at the 5' end of the primer to assist 
with restriction enzyme digestion. A restriction site, that is present in the MCS of the recipient plasmid and not present in 
the sequence of interest, in this case Xhol and EcoR1 were used: A hybridization sequence, which binds to the donor 
plasmid and allows amplification to occur, usually this is 18-21 bp, and should be checked against the rest of the donor 
plasmid for sequence identity. The forward primer contains an additional element of the KOZAK sequence, which provides 
an effective translational start. 
 
Phusion Hot start flex 2x master mix (Biolabs, M05365) was used as per manufacturer’s instructions for the 2 step PCR, due 
to the high Tm of the primers. The reactions were performed with and without DMSO, and both produced bands at the predicted 
sizes for the long and short isoform when run on a 1.5 % agarose gel.  
The restriction digests of the PCR cloning product and the recipient plasmid were performed as per the Promega protocol for 
a single step double digest in buffer D with XhoI (Promega, R6161) and EcoR1 (Promega, R6011) for 4 hours at  
37 °C. The cutting efficiency in this buffer was 75 % for EcoR1 and 100 % for XhoI.  
The RE digestion products were run on a 1 % agarose gel and the cDNA inserts and digested vector, the DNA bands of interest, 
were cut out and gel extraction performed with QIAquick Gel Extraction Kit (Qiagen, 28115) as per manufacturer’s instructions. 
The purified vector and PCR products were then ligated and inserted into the cells by transformation, done using the TA cloning 
kit reagents and protocol. Recombinant vectors were checked as for TA cloning. The ligation, transformation, colony PCR, 






Mutagenesis was performed using primers described in Table 2.1.1 on the CRACR2A containing vectors, pIRES2_EGFP and 
FG11F (Table 2.1.2), to induce the point mutations seen in the CRACR2A patients described in Chapter 3. The mutagenesis 
was performed with the Q5 kit as per manufacturer’s instructions. The full cDNA sequence in the resulting plasmids was 
checked for accuracy prior to their use in experiments.   
 
2.2.1.9 qPCR 
Both SYBR green and TaqMan probe protocols use the same reaction scheme as can be seen in Figure 2.2.4. Both were run 
on Applied Biosystem machines, QuantStudio™ 5 System 96-well and QuantStudio™ 7 Flex Real-Time PCR System, 384-
well respectively.  
 
 
Figure 2.2.4 qPCR reaction scheme  
Taken from 96 well ABI instrument, but same conditions were used for all protocols.  
 
2.2.1.9.1 TaqMan protocol 
Applied Biosystems TaqMan MGB (minor groove binder) probes are dual-labelled probes with a 5' fluorescent reporter dye 
and a 3' nonfluorescent quencher (NFQ). The NFQ offers the advantage of lower background signal, which results in better 




This method, used for the STING patient monocytes TaqMan experiment, was taken from Srikanth et al., 2019. In summary, 
monocyte stimulation was performed on negatively selected monocytes (Section 2.2.3.4 for details). Half the cell were 
stimulated for 20 hours with 100 units/mL IFN alpha 2A (Table 2.1.3). cDNA was generated (Section 2.2.1.6) and real-time 
qPCR was performed using TaqMan Universal PCR Master Mix (ThermoFisher, #4304437) using FAM-MGB probes for 
detection of the following: MX1 (Hs00895608_m1), IFI44 (Hs00951349), IFI44 (Hs00915292_m1), IFI27 (Hs01086370_m1), 
ISG15 (Hs00192713_m1), CXCL10 (Hs01124251_g1), RSAD2 (Hs01057264_m1), IFIT1  (Hs01675197_m1), 
IFI6  (Hs00242571_m1), OAS1  (Hs00973635_m1), IL6  (Hs00985639_m1), and HPRT1 (Hs99999909_m1).  
The relative abundance of each transcript was normalized to the expression level of HPRT1 to obtain ΔCT and further 
normalized to the values obtained for healthy controls to obtain ΔΔCT. 
 
 
2.2.2 Clinical Immunology 
All tests described in this section were performed by the Leeds Clinical Department at St James’s University Hospital (SJUH) 
and results supplied by Clive Carter. All tests were performed following standard protocols and standard operating procedures 
(SOP) of the clinical lab. More details can be found at https://www.leedsth.nhs.uk/a-z-of-services/pathology/.Tests run by this 
service include: 
• Cell counts 
• T cell expansions  
• Immunoglobulin (Ig) counts 
• HLA-DR levels 
• T cell spectratyping 
 
 
2.2.3 Blood work 
Patient and healthy control blood was used to obtain DNA, cDNA, protein and whole cells from PBMCs for further testing. The 




Table 2.2.2 Blood samples 
 
 
Predicted amount of cell/blood component gained from 1 mL of healthy control whole blood, using the experimental 
methods listed.  
 
2.2.3.1 Isolation and storage of PBMC 
Peripheral blood was collected by venepuncture in heparin or EDTA tubes and PBMCs were isolated by density gradient 
(lymphoprep, STEMCELL technologies) as per manufacturer’s instructions. Cells were counted and then either used in 
functional studies or stored. For functional studies the cells were cultured in RPMI or underwent additional isolation processes 
as detailed in Section 2.2.3.3. The cells were otherwise stored as follows: 
• As protein - 5-10x106 cells lysed in NP40 lysis buffer (VWR, J60766 ) with cOmplete Protease Inhibitor Cocktail (Roche) 
• As cells - 5-10x106 cells frozen at -80 °C in heat inactivated foetal calf serum with 10 % DMSO 
For calcium flux experiments using the Flex station, SepMate (STEMCELL technologies) tubes were used to speed up isolation 
of lymphocytes to allow time for further processing.  
 
2.2.3.2 Plasma preparation from whole blood 
Blood collected in serum tubes was spun for 10 minutes at 1500 x g at 4 °C. Plasma was then removed and stored in 500 µL 
aliquots at -80 °C.  
Sample  
Average yield from 1 
mL human whole blood 
Method details 
DNA 40 µg 
QIAamp DNA Blood Maxi Kit (QIAGEN, 51192) used 
on ETDA whole blood samples as per manufactures 
instructions 
RNA 3 µg See Section 2.2.1.6 
Protein 30 µg See Sections 2.2.6.1.2 and 2.2.6.2.2 
PBMC cells 5,000,000 cells See Section 2.2.3.1 





2.2.3.3 Isolation of specific cell types  
PBMCs isolated by gradient separation contain many different subtypes of immune cells (StemCell, 2019).  
 
2.2.3.3.1 T cells  
T cells were isolated from patients and healthy controls for functional studies. Different methods for cell selection were used 
based on the exact experimental requirement as well as for optimisation. 
The cell isolation and separation techniques that provide the highest purity and specificity are antibody binding passed 
techniques, such as fluorescence-activated cell sorting (FACS) and bead‐based cell sorting (Andrä et al., 2020). In this project, 
FACS was initially used to isolate CD4+ and CD8+ T cells when calcium flux was being measured by flow cytometry. When 
using this method many of the cells became activated due to the physical manipulation of the cells. This meant that the baseline 
calcium flux of the cells was very high and the cells did not respond well to further activation. Letting the cells rest after FACS 
did not always improve the baseline readings and so FACS was determined to be unsuitable for function based experiments.  
Bead based separation also uses antibodies so has high specificity but has the added benefit of negative selection. In this 
method, all cells are bound to the column except for the cells of interest, which have therefore been manipulated as little as 
possible.  
 
2.2.3.3.2 Negative selection columns 
T Pan isolation kit (MACS Miltenyi Biotec, 130-096-535) with LS columns was used on PBMCs as per manufacturer’s 
instructions (Section 2.2.3.1). 
 
2.2.3.3.3 Culturing  
Culturing PBMCs for extended period of time in the presence of specific stimuli can result in the proliferation and expansion of 




limited number of cells are available, but it can result in a biased population, which does not fully represent the distribution of 
cells in the original blood sample. This is a result of different subpopulations responding and proliferating better to specific 
stimuli (Geginat, Lanzavecchia and Sallusto, 2003; Pennock et al., 2013).  
Cells were cultured under high (anti-CD3 10 µg/mL and anti-CD28 10 µg/mL) or low (anti-CD3 2 µg/mL and anti-CD28 5 µg/mL) 
stimulation conditions with 20 U/mL IL-2 (see Table 2.1.3 for details). CRACR2A patient cells described in Chapter 3 could only 
be cultured using low stimulation due to the phenotype of the cells. 
Procedure: 
Day 1 - PBMCs(14x106 cells) that had been stored at -80 °C in freeze media for at least 72 hrs were thawed and then cultured 
in RPMI+10 % FBS for 24 hrs. 
Day 2 and 3 - Cells transferred to anti-CD3 coated plates with soluble anti-CD28 
Day 4-8 – Cells added to anti-CD3 coated plates,  with -anti-CD28 and IL-2 in the media 
Day 9 + – Cells were frozen or used in function studies 
 
2.2.3.4 Monocytes 
Monocytes were used in the TaqMan experiment (Section 2.2.1.9.1), following published protocols (Srikanth et al., 2019). 
PBMC were isolated by gradient separation (Section 2.2.3.1). Monocytes were purified from PBMCs using the Monocytes 
separation kit II (Miltenyi Biotec, 130-091-153,), which uses negative selection. This isolation leaves 3 types of sample available 
for testing: normal PBMCs, monocytes and the PBMCs without monocytes or non-monocytes (NM), the cells that bound to the 
negative selection column and was eluted as per the manufacturer’s instructions. 
 
2.2.3.5 In vitro B cell differentiation 
PBMCs were isolated from peripheral blood via density gradient centrifugation (Lymphoprep, Allere Ltd.) and incubated with 
antibody cocktail from memory B-cell isolation kit (Miltenyi, negative selection) and then anti-biotin microbeads.  
B-cell purity was assessed by flow cytometry and the cells cultured in IMDM + 10% HIFBS, Lipid Mixture 1 and MEM amino 
acids solution. The B-cells were stimulated with CD40L and F(ab’)2 anti-IgG/M and cultured sequentially with cytokines 




Enzyme-linked immunosorbent assay (ELISA) for immunoglobulin IgM and IgG detection were performed with Human IgM 
ELISA Quantitation Set (E80-100) or Human IgM ELISA Quantitation Set (E80-104) (Bethyl Laboratories Inc, USA) according 
to the manufacturer’s instructions. 
 
 
Figure 2.2.5 Method overview of B cell differentiation 
Day 0-3: hIL-2 (20 U/mL), hIL-21 (50 ng/mL) and F(ab′)2 goat anti-human IgM and IgG (10 μg/mL). Day 3-6: hIL-2 (20 
U/mL) and hIL-21 (50 ng/mL).  








Figure 2.2.6 B cell differentiation stages 
Cells were stained with hCD19, hCD20, hCD27, hCD38 and h7-AAD for analysis with flow cytometry 
 
 
2.2.4 Transient transfection methods 
2.2.4.1 Nucleofection  
Nucleofector Kit V (Lonza, VACA-1003) was used with the corresponding Nucleofector 2b Device, a single cuvette 
electroporation device, due to its high transfection efficiency reported with Jurkat cells. The kit was used as per manufacturer’s 





Transient gene silencing using RNA interference was done using siRNA. The dsRNA has a two nucleotide overhang at the 3’ 
end that activates RNAi, leading to the degradation of mRNAs in a sequence-specific manner dependent upon complementary 
binding of the target mRNA (Keefe, 2013). 
The siRNA was selected on the recommendation of Dr Lynn McKeown (University of Leeds), due to optimisation experiments 
performed in their lab using HUVEC and HEK293 cells. The siRNA (ThermoFisher, siRNA ID n341045) binds to the promotor 
region of the human EFCAB4B gene which encodes for CRCAR2A. The sequence details are not available in the genomic 
map provided by the company, which only shows where it binds in relation to the coding region of the protein as shown in 
Figure 2.2.7. 
For optimisation of siRNA experiments, transfection efficiency was tested using pmaxGFP Vector. The GFP expression was 





Figure 2.2.7 siRNA CRACR2A binding location 
This image was provided by ThermoFisher.. The XM_01152 region is the CRACR2A transcript on the human 
chromosome. The siRNA ID n341045, highlighted in green, binds to the promotor of this gene. 
As a negative control, to check transfection efficiency and the effect of siRNA delivery to the cell, Silencer Negative Control 
#1 siRNA (Invitrogen, AM4611) was used.  
 
2.2.4.2 Electroporation 
Electroporation was performed using 15 µg plasmid of interest and 5 µg FG11F with EGFP (Figure 2.2.8) in each cuvette. The 
collected cells were resuspend in 10 mL of OPTI-MEM (Gibco, 31985062), counted, spun and resuspended with 3x106 Jurkat 
cells in 400 µL OPTI-MEM per cuvette. The cells and DNA were added to the cuvette, and incubated at RT for 15 minutes, 
before being mixed and pulsed (210 V for 40 ms), then rested for 15 minute at RT in the cuvette. The cells were then 
resuspended in 2.5 mL of prewarmed media and cultured for 24 hrs. The GFP expression was checked and the cells pelleted 






Figure 2.2.8 FG11F plasmid map 
The map and plasmid were gifted by Gwack lab (UCLA). Cloning involved removal of the EGFP and insertion of the N-
FLAG CRACR2A mutants.  
 
 
2.2.5 Generation of stable cell lines 
Viral transduction was used to create knockout (KO) Jurkat cell lines, and to stably express mutant CRACR2A. A 2nd generation 
lentiviral system was used, gifted by the Gwack lab (Srikanth et al., 2016; Woo et al., 2018).  
All viral work at Leeds University was done in compliance with generic Class 2 risk assessment Ref-GM559/99.3. The lentivirus 
was made by calcium phosphate or TransIT transfection, of the plasmids into donor cells (HEK293T or 293FT cells 
respectively). The lentivirus containing FG11F or pLKO.1 plasmids was secreted into the supernatant which was added to 




incubation in 10 % Virusolse+ solution, and the target cell kept from regular culture labs until sufficient passages had taken 
place to ensure all virus is removed.  
The mutant expression vectors FG11F (Figure 2.2.8) had a N-terminal FLAG tag at the 5’ end of CRACR2A full length 
sequence. The gene was integrated and expression activated by the UbC promoter. However, expression can also occur 
without integration of the sequence in a transient manner as seen when the FG11F plasmid was used in electroporation 
experiments. No selection was used for the expression of CRACR2A mutants. Inappropriate genetic transfer was guarded 
against as the packaging and envelope proteins needed for viral production were encoded on separate plasmids (Figure 2.2.9, 
Figure 2.2.10) and only the region between the viral LTRs of the transfer vector was packaged within the viral capsid.  
 
 
Figure 2.2.9 psPAX2 map 
psPAX2 and pMD2.G were gifted by the Gwack lab and amplified by QIAGEN plasmid mini and maxi prep kits as per 
manufactures instruction. Risk of reactivation was significantly reduced by the viral components being encoded on 
separate plasmids (pMD2.G – VSV-G expressing envelope plasmid, psPAX2 – gag, pol, rev, tat), with wild-type virulence 
and replication genes deleted and the lentiviral transfer vector (FG11F) containing a modified, self-inactivating 3' long 
terminal repeat (LTR) which renders the resulting lentiviral particles replication incompetent.  






Figure 2.2.10 pMD2.G map 
See Figure 2.2.9 for description. pMD2.G was a gift from Didier Trono (Addgene plasmid # 12259 ; 
http://n2t.net/addgene:12259 ; RRID:Addgene_12259) 
 
2.2.5.1 Generating KO CRACR2A cells 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) was used to generate KO CRACR2A cells. The guide 
RNA was designed and optimised by the Gwack lab, using the LentiCRISPR lentiviral CRISPR/Cas9 and single guide RNA 
system by GeCKO (Figure 2.2.11). The one vector system, contains two expression cassettes, hSpCas9 and the chimeric 
guide RNA. The guide RNA binds to a specific region thought to be important for expression of a specific gene. The cas9 
enzyme is then able to cleave the target DNA strand and DNA repair mechanisms in the cell repair the cleavage by removing 




The method used for making KO cell lines was the same as for expressing CRACR2A mutants (Sections 2.2.5.2, 2.2.5.3 and 
2.2.5.4), but with different vectors and the additional step of 4 µg/mL puromycin (Sigma, P8833) selection 48 hrs after first 
addition of virus. 
 
Figure 2.2.11 LentiCRISPR (pXPR_001) 
The plasmid contains two expression cassettes, hSpCas9 and the chimeric guide RNA. The vector can be digested using 
BsmBI, and a pair of annealed oligos can be cloned into the single guide RNA scaffold. The oligos are designed based 
on the target site sequence (20 bp) and needs to be flanked on the 3' end by a 3 bp NGG PAM sequence. 
The CRACR2A shRNA sequence used was TTTCAGCTTGGTATTCTCAGC, referenced as hCRACR2A_shRNA2 
(mature antisense) in Woo et al., 2018, which binds in exon 7, in the region coding for amino acids 303-307. This region 
is found in the coiled coil domain that exists in both the long and short isoform of CRACR2A. 
 
2.2.5.2  Calcium Phosphate transfection 
Calcium phosphate transfections were performed on HEK293T cells that were at 60-70 % density in a 10 cm cell culturing 
plates. 8 µg plasmid of interest (FG11F, pLKO.1 scramble or pLKO.1 shRNA) and 4 µg each of packaging vectors (pMD2G, 
psPAX2) were mixed with 420 µL dH2O and 260 mM CaCl2 (Sigma, C1016). This mixture was added dropwise to 500 µL 2x 
HBS while vortexing. The solution was then incubated at RT for 1-1.5 hours and then added dropwise to the HEK293T donor 
cells. The cells were incubated overnight and transfection efficiency checked, using the FGF11 empty plasmid that expresses 
GFP, using a florescence microscope. The media was replaced with fresh media (less media was added, to make a more 
concentrated viral supernatant) and incubated for a further 24 hours, before collecting the supernatant containing the virus, by 
centrifugation at 4000 rpm for 20 minutes at RT. The supernatant could be collected for an additional day. The supernatant 
could be stored at 4 °C for 24 hours, or at -20 °C for long term storage. However, the virus is most active when fresh. 
 
2.2.5.3  Trans IT 
70 % confluent 293FT cells in T25 flasks were used for TransIT transfections. 1 µg plasmid of interest (FG11F, pLKO.1 




31985062), with 8 µL TransIT x2 (Mirus, MIR 6003), which was then incubated at RT for 15-30 minutes, before being added 
dropwise to cells. The cells were incubated at 37 °C, 5 % CO2 for 12-15 hours, before replacing the media. 
All the supernatant from the cells was collected for the next 2 days, by centrifugation at 4000 rpm for 20 minutes at RT, and 
the media replaced. 
 
2.2.5.4 Transduction 
The fresh supernatant of donor cells was generated using either calcium phosphate or TransIT protocols. 2 mL of supernatant 
containing 2nd generation lentivirus was added to Jurkat cells. 1 hour before the addition of the supernatant, Jurkat cells were 
plated at 0.5-1 million cells per well (in a 6 well plate) in 2 mL of Jurkat media, with additional 5 µg/mL of polybrene (Sigma, 
TR-1003) and 10 mM HEPES (Sigma, H0887). With the addition of the supernatant, each well contained 4 mL of media. This 
was then spun at 2000 rpm at 25-32 °C for 1 hour and incubated overnight at 37 °C (spinfection). The transduction was repeated 
the next day if transfection efficiency was low, without the addition of polybrene. 
 
2.2.5.5 MTT assay,  
MTT, a yellow tetrazole, is reduced to purple formazan in living cells. This change can be read by a plate reader and so the 
proliferation or death of cells can be monitored. In this project MTT assays were performed during the process of generating a 
puromycin kill curve, in order to determine how much puromycin would kill all cells.  
All MTT assays were performed with 3 controls, media only wells for background readings, cells only for positive/no death and 
50 % DMSO for complete death. All conditions were performed in triplicate.  
 
Day 1 - Cells are added to a 96 well plate. 50,000 Jurkat cells per well or 20,000 HEK293 cells 
Day 2 – Drug of interest added at range of concentrations. 
Day 3 or 4 – 20 µL MTT reagent (Sigma, M5655) was added to cells at 5 mg/mL for 4 hrs at 37 °C, while protected from light. 




was added immediately, the plate shook for 15 minutes to resuspend the formazan precipitate and the fluorescence read at 
560 nm.  
 
 
2.2.6 Protein studies 
2.2.6.1 Western Blot (Method A) 
Method used at the University of Leeds. 
2.2.6.1.1 Reagents 
Blocking buffer - 5 % NFDM (dried milk powder[Marvel]) in PBS  
Lysis buffer - NP40 lysis buffer (VWR, 18C1456418) and c0mplete tablets (Roche, 17113900). 
PBS - PBS (Invitrogen, 003002) tablets in denoised water 
Ponceau stain – 0.1 % (w/v) Ponceau S (Sigma-Aldrich, P3504) in 5 % acetic acid (Sigma-Aldrich, 338826) 
Transfer buffer – 1 x Bolt transfer buffer (20x Invitrogen, BT0006), 10 % Methanol (ThermoFisher) and deionised water, 
protected from light and kept at 4 °C until used.  
Wash buffer – 0.1 % Tween 20 (Sigma-Aldrich, P9416) in PBS 
 
2.2.6.1.2 Cell lysis 
The cell pellets were washed in PBS twice to remove media and then were resuspended in the lysis buffer for 10 minutes on 
ice and then centrifuged at 4 °C at 12000 x g for 10 minutes. They were then stored at -80 °C or the protein concentration 
measured immediately using a Pierce BCA Protein Assay Kit (Thermo Scientific, 23225) following manufacturer’s instructions. 
 
2.2.6.1.3 Protocol 
Samples were prepared so that 20 µg of protein was added to each well, using the BCA results. The cell lysate and 4x Bolt® 
LDS Sample Buffer (Invitrogen, B0007) were mixed and the volume made up with fresh lysis buffer. The samples were heated 




Bolt™ 4 to 12 %, Bis-Tris, 1.0 mM, Mini Protein Gel, 10 or 15 well gels (Invitrogen, NW04120BOX or NW04125BOX) were 
loaded, with protein ladder (Color-coded Prestained Protein Marker, Broad Range 11-250 kDa [Cell Signalling Technologies, 
14208]) and run for 30 minutes at 60 V and 1.5 hours 120 V in Bolt® MOPS SDS Running Buffer (20x, Invitrogen, B0001). The 
electrophoresed proteins were transferred onto Polyvinylidene Difluoride membrane (PVDF) membranes (0.4 5 µm, Roche, 
03010040001) using the wet sandwich method and cold transfer buffer at 20 V for 2 hours. 
After transfer the total protein transfer was checked using ponceau stain. The membrane was then washed twice for 10 minutes 
each on a shaking platform before blocking for 1 hour while shaking. The primary antibody was added as required and 
incubated overnight at 4 °C. The washing procedure above was then performed 3 times and the secondary antibody with a 
HRP tag (see Table 2.1.3 ) was added for 2 hours at RT.  
For visualisation the SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Scientific, 34579) kit was used as 
per manufacturer’s instructions, together with the ChemiDoc MP Imaging System (Bio-rad). 
 
2.2.6.2  Western Blot (Method B)  
Western blot method used during UCLA secondment.  
2.2.6.2.1 Reagents  
40 % Acrylamide (Sigma, A7168) 
10 % ammonium persulfate - APS (Sigma, A36376) in water  
RIPA buffer - RIPA buffer (R0278) with 1 in 2000 Leupeptin (L2884), 1 in 2000 Aprotinin (A1153), and 1 in 100 
Phenylmethanesulfonyl fluoride (PMSF, P7626) all from Sigma 
2x SDS Loading Dye with Beta-Mercaptoethanol – 4x Tris-Cl/ SDS (pH 6.8), 200 mL/L Glycerol, 40 g/L SDS, 20 mL/L of Beta-
Mercaptoethanol, 10 mg/L Bromophenol Blue 
10x SDS PAGE Running Buffer -  30.3 g/L Tris Base (Calbiochem, 643310), 144 g/L Glycine (Calbiochem, 4840), 10 g/L SDS 
(Promega, H5114) 
10x Transfer buffer – 30.4 g/L Tris Base (Calbiochem, 643310), 144.2 g/L Glycine (Calbiochem, 4840) 
Tetramethylethylenediamine (TEMED, Sigma, T9281) 
Tris-buffered saline-Tween (TBST) buffer – 20x TBS (VWR, J640), 20mL/L Tween 20 (Sigma, P1379) 
4x Tris SDS -  182 g/L Tris Base (Calbiochem, 643310), 4 g/L SDS (Promega, H5114), pH adjusted with HCl to pH 8.8 or 6.8 





The recipe for 10 % SDS PAGE gels is shown below. Reagents are listed in the order of addition. TEMED was added last. 
 
Reagent Resolving gel (mL) Stacking gel (mL) 
Water 9.78 2.55 
40 % Acrylamide 5 0.4 
4x Tris SDS 5 (pH 8.8) 1 (pH 6.8) 
10 % APS 0.2 0.05 
TEMED 0.02 0.005 
 
2.2.6.2.2  Cell lysis 
Lysate was made from 4-5 million Jurkat cells either in RIPA buffer or by sonication. The cell pellet was washed once in PBS 
before lysis. For RIPA buffer, the cells were kept on ice for 30 minutes and vortexed every 10 minutes, then spun at 4 °C at 
14000 x g for 10 minutes, then mixed at 1:1 ratio with 2x loading dye and heated for 10 minutes at 65 °C, before being spun 
down and loaded into the SDS gel. For sonication, loading dye was added directly to the washed cell pellet. The cells underwent 
ultrasonication for 2 minutes, with 10 second pulse and 10 second rests 6 times, before being heated in the same way as the 
RIPA buffer lysate. 
 
2.2.6.2.3 Protocol 
10 % SDS PAGE gel , with 15 wells was run. 20 µL of each lysate was added per lane, and the molecular weight marker used 
was Precision Plus Protein Dual colour standard (Biorad, 1610374). Gels were run at 40 V for 30 minutes and then at 100 V 
for 2 hours. Protein transfer onto PVDF 0.2 µm membrane (Thermo Scientific, 88520) was conducted at  300 mA for 1 hour in 
cold transfer buffer. All membranes were checked with Ponceau S staining after transfer.  
The membrane was washed 3 times for 10 minutes each in TBST, blocked in 5 % milk at RT for 1 hour with the liquid changed 
once during that time. Then the membrane was incubated overnight at 4 °C with the primary Abs. If the Ab was diluted in 5 % 
BSA instead of milk, additional wash steps were performed before incubation, with water, then TBST. 
For visualisation, the membrane was rinsed in running water before being washed 3 times for 10 minutes in TBST. It was then 
incubated for 1-3 hours at RT with the secondary Ab at 1:5000. Washing was repeated and the membrane was finally covered 




If the WB needed to undergo unmasking, this was done by rinsing the membrane in water before adding 10 mL of the 
unmasking buffer for 10 minutes, while shaking at 2 minute intervals, before again rinsing in water. The membrane was then 
washed 5 times with water for 1 minute each, then in TBST for 20 minutes, before re-blocking for 1-3 hours before adding the 
new primary Ab. 
 
2.2.6.3 Protein localisation 
IF was performed using an established protocol used by the Gwack lab, to investigate CRACR2A mutant localisation in stable 
cell lines. IF was performed in Nunc Glass Bottom Dishes (Thermo Scientific, 150680). Poly-L-lysine solution (Sigma, 8920) 
was coated on the dishes for 15 minutes at RT, before being washed with water 3 times and left to dry at 37 °C for 45 minutes. 
The cells were resuspended in Ringers solution (2 mM Ca2+, 116 mM NaCl, 9 mM KCl, 5.0 mM HEPES, pH 7.2) and incubated 
for 20 minutes before being washed with Ringers solution. The cells were then fixed with 4 % PFA (Polysciences, 04018) at 
RT for 20 minutes and washed with PBS. To permeabilise the cells PBS with 0.5 % NP40 was used to the cells for 30 minutes 
at RT. Blocking was performed with PBS with 0.5 % NP40 and 1 % FBS at RT for 30 minutes. Before incubation with the 
primary Ab in blocking solution for 1 hour at RT or overnight at 4 °C, the cells were rinsed in blocking buffer, before adding the 
secondary Ab for 30 minutes at RT. Phalloidin (Table 2.1.3) was used to stain the F-actin, this was done with a 1:40 dilution in 
PBS for 30 minutes at RT, followed by 2 PBS washes. The cells were stored at 4 °C in PBS.  
 
 
2.2.7 T cell functional studies 
2.2.7.1 Calcium flux 
2.2.7.1.1 Flow cytometry 
To measure the calcium flux using flow cytometry a calcium sensor dye Indo-1 AM is used, it binds to calcium in the cell. As 
Indo-1 enters the cell the acetoxymethyl ester (AM) group is cleaved off by endogenous enzymes, leaving the calcium sensor 
trapped within the cell. When Indo-1 is excited by ultraviolet (UV) light, it emits light at different wavelengths depending on if 




flux can be monitored. Thapsigargin (TG), ionomycin (I) and T cell receptor stimulation were used to induce calcium influx. TG 
induces sustained calcium influx, ionomycin causes the maximal response and TCR stimulation induces normal physiological 
influx. BTP2 is a specific CRAC channel inhibitor, which was used as a negative control.  
Peripheral blood mononuclear cells (PBMCs) isolated by Lymphoprep and incubated for 24 hrs prior to processing with or 
without 100 nM BTP2 were used. In later experiments, the cells were sorted using Fluorescence-activated cell sorting (FACS) 
before the 24 hr incubation to isolate the T cells. Cells resuspended in supplemented HBSS (1 mM CaCl2, 1 mM MgCl2 and 1 
% FBS) and Indo-1 added at 6 µg/ml and incubated at 37 °C protected from light for 40 minutes. After being washed twice, 
antibodies for gating on T cells were added (CD3 or CD4 and CD8). The cells were then resuspended in supplemented HBSS 
and run on the LSRII 4 flow cytometer. At 50 seconds the first treatment was added of anti-CD3 and CD28 anti-Biotin 
MACSiBead Particles (1:1 ratio), Thapsigargin (1 µM) or Ionomycin (0.5 µM). If the beads were the first treatment, then a 
second treatment of Thapsigargin (1 µM) was added at 7 minutes. Data was analysed using FlowJo version 10. 
 
2.2.7.1.2 Flex Station 
 
Figure 2.2.12 Calcium flux response to TG and TCR stimulation of Jurkat cells 
Performed using protocol in Section 2.2.7.1.2 for the Flex station, all conditions were performed in duplicate with n=4. To 








T cells were incubated for 1 hour at 37 °C in 0 % CO2 with 2 µM fura-2 AM in standard bath solution (SBS) with 0.01 % pluronic 
acid (Invitrogen). Cells were seeded at 5x105 cells/well. T cells were stimulated for 90 seconds by either Thapsigargin (TG) at 
1 µM or the TCR was activated by soluble CD3 at 1 µg/mL (Clone OKT3). For TCR stimulation the plate was coated with anti-
CD28 (1µg/mL, Clone CD28.2). Fura-2 was excited at 340 nm and 380 nm and emission was collected at 510 nm. 
Measurements were taken on a 96-well fluorescence plate reader (FlexStation III, Molecular Devices). Optimisation was 
performed using Jurkat cells, testing different stimulations and cell numbers. The optimal conditions mentioned above were 
used in Figure 2.2.12. 
2.2.7.1.3 Single cell imaging  
This was performed as detailed in Srikanth et al., 2016. 
 
 
2.2.8 Calcium flux 
Gaining meaningful and reproducible calcium flux data from primary patient samples was one of the main challenges in this 
project. In the literature, many different ways have been reported to measure calcium flux and three methods were tested: flow 
cytometry, plate reader and single cell imaging.  
 
2.2.8.1 Comparison of different techniques 
Flow cytometry was used to identify issues in calcium flux by our group previously, by monitoring NK cells and T cell response 
to different stimuli (Parry et al., 2016). Flow cytometry is a quantitative technique. The main benefit to flow cytometry is its 
ability to monitor a large population of cells such as PBMC and with a range of cell surface markers, and so multiple cell 
population responses can be investigated in a single experiment. However, during the optimisation flow experiments performed 
as part of this study it became apparent that using PBMCs and gating on the CD4+CD8+ cell was providing low cell numbers, 
which led to fluctuating calcium responses. As a result, cell sorting was used to isolate T cells. Due to this change in protocol 




CD4+ T helper cells, CD8+ cytotoxic T cells and with the addition of CD45RA marker, naive T cells. As described in this chapter, 
flow cytometry was eventually abandoned due to the high cell number needed for patient and HC cells. 
The main technique for monitoring the calcium flux used other than flow cytometry is confocal microscopy (Srikanth, Jung, Kim, 
et al., 2010; Srikanth, Jung, Ribalet, et al., 2010; Christo et al., 2015; Srikanth et al., 2016). Real time analysis of an individual 
cell can be monitored using a calcium sensor dye, Fura-2 AM which works in a similar way to Indo-1, where a ratio of bound 
and unbound calcium is measured to give the calcium flux in response to stimuli. The individual calcium flux results can be 
pooled to give the cell population response. Confocal microscopy is sensitive enough to measure the oscillations of calcium 
concentrations, as images are taken at regular intervals and the ratio calculated for each image (Christo et al., 2015). This 
technique was not used initially as only small, uncharacterised population of cells can be observed in a single experiment. 
However, when flow cytometry was identified as unsuitable the reduced cell numbers and large data output made this technique 
very beneficial to this project.  
Plate readers can be used to measure calcium flux, using calcium sensor dyes as well (Wilson et al., 2015; Miteva et al., 2019). 
Similarly to confocal microscopy, a small population of cells is used and characterising of the cell subpopulations is not possible 
in real time. This technique requires less specialised equipment and training, but is not as sensitive and doesn’t allow for 
individual cell readings. As a result, it is most useful for cell lines, where only a single cell population is present. 
Whole patch clamp measures the electrophysiological currents of a single cell. Using this method the intracellular calcium 
concentration of the cell can be measured and ER calcium stores depleted by dialysis of the cells, and this stimulates SOCE, 
which can be measured through changes in voltage (Hoover, Lewis and Aldrich, no date; Srikanth, Jung, Ribalet, et al., 2010; 
Mcnally et al., 2012). The main disadvantages of this technique are that the entire cells voltage is monitored, so any subtle 
changes in calcium flux may be missed and that a physiological stimulus cannot be used to induce calcium influx.  
For more subtle changes in the channel function to be detectable, cell lines are needed. As the channel of interest can be over 
expressed or even tagged with green fluorescent protein (GFP) so the channel can be identified for analysis. This means that 
this type of analysis could not be run on patient primary cells (Mcnally et al., 2012). 




Table 2.2.3 Comparison of Calcium methods used 
 
 Flow cytometry Plate reader (Flex Station) Single cell imaging 
Main limitations 
High cell number needed 
One sample run at a time 
No selection of cell possible 
Conditions (16 wells) per experiment 
Highly skilled training and equipment needed 
Only frozen samples were available 
One sample ran at a time 
Main benefit Selection of populations 
Low cell number needed 
Multiple samples run at once 




FACS sorted T cells 
Fresh, negatively selected T cells Frozen, expanded T cells 
Calcium sensor dye Indo-1 Fura-2 Fura-2 
Cell populations 
Total PBMCs measured. 
Cell types could be separated using markers 
Total T cells only 
No visibility of cell types or responses 
Individual cells, but no sub-population available 
Selection of single cells so non responders can 
be excluded 
Minimum cells per sample 10,000,000 500,000 10,000 
Sensitive Medium Low High 
Reproducible No No Yes 
Main use 
Population studies when high cell number is 
available 




The final and most reliable data produced with patient samples was by using single cell imaging. The other two methods 
required high cell numbers to produce calcium flux data, these high numbers were not obtainable from the patient. The patient 
phenotype includes low T cell numbers, which made getting the cell numbers needed even more challenging than it was from 
HC samples. The cell numbers required by flow cytometry in particular were very high, which meant no cell type or population 
calcium data was collected. Exploring the effect of CRACR2A in different cell types including NK cells, could provide more 
insight into its function. Looking at different subtypes could be performed by cell sorting patient samples prior to single cell 
imaging or through the use of mouse models, due to larger cell numbers. 
This inability to distinguish between different cell sub-populations is the main limitation of single cell imaging. Only frozen, 
expanded T cells were available from the patient and HC. The patient phenotype showsTable 3.1.2, Table 3.1.3 and Table 
3.1.4, shows a reduced T cell number, a reduced proliferation response and a greater expansion of the CD8+ T cells compared 
to HC. CD8+ T cells are less responsive to calcium than CD4+ cells (Arrol et al., 2008), and this could be the reason for the 
reduced calcium flux seen in the patient T cells compared to HC. If these experiments were to be repeated, performing flow 
cytometry subtyping after single cell imaging would confirm the cell populations and distribution in the samples. Cell sorting 
could also be performed prior to imaging, after expansion by FACS or selection columns, though it is suspected that cell 
numbers would be low and may result in cell death, particularly in the patient cells due to their reduced proliferation seen in 
culture. In order to explore further if the reduced calcium flux was a result of the CRACR2A mutations alone or the different 
distributions of T cell types, cell line studies were performed due to their single population, as described in Chapter 4. 
 
2.2.8.2 Comparison of calcium flux stimulation  
Thapsigargin was used for sustaining calcium influx through passive store depletion (Srikanth et al., 2016) by inhibiting the 
SERCA ATPase calcium transport into the ER. TG induces an extreme calcium influx as the cell tries to restore calcium to the 
depleted ER when the main channel for this is inhibited. TG is also used in ER stress tests (Beriault and Werstuck, 2013), so 
can place a lot of strain on the cell with extended use. This stimuli was not used in the final calcium flux experiments using 
single cell imaging as minimal samples were available, meaning it was more beneficial to use multiple stimuli on the same 




TCR stimulation is the best representation of the physiological calcium influx and is more likely to show the subtle response 
expected from mutations in CRACR2A as it is a regulator of the CRAC channel rather than one of the core proteins. As a result, 
it was used in all calcium flux experiments. As shown in Figure 3.3.11, TCR stimulation was followed by ionomycin stimulation. 
This is the most extreme stimulus used, as it causes the maximal response and so can be used to check the Indo-1 loading. 
This stimuli can cause cell death and cell stress at high concentrations. This stimulus is also used in cell culture to induce 
cytokine production  
YM58483 or BTP2 is a specific CRAC channel inhibitor in human T cell  which was used as a negative control, in flow cytometry 
experiments that were not shown here (Zitt et al., 2004; Yoshino et al., 2007; Tian et al., 2016). Through the CRAC channel it 
can inhibit cytokine production and proliferation in T cells (Ohga et al., 2008). If the calcium flux experiment were to be designed 
again a different drug for inhibition might be used as BTP2 can reduce the response to both TG and CD3 induced calcium 
influx. This means that any reduction in calcium response seen might have been due to the reduced response to stimuli rather 
than the loss of CRAC channel function. A possible alternative is DPB162-AE which is a very potent and selective inhibitor. It 
acts directly to disrupt the binding of STIM1 and Orai1 and so has no effect on the stimulation of calcium influx (Hendron et al., 
2014; Tian et al., 2016). However, the drugt does cause the ER calcium stores to leak, causing depletion of the store at 
concentrations required for SOCE inhibition (Bittremieux et al., 2017). This leakage from the ER could result in higher Indo-1 
ratio readouts as the calcium sensor is contained in the cytosol. The overall calcium influx should still be less than the 
uninhibited samples.  
In summary, although a mildly reduced calcium flux could be observed in primary cells the small numbers of T cells that could 
be isolated and expanded from the patient prohibited studies that could provide an insight into how the mutations identified 






2.2.8.3 JNK signalling  
This was performed as per Srikanth et al., 2016, in both primary T cells and Jurkat cells. 
 
2.2.8.4 Co-immunoprecipitation 
Co-immunoprecipitation was performed as described in Srikanth et al., 2016. 
 
2.2.8.5 IL-2 expression  
1x106 Jurkat cells were used per condition in a 12 well plate with a final volume of 1 mL per well. The cell were stimulated for 
16 hours, with the addition of BFA (1 in 1000) to all wells, including resting cells, for the last 2 hours. The conditions used were: 
• (Rest) Media only 
• (High) PMA (80nM) + I (1 µM) 
• (Low) PMA (20nM) + I (0.5 µM) 
All centrifuge steps were performed at 2000 rpm at 4°C for 5 mins.  After stimulation the cells were transferred to FACS tubes 
with an additional 3 mL of PBS, centrifuged and washed with 4 mL PBS and all liquid removed by centrifugation. The cells 
were fixed in 4 % PFA for 15 minutes at RT, on a rocker, before being washed as before. Saponin buffer (0.5 %  Saponin 
[Sigma S7900], 1 % FCS, 0.1 % sodium azide in PBS) was added with the hIL-2-PE (eBioscience MQ117H17) antibody for 45 
minutes, protected from light on the rocker at RT. The cells were washed a final time before being resuspended in 350 µL of 
PBS. 
 
2.2.8.6 Intracellular cytokine staining  
1-3x106 primary T cells (in 1 mL media per well in a 12 well plate) were rested the day before stimulation. In fresh media, the 
cells were stimulated for 6 hours with 40 nM PMA and 1 µM ionomycin or 1 µg each of  anti-CD3/CD28. 10 µg/mL of BFA was 
added for the last 2 hours. The cells were then harvested directly into a FACS tube and washed twice with 2 mL of 1 % FBS in 
PBS. The cells were then resuspended in 100 µL PBS with hCD4 FITC [eBioscience OKT4] and incubated on ice for 30 minutes 
and kept in the dark. The washing process was repeated and the cells were then fixed in 100 µL of 2 % PFA in PBS at RT for 




[PE Invitrogen,Clone 4563, Lot 1929458] and IL4 [APC,eBioscience, Clone 8D4-8, Lot E07369-1631]) and incubated for 45 




Chapter 3 CRACR2A and primary cell work 
 
3.1 Introduction 
This chapter presents a patient who fits into both primary immunodeficiency (PID) categories II and III, due to the his antibody 
deficiency (category III) but also T cell deficiency (category II), because of reduced T cell proliferation responses and abnormal 
distributions of subtype populations.  
 
 
3.1.1 STIM1 and Orai1 deficiency 
Deficiency of calcium release-activated calcium channel protein 1 (Orai-1) or stromal Interaction molecule 1 (STIM1) can result 
in severe combined immunodeficiency (SCID). Which presents with severe infections, immunodeficiency, anhidrotic 
ectodermal dysplasia (AED) and congenital myopathy. SCID can be fatal and is normally diagnosed in infancy. The severe 
infections are a result of impaired T cell activation and development. T cells are sensitive to mutations in Ca2+-release activated 
Ca2+ (CRAC) channel proteins as they do not express the homologs Orai2/3 and STIM2/3. Calcium is an essential secondary 
messenger in T cells for cytokine production, proliferation and nuclear factor of activated T cells (NFAT) and nuclear factor-κB 
(NFκB) signalling (Feske, Picard and Fischer, 2010). 
Our group previously identified a STIM1 mutation that broadened the phenotype of CRAC channel deficiencies (Parry et al., 
2016). The mutation caused impaired calcium flux, but no clinical immunodeficiency. The family had normal T cell function but 





3.1.2 CRACR2A  
Calcium release activated channel regulator 2A (CRACR2A) protein, encoded on the gene EF-hand calcium-binding domain-
containing protein 4B (EFCAB4B), was isolated by affinity protein purification and identified as a modulator of Orai1 and STIM1. 
CRACR2A interacts directly with Orai1 and STIM1, forming a ternary complex that dissociates at elevated Ca2+ concentrations. 
siRNA knockdown showed that CRACR2A is important for clustering of Orai1 and STIM1 upon store depletion (Srikanth, Jung, 
Kim, et al., 2010). 
 
3.1.2.1 CRACR2A gene, mRNA and protein 
Human EFCAB4B is located on the reverse strand of Chromosome 12, details about the gene, mRNA and protein are 
highlighted in Table 3.1.1. The details of three protein encoding transcripts are described, only the long and short transcripts 
have been confirmed by western blots in cells and so only these two transcripts are discussed further here (Srikanth, Jung, 
Kim, et al., 2010; Srikanth et al., 2016; The Human Protein Atlas, 2020). Figure 3.1.1 shows the functional domains of the long 
isoform of CRACR2A, the short isoform shares the first 373 amino acids. No confirmed 3 dimensional structure is available for 
the full length protein. Recently the EF hand domain pair structure was published (residues 47-121), as determined by x-ray 
















Biotype UniProt Domains 
CRACR2A-
Long 


















ENST00000535292.1 630 5 5 118 13.87 
Protein 
coding 
H0YFI5 EF hand 
 
 
Gene location Chromosome 12: 3,715,799-3,873,985, reverse strand. Transcript details taken from http://asia.ensembl.org/index.html (accession date 10DEC2020). 








Figure 3.1.1 CRACR2A functional regions. 
CRACR2A has two main transcripts. The short transcript containing the calcium function (amino acid 1-395) and the long transcript containing the additional GTP activity 
(amino acid 395-731). The Rab interacting lysosomal protein (RILP) homology domain functions as a novel effector domain for small GTPase. Figure was taken and 




3.1.2.2 CRACR2A in the CRAC channel  
CRACR2A is a regulator of the interaction between Orai1 and STIM1 as it interacts directly with the cytoplasmic domains of 
both proteins, forming a ternary complex. It binds to a highly conserved region of Orai1, at amino acids 64-93. CRACR2A and 
STIM1 bind to Orai1, their binding partially overlaps and as a result when CRACR2A dissociates from the complex the CRAC 
channel disassembles, as the interaction between STIM1 and Orai1 are weakened. CRACR2A contains two EF hand domains 
that can bind calcium. When the cytoplasmic calcium concentration increases, calcium binds to the second EF domain which 
causes a conformational change, which weakens the tertiary CRAC channel complex. In this way, CRACR2A acts as a 
cytoplasmic calcium sensor which can stabilise the CRAC channel or promote disassembly. In 2010, CRACR2A was identified 
as a novel EF-hand protein that regulates the CRAC channel. In this paper, a lot of work was done in Jurkat cells to learn more 
about the function of the CRACR2A protein (Srikanth, Jung, Kim, et al., 2010). Jurkat cells are an immortalised cell line of 
human T cells as described in Section 2.1.1.6. The Gwack lab showed that siRNA knockdown of CRACR2A caused a reduction 
in calcium flux by 50 % and impaired the production of IL-2, an important cytokine of the immune system. They produced a EF 
hand mutant which could no longer bind calcium, so no longer stabilised the CRAC channel in a calcium sensitive manner. 
This caused increased STIM1 clustering and an increase in cytoplasmic calcium which resulted in cell death. This paper also 
identified the homolog CRACR2B, with an overall protein sequence identity of 36 % to CRACR2A and conserved EF-hand 
motifs and coiled coil domain. The main difference observed between the two homologs is their expression levels in different 
cell types. CRACR2A is present at a higher amount in primary T cells, whereas CRACR2B is more abundant in fibroblasts. 
 
3.1.2.3 CRACR2A’s Rab GTPase related function 
The C terminal end of CRACR2A has Rab guanine triphosphatase (GTPase) related function. Rabs regulate protein transport 
along the endocytic and exocytic pathways in and participate in vesicle budding, membrane fusion, and interactions with the 
cytoskeleton (Wandinger-Ness and Zerial, 2014). Not much is known about the function of this specific domain of CRACR2A 
domain, but it has recently been linked to Jun N-terminal kinase (JNK) signalling, transport and vesicles, as described in more 





3.1.2.3.1 JNK signalling 
The GTP/ guanosine diphosphate (GDP) binding and hydrolysis domain of CRACR2A had been shown to affect JNK signalling. 
JNKs have a range of functions including signalling events underlying tumorigenesis, tumour progression and regulation of cell 
proliferation, invasive migration, therapy resistance, and cell death. JNKs also have a wide range of functions within apoptotic 
mechanisms, including those of necroptosis, ferroptosis, pyroptosis, and autophagy, through the expression of specific genes 
and modulating the activities of pro- and anti-apoptotic proteins by phosphorylation. JNKs are activated by stress, growth 
factors and inflammatory cytokines. JNK-mediated signalling involves a three-tier kinase signalling relay upstream of the JNK, 
such as mitogen-activated protein kinase (MAPK), MAP3K and MAP2K. JNK is activated by the phosphorylation of the 
threonine (T) and tyrosine (Y)-residues of the TXY motif of JNKs. JNK-regulated pathways play a crucial role in both cell 
proliferation and cell death (Dhanasekaran and Reddy, 2017). 
 
3.1.2.3.2 Dynein adaptor protein 
CRACR2A binds to dynein in the presence of calcium, making the interaction calcium dependent due to the EF domains of 
CRACR2A. CRACR2A functions as a activating dynein adaptor and as such can stabilise and activate dynein-dynactin 
complexes into a processive motor, allowing the movement of specific cargo along toward the minus end of microtubules (Wang 
et al., 2019). CRACR2A has been shown to localise to the golgi apparatus, near the minus end of microtubules, when not part 
of the immune synapse with Orai1 and STIM1 (Srikanth et al., 2016). CRACR2A is a large protein compared to classical Rab 
proteins and combines the dynein-activation and cargo recruitment function into a single protein (Wang et al., 2019).  
 
3.1.2.3.3 Weibel-Palade bodies  
CRACR2A dependent differential trafficking has been shown in P-selectin-negative Weibel-Palade bodies (WPBs). Endothelial 
cells selectively release cargo stored in WPBs to regulate vascular function. Histamine causes the release of the 
proinflammatory ligand, P-selectin, while diverting WPBs carrying non-inflammatory cargo away from the plasma membrane 




dependent retrograde transport of WPBs along microtubules. Continued histamine stimulation causes the dispersal of WPBs 




3.1.3  Case study 
The patient this chapter focuses on is an East Asian male who was diagnosed with common variable immunodeficiency (CVID) 
at age 17. There is no family history of immune system disorders or PID.  
 
 
3.1.3.1 Patient immunological profile 
The patient is a 33 year old South Asian male who was diagnosed with common variable immunodeficiency (CVID) at age 17. 
He presented initially with chronic diarrhea, profound panhypogammaglobulineamia (low levels of all immunoglobulins), 
reduced CD4 count and a low T cell activation response, as seen in Table 3.1.2. A detailed CT scan of his chest showed 
cylindrical bronchiectasis of the left lower lobe, lingua and R middle lobe. This appearance remains unchanged 11 years later 
in 2016. He is currently being treated with regular intravenous immunoglobulin (IVIG) replacement therapy. His clinical progress 
since the diagnosis has been uncomplicated and the treatment with IVIG has resulted in excellent control of respiratory 
infections. 
CVID is the most common PID and is predominantly an antibody deficiency. It is a heterogeneous group of disorders which 
have a serum Ig characterised by low IgG and IgA with or without low IgM. The phenotype can vary but most cases present 
with recurrent infections, cytopenia, enlarged lymph nodes, poor antibody response to vaccines and low switched memory B 
cells. 25 % of patients develop autoimmune complications (Giardino et al. 2016). The patient had immunological features of 
the associated with CVID, including low Ig, CD4 numbers below 200 cells/µl (Table 3.1.2, 2017 and 2019) and naive CD4 





Table 3.1.2 Immunological clinical data 
 
Year 2005 2011 2017 2019 Ref 
Lymphocytes Total  (cells/µL) 2880 990 1201 1572 1000-2800 
CD3+ Total  (cells/µL) 2505 733 891 990 700-1200 
CD3+ CD4+ 
Total  (cells/µL) 216 235 148 165 300-1400 
CD27+ CD45RA+ (naïve)%   20.92 12.65 37-97 
CD27+ CD45RA- (memory)%   42.34 47.04 13-76 
CD27-CD45RA- (memory effector)%   36.01 37.67 0.49-25 
CD25+CD127- (Treg)%   0.73 1.6 1-5 
CD3+ CD8+ 
Total (cells/µL) 2080 475 738 840 200-900 
CD27+ CD45RA+ (naïve) %    17.69 20-95 
CD27+ CD45RA- (memory) %    25.16 0.4-18 
CD27- CD45RA- (memory effector) %    16.09 4-100 
CD27- CD45RA+ (effector) %    41.07 9-65 
CD19+ 
Total (cells/µL) 245 102 73 77 100-500 
CD27- IgM+ IgD+ (naïve) %   63.1 89.18 65.0* 
CD24hi CD38hi (Transitional) %   6.7 10.3 6.2* 
CD27+ IgM+ IgD+ (non-switched) %   15.4 3.69 12.5* 
CD27+ IgM- IgD- (switched memory) %   14.7 7.15 16.4* 
Plasmablasts %   0.2 0.4  
CD56+ CD16+ NK cells Total (cells/µL) 144 139 290 486 90-600 
T lymphocyte 
proliferation test 
PHA ↓  ↓ ↓  
Anti CD3 ↓  ↓ ↓  
Immunoglobulin profile 
IgG 1.4 8.4 10.3 8.3 6-16 g/L 
IgA <0.06 <0.06 <0.06 <0.06 0.8-4 g/L 
IgM <0.06 <0.06 <0.06 <0.06 0.5-2 g/L 
IgE    <0.2 1-120 ku/L 
Patient clinical data from first attendance at clinic (2005) and at later follow ups. Data generated by Leeds Clinical Department and supplied by Clive Carter (SJUH). Results 




The patient clinical immunological workup included cell type and subpopulation analysis. The results from these tests are 
detailed in Table 3.1.2, from 2005 when the patient first presented to the clinic up to late 2019. The most immunological test 
that showed the largest deviation from HC reference results were the immunoglobulin results. All immunoglobulin types were 
low and these severely low levels were maintained throughout the four tests performed over 14 years. As a result, the patient 
was placed on immunoglobulin therapy and was suspected of having a B cell defect. However, the B cell counts of the patient 
(CD19+ in Table 3.1.2) were initially found to be in normal numbers until the 2017 and 2019 readings, where they dropped 
slightly below the normal range (100-500 cells/ µL) to 73 and 77 cells/ µL respectively. In contrast, The patient T cell numbers 
appear to be affected in the earlier testing but fall within normal ranges later on. In 2005, the total T cells (CD3+) and the 
cytotoxic T cells (CD8+) have high cell numbers compared to normal ranges. The T helper cell (CD4+) numbers are below the 
normal reference ranges. The CD3+ and CD8+ counts return to normal ranges during all further tests, but the low CD4+ 
numbers persist. The ratio between CD4+ and CD8+ cells in healthy individuals normally leans towards a larger number of 
CD4+ cell, and these are the T cells that expand more readily in response to TCR stimulation. In the patient under study, this 
ratio is shifted. The patient T cells also showed a reduced proliferation response to PHA and CD3, this diminished response 
was observed throughout the 14 years.  
This patient fits into both categories II and III, due to the antibody deficiency (III) but also into the T cell deficiency (II) due to T 
cell proliferation and abnormal populations.  
 
3.1.3.2 B cell differentiation 
The severely low level of all immunoglobulin and normal to slightly low B cell numbers seen in the patient (Table 3.1.2) meant 
a potential B cell defect could exist. The patient and HC B cells were taken into a T cell independent assay, to investigate their 
development and immunoglobulin expression. 
The assay showed normal development of patient B cells compared to HC. This was monitored by flow cytometry using key 
surface markers as described in Section 2.2.3.5, with the characteristic loss of CD20 expression during differentiation and 
CD38 and CD138 upregulated as the cells transition from plasma blasts (CD38+CD138-) to plasma cells (CD38+ CD138+). 




The cell number and expression of IgG and IgM was also found to be comparable to healthy control in ELISAs, as seen in 
Figure 3.1.2. This normal response of the patient B cells in the in vitro assay suggested that the B cells were not directly 
responsible for the patient phenotype as they are able to produce normal levels of immunoglobulins and develop normally into 
plasma cells. Instead, the patient might have disruption to the signalling needed to stimulate the B cells. The T helper cells play 
an important role in B cell development. This cell population was reduced in the patient (Table 3.1.2) and as such the function 
of the patient T cells was investigated.  
 
 
Figure 3.1.2 In vitro B cell count and Immunoglobulin expression 





3.1.3.3 T cell specific clinical tests 
The reduced proliferation response reported over multiple visits in patient T cells (Table 3.1.3), and the normal B cell 
development in vitro, meant that the T cells were a likely candidate responsible for the patient phenotype. As a result additional 
T cell tests were performed during the 2017 check-up.  
The T cell proliferation was shown to be reduced in response to both PHA and CD3 stimulation. With both stimulations the 
reduced proliferation response becomes more profound at the higher levels of stimulation. It appears that the patient cells can 
respond in a more comparable manner at rest and under lower stimulation conditions. At higher stimulation conditions a more 
dramatic difference can be seen in patient and HC, with the patient having lower number of cells, due to the reduced 
proliferation. 
 
Table 3.1.3 T cell proliferation 
 
PHA (µg/mL) 0 5 10 100 
HC 654 119112 152745 150043 
Patient 24 91642 85564 31095 
CD3 (x105 cells/mL) 0 2 1 0.5 
HC 654 123376 161025 179969 
Patient 28 110415 45778 24462 
 
Data generated by Leeds Clinical Department and supplied by Clive Carter (SJUH). Results above (red) or below (blue) 
the HC values are colour coded. The data is displayed in weakest to strongest for both stimulations. For PHA the dose 
was increased and the number of initial cells per condition stayed the same. For CD3 a standard amount of CD3 was 
coated on plates and the initial number of cells added was reduced, therefore increasing the amount of available CD3 per 
cell. 
 
Normally when T cells proliferate the CD4+ population expands faster than the CD8+ cells. The opposite seems to occur in the 
patient, as the CD4:CD8 ratio is shifted compared to HC, both at rest and when stimulated with PHA, as seen in Table 3.1.4. 
This was measured by examining HLA-DR expression in T cells, which is a marker of activated T cells. The CD8+ expansion 





The diversity and development of T cells was further investigated by looking at the β chain of the TCR in the patient, Figure 
3.1.3. Only two specificities were outside normal ranges, Vb5.2 was elevated in the patient and Vb7.2 reduced. This suggested 
that the expression and rearrangement of the β chain is comparable to HC.  
 
Table 3.1.4 T cell populations activated after stimulation 
 
  % CD4 % CD8 
HC 
- 1.26 0.84 
+ 37.56 7.73 
Patient 
- 0.7 8.41 
+ 17.8 40.72 
 
Data generated by Leeds Clinical Department and supplied by Clive Carter (SJUH). Results above (red) or below (blue) 
the HC values are colour coded. PBMCs were stimulated with PHA at 2 µg/mL or at rest for 72 hours at 37 °C. Flow 
cytometry was performed to determine the levels of HLA-DR expressed on the surface of CD4+ and CD8+ populations. 
 
 
Figure 3.1.3 T cell receptor specificities 
Data generated by Leeds Clinical Department and supplied by Clive Carter (SJUH). Flow cytometry was used to 






For this case study standard clinical data was initially available that showed the patient had low levels of all immunoglobulins 
and reduced T cell functions with a shift towards CD8 T cell proliferation. B cell differentiation studies showed that their B cells 
were able to produce IgG and IgM In vitro and so suggested that the patient phenotype was T cell related. In order to investigate 
the possible cause of this, WES was performed and no known genes previously linked to PID were identified. As a result, 
further study was needed on the potential gene candidates identified. Knowing the cause of the patient phenotype can lead 
can potentially lead to better treatment and understanding of their disease.  
In order to identify the potential candidates, the below steps were taken and the findings are detailed in this chapter: 
   
• Confirm potential mutations and their segregation in patient with PID  
• Use primary samples to determine if those mutations are pathogenic and causing of the patient phenotype, by looking 






3.2 Materials and methods 
The method strategies and patient information are described in this chapter. For full method details see Chapter 2.  
 
3.2.1 Segregation of patient mutations when parental DNA was not available  
A polymerase chain reaction (PCR) was performed on patient cDNA to amplify a region that contained all mutations of interest. 
The TA cloning protocol was then done, to isolate a single amplicon per colony within the TA cloning plasmid. The plasmid was 







The results in this chapter focus on a single patient with primary immunodeficiency (PID). Whole Exome Sequencing (WES) 
did not identify any known mutations or genes previously linked to PID.  
 
 
3.3.1 Genetic testing of patient 
WES and the filtering strategy described in Section 2.2.1.1 was performed by Dylan Lawless (University of Leeds). This 
identified mutations in two potential genes of interest: EF-hand calcium-binding domain-containing protein 4B (EFCAB4B, 
protein CRACR2A) and dehydrogenase/reductase 4 (DHRS4).  
These two genes had previously been linked to the function of the immune system but had not been linked to PID. As a result 
further functional testing was needed to determine if the mutations identified by WES could be affecting the protein function 





3.3.1.1 Confirming mutations in DHRS4 gene 
The DHRS4 gene encodes for an enzyme in the short-chain dehydrogenase/reductase (SDR) family. It has nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent carbonyl-reductase activity on a broad set of substrates. It’s role in retinol 
metabolism is of particular interest due to its association with the immune system. Dehydrogenase/reductase 4 reversibly 
converts retinol or Vitamin A to retinaldehyde which is then irreversibly converted into the biologically active, retinoic acid (RA). 
RA can inhibit the generation of B cells  and the differentiation of dendritic cells (DC) which activate naïve T cells (Chen, Welner 
and Kincade, 2009; Raverdeau and Mills, 2014). Gain or loss of function mutations in dehydrogenase/reductase 4 could disrupt 
the metabolism of Vitamin A which could result in a PID with compromised B and T cells, as presented in the patient under 
study here.  
WES was performed and identified a homozygous point mutation at cDNA position c.475 Cga>Tga, which would result in a 
premature stop codon at amino acid R158* (see Table 3.3.1). This residue is highly conserved throughout evolution 
(https://genome.ucsc.edu/) and the mutation was not listed in databases of healthy individuals (gnomAD). As with all enzymes 
the structure of the protein is highly specific and so the function can be easily affected by small changes. In this case, the point 
mutation results in a large change and a potentially truncated protein, reducing the polypeptide chain from 278 residues to 158. 
This truncated protein would not contain the two main residues of action, amino acid 169 which is a substrate binding site and 
residue 182 which is a proton acceptor active site. This means the truncated form of the protein is unlikely to function like the 
wild type protein. The premature stop codon could result in the mRNA being sent for nonsense mediated decay. The nonsense 
mediated pathway is a surveillance mechanism to detect and eliminate mRNA transcripts that contain premature stop codons, 
in order to halt the translation of these transcripts. 
PCR was performed to amplify the DHRS4 exon of interest, exon 4, using patient genomic DNA. Sanger sequencing of this 
PCR product showed the mutation to be in heterozygous form (Figure 3.3.1) instead of homozygous as had been identified in 






Table 3.3.1 DHRS4 mutation  
 
Gene 



























Figure 3.3.1 Sanger sequencing of DHRS4 exon 4 from patient genomic DNA 
Genomic DNA isolation from patient whole blood, PCR and Sanger sequencing were performed as per Sections 2.2.1.3 
and 2.2.1.4.The primers used are shown in Table 2.1.1 (primers A+B). The PCR product was amplified in duplicate and 
run on a 1.5 % agarose gel. The band was found to be about the same size as the predicted amplicon of 299 base pairs. 
They were then directly sequenced using both the forward and reverse primer, and only the forward, A, is shown. The 
black arrow indicates the point mutation C>T and the affected codon is highlighted by a box.  
 
3.3.1.2 Confirming mutations in EFCAB4B (CRACR2A protein) gene 
The two main functional regions of the full length, long isoform of CRACR2A protein are the CRAC channel interaction region 
(amino acids 1-395) and the GDP functional domain (amino acids 395-731) are shown in Figure 3.1.1. All three of the mutations 
identified in this gene by WES fall within the CRAC interaction region and are also present in the shorter isoform of the 
CRACR2A protein. The latter is 395 amino acids long and shares its first 373 amino acids (1119 nucleotides of mRNA) with 
the long isoform.  
The details of the three mutations, all heterozygous, are summarised in Table 3.3.2. Two of the mutations result in an amino 
acid change. The mutation at position 144 is from arginine to a glycine, changing the residue from a large positively charged 
side chain to a small non-polar sidechain. This could affect the  protein conformation. Residue 144 is conserved throughout 
evolution and this mutation has not been found to date in the gnomAD database of normal population. This could mean that 
this residue is important to the structure or function of the protein. The other missense mutation is at position 278, and results 
in a conservative change from glutamic acid to aspartic acid. As both amino acids have small negatively charged side chains, 
a smaller effect on function may be predicted compared to if it was a non-conservative amino acid change. This mutation is 
present in the gnomAD database, but only in the heterozygous state and at a rare allele frequency of 0.00014. The frequency 




resulted in a premature stop codon at amino acid 300, which is normally glutamic acid. This residue is highly conserved 
throughout evolution, and no mutations were recorded in gnomAD. The premature stop codon, could lead to a truncated protein, 
without the end of the coiled coil domain of the short isoform and without any GTP functional region in the long isoform. The 
mRNA may be sent for nonsense mediated decay.  
Sanger sequencing was performed on the patient genomic DNA and confirmed all three mutations in EFCAB4B, c.430 A>G, 
c.834 G>T and c.898 G>T, that were identified by WES, all of which were heterozygous, as seen in Figure 3.3.2. The orientation 
of these mutations needed to be confirmed to see if they were all present on the same allele, or if they were compound 
heterozygous, without any wild type (WT) allele being present, and therefore increasing the likelihood of the mutations being 
















Not in gnomAD. Heterozygous R144S and R144I 
reported at frequency 0.000008 & 0.000004 
Not on ExAC, Heterozygous R144S and R144I 







Heterozygous present 0.00014, 0.00085 East Asian 





p.300 E>* Stop gained Not in gnomAD Not on ExAC 
 
Transcript ENST00000440314.7, of the long isoform. Resources of exome and genome sequencing data :https://gnomAD.broadinstitute.org/ (accession data 







Figure 3.3.2 Sanger sequencing of EFCAB4B from genomic DNA of patient.  
Genomic DNA isolation from patient whole blood, PCR and Sanger sequencing were performed as per Sections 2.2.1.3 and 2.2.1.4. Primer pairs C+D, E+F, and G+H 
were used to generate PCR products that were then sequenced directly using the corresponding forward primer C, E and G (Table 2.1.1). The PCR products was 
amplified in duplicate and run on a 1.5 % agarose gel, to confirm the predicted sizes. They were then directly sequenced using both the forward and reverse primers 




G C C GG T A T G G T G G T CC T CC T CA T T C C C T C T G C T C C CA T T C C T T T G CA G
1 10 20 30 40
G C TG G AAG GT CA G T G C AC A G C C C T G C A T C A T G A CA A G C A T G A G AC CA A G G C T
50 60 70 80 90
T G A G A AT AC CA A G C T G A A A C T CA C T A A C C A G G AG C T G G C C C G G G A G C T G G A
100 110 120 130 140
AGC G G AC T T C C T G G G AG C T C C A G G A T G C T C A G C A G C A G T T G G A A A G C C T C C
150 160 170 180 190
CA G C A A G A G G C C T G C A A A C T C C A C C A A G A G A A G G A G AT G T G A G T C C A G C C T
200 210 220 230 240
TT T G T C C A C T C C T C T G C T G T C T T C C C G C A C C A C T C C C C A C T A T G G G C A T G T C
250 260 270 280 290
3_F_E01_21_11_LR_CRACR2A_DHRS4_2016-11-21.ab1  (355 bases)




TAC T T C T C A G C T T G G T C T A T T C G G AT CC T T G T G C CC T G CAC C C C C CA
1 10 20 30 40
A G G TCAC T T C T T C T T CA G C CA G A AT A A C C C A A G T CA G G A A G AT G C A G G T G A A
50 60 70 80 90
A CA G G T G G C C CA G C G C CA T G A A G A G A A G G T G T A T C T G T C C G G A G G G G AT G A G
100 110 120 130 140
G G AT C T G G G C G AC A T G G G C G A A G AT G A G G A A G C C C A G T T C C G G A T G C T G A T
150 160 170 180 190
TG G AC A G AC T T G G A G C C CA A A A G G T G T T G G A A G A G T A A G T G G T G AC A G T G AT
200 210 220 230 240
AT T T G T A G A A C G G A G A C C A G C C T G G T A G G A AC C T C T T C C T G T G T C C A T T C A A
250 260 270 280 290
1_F_A01_21_11_LR_CRACR2A_DHRS4_2016-11-21.ab1  (349 bases)




TTTTG TG A A A G G C C GG G A A A G G G G C C C T G A TGG T G A G T A G G T T C A A G G TG G G
260 250 240 230 220
GG G A A A A A A A A A A T C T A T A A C C C G G G T G T G C T A C A T T T G G G T C C T G T G T GT C C
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3.3.1.3 Mode of inheritance  
After the three heterozygous mutations found (c.430 A>G, c.834 G>T and c.898 G>T) by WES were confirmed by Sanger 
sequencing, their orientation needed to be identified to determine if a WT allele could be present or if the mutations were 
compound heterozygous. This could normally be determined by sequencing genomic DNA from the parents of the proband, to 
create a family pedigree, which would show segregation of the affected alleles. Unfortunately, initially no parental DNA was 
available. Instead cloning was performed on the patient cDNA to separate the maternal and paternal alleles. 
RNA was extracted from the patient PBMCs, and reverse transcription was performed using random primers and oligo dT 
primers, to form the stable cDNA. PCR was performed on the cDNA, to amplify the region that contained all three mutations 
within a single 731 base pairs long amplicon. The PCR product was sequenced before cloning and showed the heterozygous 
mutations at all three locations (Figure 3.3.3A), although the chromatogram showed some peaks to be present at higher 
concentrations (c.430A [WT], c.834T and c.898G [WT]). When TA cloning and transformations were done on the amplicons, 
ten colonies were selected and checked for the presence of CRACR2A using colony PCR. Of the ten selected, eight showed 
bands at the expected size on an agarose gel. These colonies were miniprepped and sequenced at all three mutation locations. 
All of the colonies contained the same sequence at the three mutations loci, c.430A [WT], c.834T and c.898G [WT], a 
representation of which is shown in Figure 3.3.3B. None of the colonies showed the c.430G and c.898T mutations, this was 
potentially as they were present at a lower concentration, as seen in the initial cDNA sequencing. This concentration 
discrepancy could have been a result of the cDNA generation, or more likely due to the presence of the premature stop codon 
caused by the mutation at position c.898T, which can result in mRNA being sent for nonsense mediated decay and so being 





Figure 3.3.3. Sanger sequencing of patient cDNA and TA clone.  
The 731 bp amplicon was created using I and L primers from Table 2.1.1 (located in exon 3 and exon 10, Ta – 66 °C). 
The 731 bp amplicon was generated from the patients cDNA and cloned using the TA cloning kit. Sequenced directly 
using the forward primer I. A) sequencing of original PCR product from patient cDNA and B) sequencing of representative 
clones 
 
The cDNA cloning and sequence analysis suggested that the mutation c.834 G>T was present on its own in one allele. This 
would imply that the other two mutations, c.430 A>G and c.898 G>T, were present on the second allele. Hence, the patient 
had compound heterozygous mutations in the EFCAB4B gene. This increases the likelihood of the mutations identified as 
being pathogenic.  
Later in the project, samples from the Mother and maternal Grandmother became available for Sanger sequence analysis. 




are shown in Figure 3.3.4 as both individuals showed the same mutations at each location. The sequencing data clearly showed 
that the heterozygous mutations were present at positions c.430 A>G and c.898 G>T, but wildtype at position c.834 G>T. This 
information, with the original cDNA and TA cloning data analysis confirms that the patient mutations are compound 
heterozygous, as summarised in Figure 3.3.5.  
 
 
Figure 3.3.4 Sanger sequencing of maternal DNA.  
The results from mother’s genomic DNA from whole blood are shown here. Experiments were performed as described in 
Figure 3.3.2. For c.834 the reverse primer sequence is shown.  
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Figure 3.3.5 Orientation of mutations in patient alleles.  
Stars indicate the locations of the mutations on the polypeptide, where these bases are WT this is indicated in the image. Maternal allele mutations confirmed by Sanger 




A pedigree for the proband was also produced from results of the sequencing of the maternal gDNA of the patient, as seen in 
Figure 3.3.6. As no paternal DNA was available for sequencing, the paternal alleles cannot be confirmed directly. However, 
segregation of the heterozygous c.834 G>T can be inferred from the patient cDNA cloning data, and clear absence of this 
mutation in the maternal line. The presence of this mutation on gnomAD as heterozygous at a very low allele frequency of 
0.00014 or 0.00095 in the East Asian population further suggests that the c.834 G>T mutation was more likely to be inherited 
through the paternal line instead of arising spontaneously in the patient.  
 
 
Figure 3.3.6. Pedigree diagram for patient.  
The pedigree diagram was generated using the software available at http://www.pedigree.varphi.com/cgi-





3.3.2 Protein expression in patient cells 
Once the orientation and the compound heterozygous nature of the CRACR2A mutations was confirmed, the expression of the 
protein in a healthy control (HC) and patient PBMCs was compared using western blots. A range of CRACR2A antibodies were 
tested in Jurkat cells and with HC PBMCs with varying results. The bulk of the repeats were performed with a Proteintech Ab 
in Table 2.1.3. When it came to western blotting using protein lysates from patient cells, there were a range of issues that 
presented themselves. There was limited sample available and the majority was used for calcium flux experiments. Thus, for 
some western blots the samples were from the flow though of the negative selection T cell columns, so both experiments could 
be performed from a single blood sample, as seen in Figure 3.3.7. This limited the amount of T cells in the PBMCs which was 
already low due to the patient phenotype. Low T cells were a problem, since these cells are known to have the highest level of 
expression of CRACR2A in PBMCs (Srikanth, Jung, Kim, et al., 2010). The patient had a lower total protein concentration 
compared to HCs, as determined by BCA assay and total protein staining of the WB membrane by ponceau S staining. As a 
result, for every WB run with patient sample the maximum amount of patient lysate was loaded, which often appeared to be 
less than the target of 20 µg per well, as seen in the loading controls. 
An example of the western blots produced with fresh patient cells and HC is presented in Figure 3.3.7. The loading control 
GAPDH is low for the patient compared to the HC. The long full length isoform of CRCRA2A (90 kDa) appears to be present 
at a comparable density to HC. The short isoform of CRACR2A  
(45 kDa) was only present faintly or not detected in the patient cells when compared to HC. No band was seen at the predicted 






Figure 3.3.7 CRACR2A protein expression in PBMCs 
Lysate for the non T cells samples was the flow through of the negative section T cell column, using methods in Sections 
2.2.3.3.2. Lysate made in NP40 buffer and 20 µg loaded per well, or maximal loading for the patient, into 4-15 % BioRad 
gradient gels. Protein was blotted with primary antibodies CRACR2A (ProteinTech) 1:800 and GAPDH at 1:10000. More 
details can be found in Section 2.2.6.1. 
 
The western blots were repeated in cultured and expanded T cells for the patient and HC (Figure 3.3.8). The same outcomes 






Figure 3.3.8 CRACR2A protein in expanded T cell population 
This WB data was generated by Sonal Srikanth (UCLA). PBMCs were cultured and the T cells expanded before lysate 
was made by sonication. All method details can be found in Section 2.2.6.2. 
* represent nonspecific bands. These bands are thought to be unspecific as no cleavage sites are seen in the protein 
which would give these theoretical sizes. Due to the small amount of sample available antibody dilutions or no primary 
controls were not performed at this time, but could be run in the future to see if the bands are non-specific.  
 
 
3.3.3 Calcium flux in T cells 
The reduced proliferation response in patient T cells and the normal B cell development observed in vitro, meant that the T 
cells were a likely candidate for the patient phenotype. This was enforced by CRACR2A role in the CRAC channel which is 
essential for T cell function such as cytokine production and proliferation. T cells are particularly sensitive to changes in calcium 




In order to determine if the compound heterozygous mutations identified in CRACR2A were pathogenic, the calcium flux 
response was measured in the patient T cells and compared to a healthy control. Measuring calcium flux in T cells can be done 
using a range of techniques using calcium sensor dyes. The dyes are retained in the cells and fluoresce at different wavelengths 
depending on whether calcium is bound or unbound. The change in florescence can be measured at the two wavelengths and 
the ratio calculated (bound : unbound calcium). A higher ratio means more calcium is bound to the dye, and so shows that 
more calcium is present in the cell.  
The techniques used to measure calcium flux in the patient T cells included:  
• Flow cytometry 
• Florescent plate readers 
• Live cell imaging 
 
 
3.3.3.1 Calcium flux using flow cytometry 
Flow cytometry is a powerful technique as it allows for the grouping of cell types in a mixed population of cells. The markers 
used to separate the different populations can be either internal or external proteins, using specific antibodies with fluorophores 
attached that absorb and emit at different wavelengths. Flow cytometry had been used to compare the calcium flux response 
in STIM1 patient T and NK cells with healthy control in our lab previously (Parry et al., 2016). 
Using flow cytometry to compare the calcium flux response of HC and patient T cells was not feasible. Multiple protocols and 
parameters were tested using both the Jurkat cell line and HC PBMCs. The main limitation of this method was small cell 
numbers isolated from PBMCs. This meant there was only a small number of repeats and conditions that could to be tested 
with each blood sample. The low cell numbers also meant no data was gained from subpopulations of T cells such as T helper 
cells and the high baseline measurements due to manipulation and agitation of the cells. The many limitations of this method 





3.3.3.2 Calcium flux using plate readers 
Due to the issues with low cell numbers during flow cytometry experiments, the Flex Station was a possible alternative method 
of measuring calcium flux in patient and HC T cells. The Flex Station is a fluorescent plate reader that takes multiple readings 
over time. Fura-2 was the calcium sensor dye used with this method. As a plate reader is used, the same cells are measured 
over the length of the experiment, which reduces the cell numbers required compared to flow cytometry, which uses a stream 
of cells. Previously, this techniques has been used to monitor the effect of CRAC channel changes in adherent cell lines, and 
so some method development was needed for suspension cells. Jurkat cells were used to work up the protocol and drug 
stimulations before using HC or Patient T cells, both  isolated using the negative selection columns.  
The experiments differ from the flow cytometry protocol, as more flexibility was available. Instead of having the cell in calcium 
and stimulating them with TG or TCR activation, the cells start in calcium free media. This means that when the cells are 
stimulated the initial response is from the emptying of the calcium stores. In the human primary T cells, not much changes in 
the calcium ratio at this stage. This could be due to the small calcium stores of T cells or because the stores are depleted due 
to processing. Jurkat cells in the initial optimisation showed an emptying of these stores at this time in the experiment and the 
flux response returned to baseline by 900 seconds. At this point calcium is added back into the cells, the stores are replenished 
and the effect of the stimulation is shown. The calcium add back experiments provide additional data points and measurements.  
Patient sample became available for five Flex Station experiments. For the last two of the experiments, a single well of Jurkat 
cells was run as a system check, and both experiments had comparable Jurkat responses to those seen when optimising the 
protocol. Jurkat cells were introduced as an additional control, as well as the HC, because on the 2018-02-12 neither HC or 
patient T cells responded to stimuli or calcium being added back into the system.  
The calcium flux experiments run using patient T cells are summarised in Table 3.3.3. For all of these experiments HC was run 
at the same time as the patient samples. HC gave a response to TG and TCR in most experiments, though there was a lot of 
variability in the maximal calcium influx. This may be because the same HC individual was not available for blood donation for 










HC response Patient response 
2017 10 27 x 
HC with duplicate wells, 
good response 
Low cell number, single 
well only, low/no 
response 
2017 11 22 x 
Had  abnormal response 
 
2 samples isolated 
separately for patient, 
low/no response 
2018 02 12 x 
No response, not added to 
Figure 3.3.9 
No response, not added 
to Figure 3.3.9 
2018 03 14 √ 
Had good response with 
TG and TCR stimulations 
Patient unable to attend  
2018 03 16 √ Had good response 
Peak response 
comparable to HC, 
reduced sustained 
response 
2019 04 13 √ 
Cell number too low, not 
added to Figure 3.3.9 
Cell number too low, not 
added to Figure 3.3.9 
 
The patient T cells gave little to no response in most cases. However, during the 2018-03-16 experiment there was a response 
seen in the patient cells, as seen in Figure 3.3.9. The initial add back response appeared to be comparable to the highest HC 
response, this calcium influx was not sustained, but instead drops off over time which had not been seen in any HCs, giving a 
similar profile as that seen in the Jurkat cell line (Figure 2.2.12) rather than the HCs. 
The Flex Station produced more reliable data than that produced by flow cytometry. However, there were still limitations. There 
was still a higher number of cells needed, only eight wells could be run at one time, no population or single cell calcium data 
was possible and varied responses were seen from the patient sample. Hence, it was hard to fully trust the calcium flux data 
produced using this technique. So, a collaboration was established with the Gwack laboratory (UCLA) to gain access to 





Figure 3.3.9 Calcium flux response to TG, CRACR2A patient T cells compared to HC 
Data from patient and HC displayed from 2018-03-16 (Table 3.3.3). For all these samples a DMSO control was run at the same time and showed a reduced calcium 






3.3.3.3 Calcium flux using single cell imaging 
The Gwack lab used single cell imaging to measure calcium flux in cell lines and primary T cells. This is a sensitive and 
established method and it too uses Fura-2 as the calcium sensor dye. Cells are adhered to a coverslip and solutions can be 
passed over the cells, allowing for changes in calcium concentration and stimulation of the cells with drugs. The cells are 
imaged in real time, with a fluorescent microscope, therefore allowing for a Fura-2 ratio to be generated. Once the experiment 
is complete, the calcium flux of individual cells can be observed over time. The system allows for the filtration of non-responding 
cells during analysis. For each sample, fifty cells were randomly selected for further data collection from the total population 
captured on the coverslip. 
 
3.3.3.3.1 Culture of T cells from frozen 
Due to the nature of the international collaboration, fresh primary samples could not be available for the experiment using 
patient cells. Instead the patient PBMCs were isolated and frozen at -80 °C in Leeds, before being shipped on dry ice to UCLA. 
A T cell culturing and proliferation protocol needed to be developed to expand the T cell population of the patient samples 
available, as freeze/thawing results in a decrease in the viable cell number. 
Before using the patient sample, the experimental approach was tested and optimised using a HC sample. HC PBMCs (14x106 
cells) were stored at -80 °C with 10 % DMSO for 72 hrs and then cultured in RPMI+10 % FBS for 24 hrs to rest the cells. The 
cells were stimulated with anti-CD3 10 µg/mL, anti-CD28 10 µg/mL and 20 U/mL IL-2 for 4 days, before being frozen, revived 
and rested (2nd Defrost) or kept at rest for 38 hrs (1st Defrost). In order to test the function of the expanded T cells, cytokines 
were measured by flow cytometry after PMA and ionomycin stimulation. The CD4+ population was gated on and the expression 
of IFNγ and IL4 measured. 
The cytokines measured were chosen as they are produced by different subpopulations of T helper cells. Th1 cells produce 
IFNγ and are essential for the establishment of cellular immune responses. Th2 cells produce IL4 and facilitate immunoglobulin 




The culturing and freeze thawing of the HC T cells did not negatively affect the function of the cells as seen in Figure 3.3.10. 
The CD4+ population was still present and the cytokines IFNγ and IL4 were both produced, meaning that the both Th1 and 
Th2 populations expanded.  
This culturing scheme was performed on the patient and HC PBMCs stored in parallel. The patient cells did not expand to the 
same extent as the HC, as was seen in the clinical tests presented in Table 3.1.4. The cell populations did expand sufficiently 
well for functional tests to be performed. However, the CD8 population expanded to a greater extent in the patient than the 
CD4 cells, meaning the patients CD4:CD8 ratio was even more in favour of the CD8 cells then what had been observed in a 
fresh sample. This shift in the ratio of T cell populations is part of the patient phenotype, as seen in Table 3.1.4, but may be 






Figure 3.3.10 Intercellular signalling of HC T cells after expansion 
Culturing and flow cytometry protocols can be found in Sections 2.2.3.3.3 and 2.2.8.6.  
 
3.3.3.3.2 Calcium flux of patient T cells 
The calcium flux for expanded T cells for the patient and HC was performed using single cell imaging (Figure 3.3.11). The cells 
were kept in calcium containing solution during the experiment and were stimulated with CD3 x-link for a physiological relevant 
response and with ionomycin to show the maximal response of the cells. Figure 3.3.11B shows the zoomed in response of the 
patient and HC cells with TCR activation. The patient shows a reduced calcium flux response compared to HC, though there 




ionomycin response can also be seen, the maximal response of the patient is not as high as that seen in the HC. The cells 
seem to take longer to reach the maximum calcium influx and there is more variability between the cells, compared to the tight 
groupings seen in the HC.  
In summary, in order to understand if the patient compound heterozygous mutations in CRACR2A were pathogenic, the calcium 
flux response was measured in the patient T cells and was found to be reduced compared to HC, whether using single cell 
imaging or the plate reader method. Although the  calcium flux was reduced, this was not to the same extent as seen in patients 
with deficiency of STIM1 or Orai1.  
 
Figure 3.3.11 Calcium flux of expanded HC and Patient T cells 
Data generated in collaboration with the Gwack lab (UCLA). Each sample represents  
50 cells. For method details see Section 2.2.7.1.3. A) CD3 and ionomycin response of HC and patient T cells. B) zoomed 
in on the CD3 response, displaying the same data as in A).C) Averaged (± SEM) SOCE responses of B) from six 
independent experiments.  
For this data the author developed the expansion method for these cells and performed the initial isolation of the PBMCs 
from the HC and patient blood, see methods in Sections 2.2.3.1 and 2.2.3.3.3. During the initial test the author observed 




3.3.4 JNK signalling in T cells 
The compound heterozygous mutations in CRACR2A appeared to have reduced the calcium flux response in patient T cells 
compared to HC. Another function of the protein is within JNK signalling due to the GTP/GDP binding and hydrolysis domain.  
The p-JNK signalling was measured in the expanded T cell populations for the patient and HC. Compared to HC, the JNK 
signalling was significantly reduced in the patient CD4+ cells when the TCR was activated (Figure 3.3.12). The patient cells 
did not increase the p-JNK levels upon stimulation and remained at baseline levels.  
 
 
Figure 3.3.12 p-JNK of expanded HC and Patient T cells 
Data generated in collaboration with the Gwack lab (UCLA). Method details are given in Section 2.2.8.3.  
For this data the author developed the expansion method for these cells and performed the initial isolation of the PBMCs 
from the HC and patient blood, see methods in Sections 2.2.3.1 and 2.2.3.3.3. 
 
 
3.3.5 Cytokine studies 
An additional functional test performed on the expanded T cell population of the  patient and HC was to look at the cytokine 
expression in response to PMA and ionomycin stimulation. The CD4+ population was gated on and the expression of IFNγ and 
IL-4 was measured by flow cytometry, as seen in Figure 3.3.13. 
The patient cytokine profile shows a shift towards Th2 cells with the high expression of IL-4. These cells facilitate 
immunoglobulin E synthesis by B cells and immunoregulation and are normally present at a lower level than Th1 cells, which 






Figure 3.3.13 Cytokine expression of expanded HC and Patient T cells 
Data generated in collaboration with the Gwack (UCLA). Culturing and flow cytometry protocols can be found in Sections 
2.2.3.3.3 and 2.2.8.6.  
For this data the author developed the expansion method for these cells and performed the initial isolation of the PBMCs 







3.4 Key Findings 
In this chapter, a range of tests were performed on primary samples of a single patient to further understand the cause of their 
disease. WES identified two potential genes of interest DHSR4 and EFCAB4B.  
 
• The mutation, c.373 Cga>Tga (p.125 R>*), in DHSR4 was considered unlikely to be pathogenic as it was a heterozygous 
mutation, with a WT allele being present in the patient.  
• The mutations in CRACR2A , R144G, E278D and E300*, were confirmed to be compound heterozygous mutations, 
through cloning of the patient cDNA and sequence analysis of maternal genomic DNA  
• Functional studies on patient primary cells showed: 
o Patient B cells function normally in vitro (T cell independent assay) 
o Mildly reduced calcium flux in patient T cells compared to HC 
o Significantly reduced p-JNK signalling in patient T cells compared to HC 






The aims of this chapter were to confirm potential mutations and segregation in a patient with PID and to determine if these 
mutations were pathogenic and responsible for the patient phenotype, by looking at protein specific function in primary samples. 
The key findings summarised above show that these aims where mostly achieved. The CRACR2A mutations, R144G, E278D 
and E300*, and their segregation were confirmed in the patient. A significantly reduced function of p-JNK signalling and a mildly 
reduced calcium flux was found in patient primary T cells compared to healthy control. Both functional pathways have been 
linked to CRACR2A specific function previously in the literature (Srikanth, Jung, Kim, et al., 2010; Srikanth et al., 2016).  
 
 
3.5.1 Whole Exome Sequencing 
The importance and limitations of WES in identifying novel mutations is rare disease is heavily documented in literature 
(Richards et al., 2015; Biesecker and Harrison, 2018) and is highlighted in this chapter. WES has expanded the field of PID 
and led to the discovery of many novel genes and mutations associated with this disease (Gallo et al., 2016). WES was able 
to identify novel mutations in the patient discussed here and through filtration using databases and the patient phenotype this 
list of potential genes was filtered down to two candidates. These two genes are not currently on any NHS PID gene panels 
and the mild phenotype of the patient meant these mutations were unlikely to be discovered by methods other than WES. 
However, WES produces sequencing data for all coding regions of the genome but the coverage is not deep. This means that 
mistakes can arise. This is shown with the DHRS4 gene. The WES approach identified the gene to have a homozygous 
mutation, but when this exon was sequenced by Sanger sequencing the mutation was found to be heterozygous (Figure 3.3.1). 
This meant the mutation was unlikely to be pathogenic as there is still a WT copy of the gene present in the patient. This 






3.5.2  CRACR2A mutations 
In this case study, three heterozygous mutations were confirmed in CRACR2A. The mutations were found to be compound 
heterozygous through cloning of the patient cDNA and sequencing of the maternal genomic DNA. The maternal allele (R144G 
and E300*) and the potential paternal allele (E278D ) can be seen in Figure 3.3.5.  
The maternal allele is not likely to be expressed in the patient due to the lack of truncated protein seen in WB of patient T cells 
(Figure 3.3.8) and due to the low levels of this allele being present in patient cDNA observed during cloning. As a result only 
the E278D allele is expressed in vivo in the patient. Since CRACR2A is expressed at comparable levels, for the long isoform 
and reduced for the short isoform, compared to healthy control the mutation is unlikely to affect protein stability, but could affect 
protein function. 
The compound heterozygous state may lead to a functional deficiency as no WT protein is present in the patient. This means 
that recessive mutations could now cause changes in function in cells. As the maternal allele is unlikely to be expressed this 
means that the mutations could also cause disease through haploinsufficiency, the second allele is unable to produce sufficient 




3.5.3 Use of primary samples 
Performing functional studies on primary samples is a very powerful way of looking at a patient phenotype, especially when the 
mutations are known so particular pathways of interest can be tested. However, using primary samples has a host of associated 
risks and limitations. The samples are rare and precious, so not many replicates are available, this can limit the confidence in 
the results. The primary blood samples contain multiple cell types as well as sub populations which can lead to natural variation 
between individuals before the mutations of interest comes into consideration. This variability cannot be controlled for, especially 
when few patients with the same mutation or affected protein are available. This is especially true here where the patient number 
n=1.  
The final primary patient functional data presented in this chapter used cultured patient cells, instead of fresh patient sample. 
Fresh patient blood samples were not available when working with the Gwack lab and so isolated PBMCs were shipped to LA 
and then expanded prior to use in experiments. This meant that the calcium, cytokine, p-JNK and protein expression data (Figure 
3.3.8, Figure 3.3.10, Figure 3.3.11, Figure 3.3.12 and Figure 3.3.13), was all generated using these expanded cells which is not 
the ideal representation of patient primary samples. This is especially true due to the patient phenotype, which showed that the 
CD8+ T population proliferated more than it did in the HC sample, and the already low C4+ cells did not expand as well as they 
did for the HC.  
In order to test if the expanded cells were comparable to fresh samples an experiment was planned that tested three HC samples. 
The PBMCs were isolated and half were used in functional experiments, including JNK, calcium flux and cytokine studies. The 
other half were frozen and the culturing method and functional studies performed. Unfortunately, due to time constraints and 
equipment issues not all planned experiments could be completed. This experiment was expected to show minimal differences 
between the fresh and the frozen and expanded cells in regards to functional studies but with potentially reduced viability 






Chapter 4 CRACR2A cell line work 
 
4.1 Introduction 
As seen in the previous chapter, there are many challenges in using primary patient cells to determine if the identified mutations 
are responsible for the phenotype observed in the patient. In this case, with confirmed compound heterozygous calcium release 
activated channel regulator 2A (CRACR2A)  mutations (Allele 1: E278D and Allele 2: R144G and E300*), the patient T cells 
appeared to be the most affected. However, the low T cell numbers present in the patient blood samples and difficulties 
expanding this T cell population in the laboratory made it difficult to generate reproducible and reliable functional data. As a 
result, alternative methods were used to further explore if the mutations identified in this patient could be affecting the function 
of CRACR2A and, therefore, be causing the phenotype seen. There are several in vitro approaches available to do this, and in 
this chapter I will be focusing on the use of established cell lines.  
 
 
4.1.1 Cell lines as a model for studying effects of mutations 
The use of cell lines to investigate the effect of mutations on a cell type is well established. The two main avenues of investigation 
using cell lines are stopping the expression of a specific protein or expressing mutant proteins. Gene silencing can elude to the 
function of the protein and provide information about pathways the protein may affect. Knock out (KO) cell lines can also be 
used in combination with expression of mutant proteins, as the endogenous protein would not be present in the cells.  
In vitro modifications to cell lines can be induced in a transient manner or permanently by creating stable cell lines. Transient 
changes by use of RNA interference (RNAi) or expression plasmids are a good tool for investigating the effect of mutations and 
proteins, in short term studies. However, transient modifications are not useful for long term functional studies as the DNA 




4.1.1.1 Gene silencing 
Transient gene silencing is achieved by RNAi. The expression of a target gene is silenced or knocked down by the selective 
inactivation of its corresponding mRNA by double-stranded RNA (dsRNA), that is delivered to the cytoplasm of cells. Small 
interfering RNAs (siRNAs) lead to the degradation of a target mRNA, therefore stopping the production of the protein of interest, 
leading to a decrease in its levels within the cell and eventually knockdown (KD) (Keefe, 2013). 
Stable gene silencing is induced by changing the cell genome, rather than the mRNA. Clustered regularly interspaced short 
palindromic repeats (CRISPR) and CRISPR associated protein 9 (cas9) are useful tools for causing specific genome editing. 
Guide RNA binds to a specific region important for the expression of a specific gene. The cas9 enzyme is then able to cleave 
the target DNA strand and DNA repair mechanisms in the cell repair the cleavage by removing the remaining complementary 
sequence in this region, therefore, allowing  genome editing (Adli, 2018). 
 
4.1.1.2 Expression of recombinant protein 
Transient expression of recombinant protein in cell lines requires expression plasmid vectors, with the protein of interest 
encoded, to be transfected into the cell. The recombinant protein is normally overexpressed in these systems as the expression 
is not controlled by the genome. The recombinant protein can be designed to have a variety of modifications compared to the 
endogenous protein, depending on the experiment. Tags on the protein such as FLAG and His, allow for detection and capture 
of the protein. Fluorescent tags can allow for live cell imaging and mutations can be included into the protein to explore their 
effects.   
Stable cell lines can also be made, which incorporate similar changes as mentioned above into the genome. This can be 
achieved by viral transduction or CRISPR. In stable cell lines the expression of the protein can be controlled and maintained. 
This means the expression of the protein can be made comparable to the endogenous levels and can therefore provide a better 






4.1.2 Use of cell lines in CRACR2A research 
The main cell type used for CRACR2A research is the Jurkat cell line, an immortal T cell. CRACR2A expression is shown to be 
high in lymphoid cells, especially basophils, NK cells and T cells, particularly memory T cells (Uhlen et al., 2010; The Human 
Protein Atlas, 2020). In 2010, siRNA KD of CRAC2A were performed in Jurkat cells and HEK-293 cells (Srikanth, Jung, Kim, et 
al., 2010). Both cell lines showed a decreased thapsigargin (TG)-induced store-operated calcium entry (SOCE) and reduced 
interleukin-2 (IL-2) synthesis. Jurkat cells also showed reduced the clustering of transfected stromal interaction molecule 1 
(STIM1) and calcium release-activated calcium channel protein 1 (Orai1) in response to depletion of endoplasmic reticulum (ER) 
Ca2+ stores by TG treatment. Expression of CRACR2A increased SOCE and apoptosis in these KD cells. A CRACR2AEFMUT 
was expressed which was constitutively active and resulted in STIM1 clustering, increased SOCE and apoptosis. HeLa cells 
were also used in this paper for immunoprecipitation experiment and showed that CRACR2A was a binding partner of Orai1.  
Jurkat cells in combination with mouse T cells have been used to identify the function of the CRACR2A long isoform (Srikanth 
et al., 2016). The isoform was shown to localise to vesicles that translocate toward the immunological synapse and regulate 
JNK activation downstream of the T cell receptor (TCR). The role of CRACR2A in dynein transport was also demonstrated in 
Jurkat cells, though purified protein and HEK293 cells were also used (Wang et al., 2019).  
The other main cell line used is primary human umbilical vein endothelial cells (HUVEC). These have been used to identify 
CRACR2A role in endothelial tube formation and Weibel-Palade bodies (WPBs). In these cells, CRACR2A KD showed no effect 




4.1.3 Aims  
The primary cell work presented in Chapter 3 strongly suggested that the CRACR2A mutations could be causing the patient’s 
phenotype in this case study. However, the most compelling functional data was all performed in expanded T cell populations 
from the patient. The subtypes of the patient T cells were likely to be biased towards the CD8 population (Table 3.1.4) which 
have been shown to be less receptive to calcium flux stimuli (Arrol et al., 2008). As a result any difference seen between patient 
and HC cell (Figure 3.3.8 tot Figure 3.3.13) could be a result of the T cell subtypes rather than the CRACR2A mutations directly. 
As a result, it was important to look at the patient alleles in isolation, using cell lines. The E278D mutation was of particular 
interest as the allele with the 300* mutation was shown to not be present in T cells (Figure 3.3.8). 
 
The aims of the work presented in this chapter were: 
• To make CRACR2A KO Jurkat cells  
• Express patient mutations in KO cell lines 
• Determine if these mutations affect the expression, location and function of CRACR2A 
 
A collaboration was put in place with the Gwack lab at UCLA (Department of Physiology, UCLA, Los Angeles, USA). A three 
month secondment was organised with the aim to further explore the CRACR2A mutations identified in the patient presented in 
Chapter 3.This lab has been instrumental to CRACR2A research as they discovered this protein’s role within the CRAC channel. 
Importantly, they had established protocols in place for the generation of KO CRACR2A Jurkat cells, retroviral transduction of 






4.2 Method Strategies 
In this chapter multiple methods and reagents were used in similar experiments, as they were performed in different laboratories. 
This is because not all the same reagents were available in all locations. During the secondment in LA, the Gwack Lab standard 
protocols and reagents were used rather than ones I had previously optimised. The protocol used is specified in the legends for 
all figures. 
The simplified protocol for viral transfection is shown in Figure 4.2.1 and more details can be found in Chapter 2.  
 
Figure 4.2.1 Simplified viral transduction method 







4.3.1  CRAC channel proteins expression in Jurkat cells 
In order to explore the effect of the patient mutations, R144G, E278D and E300*, on the function of CRACR2A, the Jurkat cell 
line was used as a T cell model. The patient T cell related phenotype led to this selection due to the reduced T cells proliferation, 
cell number reduced calcium flux seen in the patient T cells. Jurkat cells express the main proteins of the CRAC channel, Orai1, 
STIM1 and CRACR2A, at detectable levels as can be seen in Figure 4.3.1. As a result, this cell line is a good model to study 
the effects of mutations on the function of the CRAC channel. 
At the beginning of this project, the expression of CRAC channel related proteins was looked at in the following three cell l ines 
that were planned to be used in future experiments: Jurkat cells as a T cell model, HEK293 to check transfection and transduction 
efficiency and HEK293T as donor cells in viral transduction. All three cells lines examined express the CRAC channel proteins 
at their expected sizes, although the level of expression differs (Figure 4.3.1). HEK293 and HEK293T cells have a higher level 
of STIM1 expression than Jurkat cells. The Jurkat cell line gives two bands for Orai1 compared to the single band at 50 kDa of 
the glycosylated protein seen in the two HEK derived lines (Cox et al., 2013; Dörr et al., 2016). CRACR2A is expressed in all 






Figure 4.3.1 CRAC channel protein expression 
Three cell lines were examined for the expression of the CRAC channel proteins. 20 µg total protein from each cell line/lane 
was resolved in 15-well gels and blotted as described in Section 2.2.6.1. Antibody details are given in Table 2.1.3 and 
dilutions used in this experiment were GAPDH (1.10000), Orai1 (1.100), STIM1 (1.250), CRACR2A (proteintech 1.700)  
 
 
4.3.2 Immunofluorescence to examine CRAC channel proteins 
IF was attempted to look at the interaction of CRACR2A in cells, with the CRAC channel components, STIM1 and Orai1. The 
aim was to explore potential differences between patient and HC T cells, and between cell lines expressing different patient 
mutations. This avenue of study was started due to the difference in the calcium flux response shown in patient and HC T cells 
using the Flex station (Figure 3.3.9), where the patient cells do not have a sustained calcium flux, but instead this dropped off 
after the initial peak. This lack of sustained calcium influx was hypothesised to be due to fast dissociation of the CRAC channel, 
possibly arising from the patient mutations altering the effect of CRACR2A which is known to have a role in stabilising the 
complex. However, because of issues with high background and non-specific staining with all rabbit primary antibodies, these 




The single cell calcium flux data gathered on patient and HC T cells showed this hypothesis to be unlikely, as the patient cells 
were observed to have sustained calcium flux using this more sensitive calcium sensing technique, as shown in Figure 3.3.11.  
 
 
4.3.3 Transient expression models  
Electroporation was used to perform transient transections in Jurkat cells to generate knock down CRACR2A using siRNA and 
to express CRACR2A mutants.  
 
4.3.3.1 CRACR2A knock downs 
siRNA is used to knock down genes of interest in a transient manner. As siRNA is small and the CRACR2A siRNA had previously 
been published (Srikanth, Jung, Kim, et al., 2010; Wilson et al., 2015; Miteva et al., 2019), initial tests were run using the 
recommended nucleofection protocol, provided by the supplier. The siRNA knock down initial test was repeated twice. The initial 
test was performed after 24 hours. RNA was isolated and cDNA produced by reverse transcription. PCR was performed on the 
cDNA, with a range of primer pairs, including β-actin primers (Gertsch et al., 2002) and CRACR2A var1 and 2 (Table 2.1.12, 
I+J, K+L). A positive control of fresh cDNA from the cell line showed visible PCR product with all primer sets. The transfected 
cells with and without siRNA resulted in PCR product that could not be visualised on a 3 % agarose gel and so the cDNA quality 
was determined to be poor.  
The above test was repeated and cell lysate isolated after 36 hrs for protein analysis. The cell lysate did not contain much protein 
due to the low number of transfected cells, although some protein was detected by WB (Figure 4.3.2). The mock transfected 
cells showed less CRACR2A expression than the cells transfected with the siRNA. This was opposite to the expected result as 
siRNA transfection should have lowered the amount of CRACR2A protein produced in the cell. So further optimisation was 







Figure 4.3.2 siRNA KD test  
Amaxa® Cell Line Nucleofector® Kit V was used as per manufactures instructions, using the Jurkat specific protocol and 
siRNA CRACR2A (siR2A), siRNA scramble (siSCR) or no DNA (mock), as detailed in Section 2.2.4.1. Protein lysate was 
generated 36 hours post transfection, using NP40 lysis buffer, and loaded at 20 µg protein/lane as calculated using a BCA 
assay. WB was run using the protocol described in Section 2.2.6.1. CRACR2A Ab from Proteintech was used.  
 
 
4.3.3.2 Monitoring the transfection  
To optimise the nucleofection, a better way to measure transfection efficiency was needed. A plasmid containing EGFP was 
used, with an IRES2 linker connecting to CRACR2A cDNA in the same transcript. This allowed for the transfection efficiency to 
be monitored without the need for RNA or protein extraction, as the GFP expression could be seen using fluorescence, providing 
a more immediate readout of transfection efficiency, which made optimisation easier.  
The transfection was performed and visualised after 24, 36 and 72 hours, and no GFP positive cells were found. This lack of 
expression could have been a result of a failed transfection. Flow cytometry was performed and this also showed no difference 
in GFP expression between mock and pIRES2_EGFP_empty transfected cells.  
 
4.3.3.3 Testing other transfection protocols 
Due to the lack of GFP expression in Jurkat cells with the recommended protocol, further tests were performed with HEK293 as 
a positive control, since this is an easily transfected cell line. The Jurkat protocol and the HEK293 protocol were performed on 
both cell lines using the pMAX GFP vector supplied by the manufacturer, which has a high transfection efficiency due to its small 




The recommended protocol for Jurkat cells resulted in GFP expression in the HEK293 cells but not Jurkat cells (Figure 4.3.3). 
This explained the lack of response to siRNA and plasmid expression in the earlier experiments. However, the HEK293 protocol 
resulted in GFP visualisation in both cell types (Figure 4.3.4). The expression in Jurkat cells after 24 hrs in particular showed a 
large amount of GFP. The main differences between these two methods are in the machine programme (length and voltage of 
pulse). The HEK293 protocol also required a harder speed of centrifuge before transfer to cuvette (90 x g compared to 200 x g) 
and the Jurkat protocol left the cells incubating at room temperature in the cuvette for a further 10 minutes before being 
transferred to the cell culture plates. To identify the specific benefits of the HEK293 protocol, further experiments would need to 
be performed.  
As shown, nucleofection is a viable way of transfecting Jurkat cells, though further optimisation would need to be performed with 
the CRACR2A plasmids and siRNA before use in further experiments. However, electroporation only results in transient 
expression, so only short term experiments could be performed using these reagents, as GPF expression was minimal after 48 
hrs (images not shown here). Transient expression also results in low cell numbers, as daughter cells do not carry the 






Figure 4.3.3 Recommended protocols for Jurkat cells 
Nucleofection of 1000,000 cells with pMAX GFP vector (2 µg). Lonza recommended protocol for Jurkat cells was used, 
with the X-001 programme (Section 2.2.6.1). HEK293 p6 were transferred to a 6 well plate, while Jurkat p11 were 
transferred to a 12 well plate. The cells were imaged on a Zeiss, AxioImager.Z1 fluorescence microscope, with a x20 






Figure 4.3.4 Recommended protocols for HEK293 cells 
Nucleofection of 1000,000 cells with pMAX GFP vector (2 µg). Lonza recommended protocol for HEK293 cells was used, 
with the A-023 programme (Section 2.2.6.1). HEK293 p6 were transferred to a 6 well plate, while Jurkat p11 were 
transferred to a 12 well plate. The cells were imaged on a Zeiss, AxioImager.Z1 fluorescence microscope., with a x20 














4.3.3.4 Electroporation to test expression plasmids 
As the project moved away from transient expression systems, due to the difficulties with measuring functional effects of mutated 
protein in these, stable cell lines were created. These cell lines were generated using viral transduction, which will be discussed 
in more detail in later sections. However, this methodology used FG11F expression plasmids containing CRACR2A. These 
vectors can be used in viral transduction and the sequence of interest incorporated into the cell genome, but they can also cause 
expression of protein of interest without the packaging vectors through transfection. 
Electroporation tests were performed using the FG11F plasmids to check if the CRACR2A mutant proteins could be expressed 
in Jurkat cells. Electroporation is a good test for this as it is quick and the cells can be harvested after 24 hours, rather than after 
the two weeks of viral transduction. The method used for electroporation with FG11F plasmids differed from the nucleofection 
methods above, as the experiments were performed using the established Gwack lab protocol, as described in Section 2.2.4.2.  
The main disadvantage of this technique is the transient nature of the expression and the large cell numbers and high DNA 
amount needed. Between four and eight cuvettes were needed for each sample type to produce enough positively transfected 
cells to make a lysate containing sufficient protein for western blotting. This is due to the variability between the transfection 
efficiency which was determined by GFP expression visualised after 24 hours. Good transfection efficiency was defined as when 






Figure 4.3.5 Electroporation test 
300,000 Jurkat cells, 15 µg plasmid of interest and 5 µg FG11F empty for visualisation were used per transfection. The 
protocol for electroporation is given in Section 2.2.4.2. Cells were collected at 24 hrs after transfection. Samples are pooled 
from multiple transfections, 4 (pCDNA3.1 and mutant) or 8 (R2A WT) cuvettes, depending on transfection efficiency. WB 
protocol used is described in Section 2.2.6.2. 
pCDNA3.1 was used as a control plasmid, containing unrelated DNA, to show endogenous CRACR2A expression after 
electroporation  
 
The CRACR2A WT in particular had poor transfection efficiency, with < 50 % of the cells having GFP expression, so double the 
amount of cells were transfected. The lysate produced for the WT sample was less concentrated than that from the other two 
samples, as seen by the faint β-actin loading control band (Figure 4.3.5). It was less concentrated due to the high volume of 
loading dye used to resuspend the cells, which was more than double that of the other samples. When a comparable amount of 
loading dye was added to the WT cells, the lysate was too thick to pipette, so more loading dye and vortexing was performed 
on the sample, until it could be pipetted into the loading tips and loaded in the SDS-PAGE gel.  
The aim of transient expression was to rapidly test the expression of different plasmids and mutant proteins in Jurkat cells lines. 
Electroporation was shown to be a good method for this, as confirmed by western blots. In order to determine if mutant proteins 





4.3.4 Creating stable cell lines  
The aim of making stable cell lines was to compare the function of mutant CRACR2A to WT protein, to see if the patient mutations 
affected the protein function. In order to achieve this, knockout (KO) cells were generated that lacked any endogenous 
CRACR2A protein. 
 
4.3.4.1 KO CRACR2A Jurkat cells 
KO CRACR2A Jurkat cells were generated using viral transduction and CRISPR reagents as described in Section 2.2.5 and 
Figure 4.2.1.  
 
4.3.4.1.1 Puromycin Kill curve 
Using the CRISPR system, puromycin was used to select for cells that take up the CRISPR-shR2A vector (Figure 2.2.11). In 
the literature, the recommended concentrations of puromycin is 1-10 µg/mL for eukaryotic cells and 4 µg/mL for Jurkat cells. In 
order to confirm that 4 µg/mL would work in this system, a puromycin kill curve was generated to find the lowest concentration 
possible that killed 100 % of  untransduced cells in 48 hrs. MTT was used to measure the cell viability (Section 2.2.5.5). MTT is 
a yellow tetrazole that is reduced to purple formazan in living cells, and this colour change can be measured at 560 nm 
wavelength in a plate reader. In all MTT experiments, the controls were 50 % DMSO for complete death (<0.05 blank corrected 
Abs), media only wells and for the puromycin kill curve experiment the additional control of cells only was included. 
Adherent cells are normally used in MTT assays so HEK293T were a control for the initial optimisation of Jurkat cell numbers 
required. The range of cell numbers tested for Jurkat cells (5,000 to 500,000 cells per well ) was much higher than HEK 293T 
(2,500 to 5,000 cells per well) due to the smaller size and increased risk of losing cells when the supernatant was removed from 
spun down suspension cells. 50,000 Jurkat cells was selected as the optimal cell number per well. 
A range of puromycin concentrations (0.25-20 µg/mL) were tested in triplicate, with 3 biological replicates. Puromycin at 4 µg/mL 
was found to be the lowest concentration of drug that killed the majority (<10 % viability) of the cells (Figure 4.3.7), as also 






Figure 4.3.6 Optimising cell number per well for MTT assay 
Cells were incubated at 37 °C for 24 or 48 hrs, in 200 µL of media. All absorbances are corrected against media only wells. All samples run in triplicate. A) HEK293T 
cells, B) Jurkat cell line. 
Large standard deviations can be seen at each drug concentration, likely due to variability between wells of cell number at the initial loading. This has tried to be 








Figure 4.3.7 Puromycin kill curve 
MTT assay performed as per Section 2.2.5.5. 50000 cells/well in 100 µL media were cultured overnight, then 100 µL of puromycin was added to a final concentration 
0.25-20 µg/mL and left for 48 hrs. All samples were run in triplicate and data shown here is from 3 biological replicates. Every well was blank corrected using absorbance 




4.3.4.1.2 Production of donor cells 
Published data by the Gwack lab used calcium phosphate transfections to introduce the CRACR2A KO plasmid and viral 
packaging vectors, specified in Table 2.1.2, into the HEK293T cell line, before the supernatant could be added to Jurkat cells 
for transduction (Srikanth et al., 2016). An initial test was performed using the published method with CRISPR-shR2A KO 
plasmid, and CRACR2A visualised in Jurkat cells by western blot after puromycin selection at 4 µg/mL. The amount of 
CRACR2A in these KO cells was comparable to WT Jurkat cells, implying the transduction had poor efficiency. Due to the 
failure of the viral transduction to generate KO CRACR2A cells, the calcium phosphate transfection method was repeated with 
different plasmid reagents that could be more readily measured, namely N terminal FLAG tagged CRACR2A in FG11F plasmid. 
West blots showed the level of CRACR2A in these cells to be comparable to cells transfected with an empty FG11F plasmid, 
and FLAG antibodies detected very low levels of recombinant protein. Calcium phosphate transfections are known to have 
variable efficiency and to be sensitive to changes in pH (Guo et al., 2017). 
Due to the poor efficiency of the calcium phosphate transfection, a different method was tested to produce viral supernatant, 
as detailed below.  
 
4.3.4.1.3 Alternate transfection method 
The TransIT method was recommended by Dr Julie Burns (University of Leeds) as a more reliable and reproducible alternative 
to calcium phosphate transfection. The chemical transfection was performed on HEK293FT cells and then the supernatant 
transferred to Jurkat cells as before.  
The efficiency of this method was tested with the CRISPR CRACR2A KO reagents and the FG11F R2A WT plasmid. A full 
transduction protocol was performed, as a fluorescent microscope was not available to visualise the Class 2 virus infected cells 
for a quick determination of transfection efficiency. Instead, the cell lysates were western blotted with CRACR2A Ab and a 





Figure 4.3.8 Trans-IT transfection test 
Transduction of Jurkat cells using Trans-IT reagents and performed using methods detailed in Section 2.2.5.3. Puromycin 
selection was done for 48 hrs at 4 µg/mL on the KO cells. The WB was performed and visualised using the Method A 
(Section 2.2.6.1).  
 
 
The KO reagents did not appear to have worked, due to the band present at the expected size of CRACR2A with the 
corresponding antibody. However, there was expression of the FG11F R2AWT, due to the strong band detected with the FLAG 
antibody, which is not seen in the WT Jurkat or the KO cells, suggesting transfections had worked well. So, the KO cells 
underwent a second puromycin selection at a range of concentrations, to see if there were cells present that had incorporated 






Figure 4.3.9 Second puromycin selection treatment on KO CRACR2A Jurkat cells 
KO CRACR2A Jurkat cells were incubated at a range of puromycin concentrations for 48 hrs, and left to rest for 24 hrs 
before NP40 lysate was generated and a WB performed with the CRACR2A Ab as per Section 2.2.6.1, with the additional 
step of washing the membrane overnight in 5 % Milk after the secondary incubation. The membrane images were 
analysed using Image J software, to calculate the area and percentage of the CRACR2A band and the loading control 
GAPDH. The relative density of GAPDH was set as 1.0 for each sample and the relative density of the CRACR2A was 
calculated in relation to the control band, to normalise the expression of each sample. The % of WT R2A was calculated 
by the WT Jurkat relative density being set as 100 % and the other samples being calculated in relation to it (Miller, 2010). 
 
After the second selection with puromycin, the expression of CRACR2A had reduced in all samples ( 
Figure 4.3.9). The cells treated with 15 µg/mL of puromycin for 48 hrs had 10 % of CRACR2A expression compared to WT 
Jurkat cells. Thus, complete knock out was not seen in these cells after viral transduction with KO CRACR2A reagents. 
However, the level of CRACR2A was considered to have reduced sufficiently to test the calcium flux response in these cells, 
to see if an equivalent reduction was seen compared to WT Jurkat cells (Srikanth, Jung, Kim, et al., 2010).  
 
4.3.4.2 The function of CRACR2A KO cells 
The function of the KO CARCR2A Jurkat cells was tested to determine if a large enough window was available in the response 





4.3.4.2.1 Calcium flux  
To compare the level of calcium flux response of KO CRACR2A and WT Jurkat cells, the Flex Station was used (Section 
2.2.7.1.2). Minimal calcium flux was seen in both cell line when TG is added in calcium depleted conditions, but when calcium 
was added back into the system the calcium flux increased and the area under the curve could be measured (Figure 4.3.10). 
The area under the curve was significantly reduced in KO cells compared to WT cells, with or without TG. However, the peak 
response was comparable between the cell lines and so not shown here.  
 
 
Figure 4.3.10 Calcium flux response to TG with Jurkat KO cells 
Method was as described in Section 2.2.7.1.2. All samples were run in duplicate and performed to n=3. Data was analysed 
using Prism and significance was calculated using the ordinary one way ANOVA multiple comparisons. P values : ns P > 
0.05 (ns), P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤ 0.001 (***), P ≤ 0.0001 (****) 
An experimental error occurred during data collection that lead to high responses from all DMSO samples. This data is 
still deemed to have a value as it allows for the comparison of calcium flux responses between the WT and KO cells. This 
could be due to the cells being kept in calcium free medium for an extended period of time, or TG being present in the 
DMSO controls. From this experiment the Flex Station was found to be not sensitive enough for subsequent experiments 
with CRACR2A variants.  
 
 
The window between KO and WT cells measured using the Flex station was not large enough to observe potential differences 




needed, so a collaboration and secondment was initiated to gain access to more sensitive equipment in order to complete this 
aspect of the project.  
 
4.3.4.3 Stable cells lines with CRACR2A mutants 
The Gwack lab collaborators already had a KO CRACR2A Jurkat cell line, generated using calcium phosphate transfection 
and viral transduction (Srikanth et al., 2016). This established KO CRACR2A cell line was used in all subsequent transductions. 
Viral transduction was used to generate stable cell lines that express mutant CRACR2A. Transfection efficiency was monitored 
using GFP expression in both the donor cell and Jurkat cell lines, transfected with FG11F an empty plasmid, and visualised 
using a fluorescent microscope. Stable cell lines were created when the virus produced by the donor HEK293 cells were used 
to infect the Jurkat cell lines, resulting in the plasmid of interest being incorporated into the genome and enabling the cell to 
express the CRACR2A mutant proteins. 
Western blots were performed on the donor HEK293 cell lysates to check that the mutants expressed in the cells and in the 
final stable Jurkat cell lines. The expression of the recombinant protein was detected using CRACR2A Ab, which was also able 
to detect endogenous protein, and the FLAG Ab. The mutant vectors were all designed to have an N-terminal FLAG tag. The 
Western blot data are shown in Figure 4.3.11 and Figure 4.3.12 respectively. 
The KO Jurkat cell lines had no full length CRACR2A in the FG11F transduced samples, confirming the complete KO of 
endogenous CRACR2A in these cells. The western blots confirmed expression of mutant CRACR2A in HEK293 and Jurkat 
KO cells. The double mutant cell lines had a truncated protein, as a result of the premature stop codon at amino acid 300. 
A band can be seen in the HEK293 samples, in Figure 4.3.11, around 40 kDa for the cells expressing the full length CRACR2A 
(lysates WT, R144G and E278D). This is near the expected size of the short isoform of CRACR2A of 45 kDa. However, it is 







Figure 4.3.11 Stable cell line blotted with anti-CRACR2A Ab 
Western blots performed using Method B (Section 2.2.6.2). A) HEK293 cells were collected 4 days post transfection, after supernatant used for viral transduction. B) 





Figure 4.3.12 Stable cell lines blotted with anti-FLAG Ab 
Data and figure generated in collaboration with the Gwack lab. The method details are found in Sections 2.2.5 and 2.2.6.2. 
A) HEK293 cells, B) Jurkat KO cells. 
This experiment was initially performed by the author using the cell lines shown in Figure 4.3.11, and showed the same 
results. This figure represents the pooled data of n=3 which was generated by the Gwack lab for publication.  
 
The patient mutations were expressed initially as single mutations R144G, E278D and E300* (Figure 4.3.11). Due to the high 
number of cell lines created with the additional controls of WT CRACR2A and empty FG11F cells, the functional experiments 
were performed on only the E278D cell line and a cell line generated with both the R144G and E300* (double mutant [DM]). 




4.3.5 CRACR2A function in stable transfected cell lines  
The CRACR2A patient allele mutations, E278D and the DM (R144G and E300*), were expressed in the KO CRACR2A Jurkat 
cells to create stable cell lines, the expression was confirmed by western blot as described above. In order to further examine 
the function of these patient mutations, tests were performed to check the general function of the Jurkat cells, through IL-2 
expression, and more specific CRACR2A related function, by calcium flux, JNK expression and protein localisation.  
 
4.3.5.1 Localisation of mutant proteins 
CRACR2A is known to localise to the Golgi and vesicles (Srikanth, Jung, Kim, et al., 2010). The localisation of CRACR2A 
protein was tested in the stable cell lines using IF (Section 2.2.6.3) to check if the patient mutations affected protein localisation. 
The localisation was initially tested with Anti-FLAG antibody, which only binds to recombinant CRACR2A as shown in Figure 
4.3.13. F-actin was stained in the cells using phalloidin, a molecule that binds F-actin with a conjugated fluorophore. F-actin 
was used do show the  overall shape and structure of the cells. Localisation was comparable for WT protein and the E278D 
mutant, with the expected localisation to the Golgi and vesicles. However, the DM was not detected in the cells, even though 






Figure 4.3.13 Localisation of mutants using FLAG Ab 
z-stack microscope images were taken for each cell. For single channel images, the middle of the cell is shown. Stained with anti-FLAG. Images of between 8-12 cells 
were taken per cell line (Figure 4.3.11) and a single representative cell is displayed. For the max intensity projection of E278D, a different cell is imaged than the one 






Figure 4.3.14 Localisation of mutants using CRACR2A Ab 
z-stack microscope images were taken for each cell. For single channel images, the middle of the cell is shown. Stained with anti-FLAG. Images of between 8-12 cells 




The absence of CRACR2A DM detection with the anti-FLAG Ab, meant further IF was performed with the Anti-CRACR2A Ab 
as shown in Figure 4.3.14. This Ab is able to bind to both endogenous and recombinant CRACR2A. As an additional control, 
normal Jurkat cells where stained, to show the endogenous localisation of CRACR2A protein. The localisation of endogenous 
CRACR2A seen was comparable to that detected with the anti-FLAG Ab in WT and E278D cell lines, although there was 
potentially additional vesicle staining in the normal Jurkat cells. The KO cell line was also stained and no protein was detected, 
confirming the absence of detectable CRACR2A as seen in the WB earlier (Figure 4.3.11 and Figure 4.3.12). The E278D cell 
line was stained with the anti-CRACR2A Ab, and showed the same localisation as with the anti-FLAG Ab to the Golgi and 
vesicles. The DM was detected with the anti-CRACR2A, but did not show the normal localisation seen for the other recombinant 
proteins. Instead, the DM protein was seen in the cytosol of the cells. 
The localisation of CRACR2A was tested by IF, the E278D mutation did not appear to affect the localisation of the protein to 
the Golgi and vesicles. The DM did affect the localisation, which appeared as distributed throughout the cell. Interestingly, the 
DM was not detected by an anti-FLAG Ab, suggesting that something may have affected the N-terminal FLAG tag, even though 
the same Ab was able to detect the protein in a WB.  
 
4.3.5.2 IL-2 expression 
Interleukin 2 (IL-2) is a good functional test for Jurkat cells, comparable to the cytokine expression experiments done in patient 
primary T cells (Section 3.3.5). IL-2 is expressed in Jurkat cells in response to phorbol myristate acetate (PMA) and ionomycin 
(I) (Weiss A, Wiskocil RL, 1984; Held, 2018).  
The stable cell lines were stimulated at two concentrations for 16 hrs (PMA [80 nM]+ ionomycin [1 µM] and PMA [20 nM]+ 
Ionomycin [0.5 µM]) or unstimulated. The higher stimulation conditions were chosen as they were in excess of the half maximal 
effective concentration (EC50) of both drugs, in order to show the maximal response of the cells. The experimental EC50, 
determined by the Gwack lab, with normal Jurkat cells was PMA [10 nM]+ ionomycin [0.2 µM]. The lower stimulation was 
double the EC50 of both ionomycin and PMA, and as such more subtle differences between the mutants response would be 
expected to occur. A lower stimulation at the EC50 was initially tested, but produced only low levels of detectable IL-2 expression 
in WT Jurkat cells, with a max response of 3 % expression when stimulated, compared to 0.8 % expression at rest, and so it 




all cells two hours before processing, including those under resting conditions. BFA blocks transport of proteins out of the cell. 
This means that the cytokine can build up in each cell and so can be measured using internal staining techniques, such as cell 
fixation with PFA. 
Jurkat cells transduced with CRACR2A KO and later CRACR2A mutants and Jurkat cells transduced with shRNA-Scramble 
(SCR), so express endogenous CRACR2A, were also tested here for IL-2 expression. However, no IL-2 expression was seen 
from any of the cells. The SCR transduced cells may have been of poor health prior due to the transduction, as all the cell lines 
gave minimal IL2 expression and the cell growth rate was slower than for KO cells. As a result further functional testing of these 
cells was not continued as the basic machinery of the cells was not responding. The SCR cell lines would have been a good 
control to include in experiments. It would have been a control for the initial CRACR2A KO transduction, as cells with 
endogenous CRACR2A expression levels and to see if the mutated CRACR2A had any effect on the endogenous protein. 
The IL-2 expression could be measured successfully in the stable cells lines, as seen in Figure 4.3.15 Both E278D and the DM 
resulted in significantly lower expression compared to WT CRACR2A. This was observed at both high and low stimulation 
conditions. This showed that the mutant CRCAR2A studied herein were not able to rescue the reduced IL-2 phenotype in the 






Figure 4.3.15 IL2 expression for stable cell lines 
The data and this figure were generated in collaboration with the Gwack lab. n=3. Jurkat stable cells lines were cultured 
for 16 hrs with high, (PMA [80 nM]+ Ionomycin [1 µM] ), low  (PMA [20 nM]+ Ionomycin [0.5 µM]) stimulation or at rest in 
media, with BFA added at hour 14. Methods details are given in Section 2.2.8.5.  
This experiment was initially performed by the author using the cell lines shown in Figure 4.3.11, and showed the same 





4.3.5.3 Calcium flux  
Calcium flux was performed on the stable cell lines to see if the patient mutations affected the calcium flux response in Jurkat 
cells. Previously, KO of CRACR2A was shown to reduce calcium flux response in Jurkat cells by 50 % (Srikanth, Jung, Kim, 
et al., 2010). 
The calcium flux experiments were performed using a fluorescent microscope and fura-2 as the calcium sensor dye, using the 
same methodology as for the patient T cell experiments presented in Section 3.3.3.3.2. The cells are stationary with fluid being 
moved over the cells.  
The calcium data, shown in Figure 4.3.16, illustrates the response to multiple challenges. In panel A, the physiological TCR 
activation response is modelled by the addition of CD3 Ab into calcium containing cells. Ionomycin is used to show the maximal 
response of the cells. In B, calcium add back is measured, the cells are first in a calcium free buffer, TG is then added which 
causes the calcium channels to be opened and the stores to the depleted. Calcium is then added back into the system, and 
the maximal calcium entry occurs.  
The calcium flux response to all stimuli showed the same pattern. The KO Jurkat cell line had reduced flux compared to normal 
Jurkat cells (control). This defect was rescued in the KO cells with expression of WT CRACR2A. Both of the cell lines expressing 
the patient alleles were able to partially rescue the effect of knocking out the CRACR2A, but the response was not as high as 
for the WT protein. The calcium response was very similar with both patient alleles (E278D and the DM), however the DM 






Figure 4.3.16 Calcium flux of stable cell lines 
The data and this figure was generated in collabouration with the Gwack lab. There are 3 biological replicates for each sample, and each replicate is 50 cells. Some of 
the data was processed and analysed by the author. A) TCR activation and ionomycin response in calcium containing conditions. B) calcium add back response, as 
described in Section 2.2.7.1.3. P values : ns P > 0.05 (ns), P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤ 0.001 (***), P ≤ 0.0001 (****) 
The author observed the initial experiment with cell lines see in Figure 4.3.11 and performed the data analysis, including picking individual cells and statistics. The 





The pJNK expression was measured to look at the secondary function of CRACR2A. The JNK signalling was measured in the 
stable cell lines using a previously published method (Srikanth et al., 2016) for primary cells but with tighter time points here, 
as the Gwack lab had determined Jurkat cells response occurs in the first 30 minutes of activation. 
JNK signalling in the Jurkat stable cell lines expressing patient mutations was measured after TCR stimulation for 0, 10, 20 
and 30 minutes, as seen in Figure 4.3.17. The normal Jurkat cells (control) showed the most expression of p-JNK under all 
stimulated conditions. The KO cells gave a reduced expression compared to normal Jurkat cells. Expression of the WT 
CRACR2A in KO cells rescued this defect at the 10 and 20 minute time points, but not at 30 minutes. The E278D mutant was 
also able rescue the phenotype at 10 and 20 minutes. The DM mutant was not able to rescue the KO phenotype, and the level 
of p-JNK was significantly reduced compared to WT CRACR2A at the 10 and 20 minute time points. 
The results of this experiment suggest that the E278D mutation has no effect on the CRACR2A JNK related function, while the 
DM mutant does. 
 
Figure 4.3.17 p-JNK response of stable cell lines to TCR stimulation 
Data and figure were generated in collaboration by Gwack lab. The experiment was repeated to give an n=3. See Section 
2.2.8.3 for method details. 






4.3.5.5 Interaction with CRAC channel proteins 
The binding efficiencies essential for CRACR2A function were tested using co-immunoprecipitation (co-IP), as shown in Figure 
4.3.18. The interaction of CRACR2A mutants was observed with Orai1, STIM1 and vav guanine nucleotide exchange factor 1 
(VAV1). This was done by transducing the binding proteins of interest into the cells, so they were present in abundance to 
allow for better visualisation. The CRACR2A mutants were captured by their FLAG tag and the binding partners visualised 
using primary antibodies. E278D mutation did not appear to affect binding to Orai1, STIM1 or VAV1, and gave comparable 
results to WT CRACR2A.  
The DM was not able to bind to any of the proteins tested. As the pull down was performed with the anti-FLAG antibody, this 






Figure 4.3.18 IP of stable cell lines  
Data and figure were generated in collaboration with the Gwack lab, as described in (Section 2.2.6.5). CRACR2A was 
captured using anti-FLAG antibody as described in Srikanth et al., 2016. Recombinant Orai1, Stim1 with a His tag, or 




4.4 Key findings 
• Generation of KO CRACR2A Jurkat cells, confirmed by WB, which gave reduced calcium flux response, pJNK signalling 
and IL2 expression. Expression of both patient mutant alleles E278D and DM (R144G and E300*) in HEK293T, FT cells 
and Jurkat cells, which was confirmed by WB. 
• E278D mutant had normal CRACR2A localisation to the Golgi and vesicles. This mutant had significantly reduced IL2 
expression and was able to only partially rescue calcium flux response seen in the KO cells. The JNK signalling was 
comparable to WT CRACR2A. The mutant was able to bind to Orai1, STIM1 and VAV1.  
• DM resulted in a truncated protein at the predicted size for the E300* mutation, which was not visualised in patient 
primary T cells. This mutant had abnormal localisation, being present throughout the cytosol rather than only at the Golgi 
and vesicles. The IL2 expression, calcium flux and JNK signalling were all significantly reduced compared to WT 






The in vitro experiments described in this chapter allowed examination of the individual mutants and showed that the mutations 
E278D and the DM (R144G and E300*) were able to alter the function of CRACR2A as summarised in the key findings. These 
findings support the primary cell data discussed in Chapter 3, reinforcing that the CRACR2A mutations identified were causing 
the patient phenotype.  
 
 
4.5.1 Cell lines as a model for CRACR2A mutations 
Transient expression was performed in Jurkat and HEK293 cells using nucleofection and electroporation. These expression 
systems are good for having a quick look at the effect of KD or confirming the expression of mutant proteins, but don’t allow  
for longer term functional experiments. As a result, all functional data was generated using stable cell lines, after the expression 
of the CRACR2A mutants was shown to be possible by electroporation and western blot.  
There are many advantages of stables cell lines over primary cells, including high cell numbers, expression of a single selected 
allele, controllable cell populations and their expansion. These features were particularly beneficial to this project because of 
the low cell numbers and different expansion profiles of the T cell populations as seen for the patient primary cells in Chapter 
3.  
However, stable cell lines do have limitations when studying patient specific mutations. A range of proteins can be expressed 
in vitro, which may not occur in patient cells, so primary samples are needed to confirm expression in vivo. T cell subpopulations 
are not present in cell lines, so primary samples or mouse models are needed. The level of expression of the protein is often 
higher in stable cell lines and is not controlled between individual cells or cell lines, meaning potentially that the functional 
difference for mutations could also be a result of protein expression levels. The comparison between cell lines in this project 
was monitored by WB through loading controls, as well as by IF. The level of CRACR2A expression between the cell lines 




The use of mouse models can help overcome many of the limitations of using cell lines and primary samples when investigating 
the effects of mutation(s) in a single allele. These investigations in mouse models are currently in progress in the laboratory.  
 
 
4.5.2  CRACR2A patient alleles 
The functional data for the patient case study from primary cells (Chapter 3) and cell lines (Chapter 4) is summarised in Table 
4.5.1. 
In the patient primary T cells, the double mutant (DM, R144G and E300*) allele could not be detected by western blot (Figure 
3.3.8) and it is likely that the transcript from this is sent for nonsense mediated decay. The DM was expressed in cell lines and 
a truncated protein was detected (Figure 4.3.11). The expression of mutant proteins not seen in vivo could be a result of altered 
nonsense mediated pathways in cell lines (Pereverzev et al., 2015) or the particular expression system used to express the 
mutant. This difference was also observed in Chapter 5 for STIM1 P2, p.Leu74Pro mutation (Section 5.3.1.4.3). This 
discrepancy found between cell lines and patient cells highlights the need for both systems to be used to investigate the effects 
of disease causing mutations. 
As the DM is not observed in patient cells, this implies that only the E278D mutant is likely to be expressed in the patient cells. 
In both primary cells and cell lines, this E278D mutant reduced the calcium flux response. However, in cell lines the JNK 
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4.5.2.1 Localisation of mutant proteins 
CRACR2A is known to localise to the Golgi and vesicles (Srikanth, Jung, Kim, et al., 2010). The localisation of CRACR2A was 
tested by IF. The E278D mutation did not appear to affect the localisation of the protein to the Golgi and vesicles (Figure 
4.3.13).  
The DM (R144G and E300*) was not able to localise to the Golgi and vesicles, and appeared to be distributed throughout the 
cell (Figure 4.3.14). Interestingly, the DM was not detected by an anti-FLAG Ab, suggesting that something may have affected 
the N-terminal FLAG tag, even though the same Ab was able to detect the protein in a WB (Figure 4.3.12). Potentially this 
could be due to changes in the 3D conformation of the protein, which could leave the FLAG tag unavailable for binding within 
the cells. During WB the samples are heated and the proteins denatured which would expose the tag and so allow for the 




for this mutant in IL2 expression, calcium flux and JNK signalling. The DM may not be expressed in patient cells as it was not 
detected by WB (Figure 3.3.8).  
Localisation of CRACR2A was not studied in patient samples due to the limited numbers of cells available. Functional tests 
such as calcium flux were prioritised over localisation. It would be beneficial to confirm that CRACR2A localises normally in the 
patient, which is expected due to the results for the E278D mutant in the cell lines. Use of IF in patient cells could also indicate 
the level of expression of CRACR2A and show if the mutant E278D affects polypeptide levels.  
 
4.5.2.2 IL-2 expression 
IL-2 expression can be used to monitor the cell’s ability to produce cytokines, the T cell response and the general health of the 
cell line. In primary T cells, it causes the differentiation of T cells into effector T cells and memory T cells when stimulated by 
an antigen (Qiu et al., 1999). 
PMA and ionomycin can bypass the TCR complex and activate the T cell by activating protein kinase C (PKC) and increasing 
the calcium concentration (Kozak and Putney, 2017). T-cell activation occurs with the activation of the TCR and co-stimulatory 
molecules. This triggers the rapid hydrolysis of inositol phospholipids to diacylglycerol and inositol phosphates by PLC. 
Diacylglycerol is an allosteric activator of PKC activation and inositol phosphates, which trigger calcium release and 
mobilization, resulting in a cascade of additional cellular responses mediating T-cell activation. One of these cellular responses 
is the production and secretion of IL-2. This mechanism of action can be bypassed in vivo with PMA and ionomycin, which 
when used in combination strongly enhance IL-2 production. PMA is a small organic compound, with a structure analogous to 
diacylglycerol, that diffuses through the cell membrane into the cytoplasm where it directly activates PKC. Ionomycin is a 
calcium ionophore that triggers calcium release. Previously, siRNA-mediated depletion of CRACR2A in Jurkat cells have been 
shown to have reduced IL2 expression compared to control cells (Weiss A, Wiskocil RL, 1984; Srikanth, Jung, Kim, et al., 2010; 
Held, 2018). 
Both E278D and the DM cell lines showed significantly lower expression of IL-2 compared to WT CRACR2A. This was observed 
at both high and low stimulation conditions. This showed that both mutant CRCAR2A polypeptides studied were not able to 




compared to healthy control, due to a shift towards Th2 cells with the high expression of IL-4 cells. In order to understand what 
other cytokine pathways are affected by these mutations, further experiments are needed in patient cells or mouse models. 
Potentially, cytokine and pathways of interest include IL-10 due to the patient B cell phenotype and mitogen-activated protein 
kinase (MAPK), nuclear factor of activated T-cells (NFAT), nuclear factor-κB (NF-κB). 
 
4.5.2.3 Calcium flux  
Calcium flux was performed on the stable cell lines to see if the patient mutations affected the calcium flux response in Jurkat 
cells. Previously, KO of CRACR2A was shown to reduce calcium flux response in Jurkat cells by 50 % (Srikanth, Jung, Kim, 
et al., 2010). 
Using single cell imaging the calcium flux response was measured in the different cell lines, as shown in Figure 4.3.16. The 
KO Jurkat cell line had reduced flux compared to normal Jurkat cells (control), which was rescued in the KO cells with 
expression of WT CRACR2A. The cell lines expressing the patient alleles had significantly reduced calcium flux compared to 
WT protein. The mutants were able to, therefore, only partially rescue the effect of knocking out CRACR2A. The DM showed 
slightly better calcium flux compared to E278D, although the difference was not statistically significant. Patient T cells also 
showed reduced calcium flux results, so this is very likely to have been a direct result of the mutations.  
Further investigations are needed to determine exactly how the mutation E278D could be altering the function of CRACR2A in 
regards to calcium flux , as the mutant has normal localisation and can interact with CRAC channel proteins. It may be that the 
reduced expression of the short isoform could be the cause as no data is available comparing the efficiencies of the long and 
short isoforms.  
 
4.5.2.4 Calcium flux sensitivity 
As discussed previously in Chapter 3, there are many challenges in measuring calcium flux in cells. In this chapter, data was 
collected using the plate reader methodology and single cell imaging. The main challenges of gathering calcium flux data from 
primary cells were overcome by using cell lines, as high cell numbers are available. Instead, sensitivity of the technique became 
the main limitation. The Flex Station methodology comparing KO CRACR2A and WT Jurkat cells showed very similar 




expected in the mutant cell lines were unlikely to be detected using this method. As a result, single cell imaging was used. This 
method is sensitive and the calcium flux response measured between KO and WT cell lines showed a significant difference, 
which the mutant cell lines fell between. The smaller changes in calcium response between the different mutants was also 
detectable, although no significant difference was seen between the E278D and DM cell lines.  
The single cell imaging method is not routinely available, and requires highly specialised expertise to run the experiments. As 
a result, single cell imaging was only performed during the secondment or by the Gwack group.   
 
4.5.2.5 pJNK 
The pJNK expression was measured to look at the secondary function of CRACR2A. Previously, JNK signalling was shown to 
be significantly reduced in mouse CRACR2A deficient CD4+ T cells upon TCR activation (Srikanth et al., 2016). The JNK 
signalling was measured in the stable cell lines using a similar method as that used on patient T cells. The E278D mutation 
has no effect on the CRACR2A JNK related function and was comparable to WT in the cell lines. The DM resulted in a reduced 
p-JNK response.  
Only the E278D mutant is likely to be expressed in the patient cells. However, in cell lines the JNK signalling is normal for this 
mutant but not in primary cells. This suggests the reduced JNK signalling seen in the patient cells may not be directly due to 
the mutation in CRACR2A. However, this protein can affect this signalling pathway as seen in the KO cells herein and Srikanth 
et al., 2019. JNK signalling is affected by cytokines expression,  stress stimuli and has different roles in T cell subtypes (Conze 
et al., 2002). As a result, the reduced JNK signalling seen in patient T cells compared to healthy control (HC) could be a result 
of different cytokine profiles (Figure 3.3.12) or subtype distributions (Table 3.1.2). This means further experiments would be 
needed to determine the cause of the reduced signalling, such as cell typing during flow cytometry experiments and looking at 
other pathways affected in the cells.  
Examining other pathways affected by CRACR2A in addition to p-JNK was an avenue of the project which was not investigated 
due to time constraints. The plan was to perform PTMScan proteomics analysis using Cell Signalling Technology. No other 





4.5.2.6 CRACR2A interaction with CRAC channel proteins 
The binding efficiencies essential for CRACR2A function were tested using co-immunoprecipitation (co-IP), as shown in Figure 
4.3.18. The E278D mutation did not appear to affect binding to Orai1, STIM1 or VAV1, and gave comparable results to WT 
CRACR2A.  
The DM was not able to bind to any of the proteins tested. As the pull down was performed with the anti-FLAG antibody, this 
result may be because of binding issues between this antibody and the DM rather than the protein binding partners tested. 
Issues between anti-FLAG and CRACR2A DM were also seen during IF, where the DM was not detected (Figure 4.3.13), 
although interaction between the Ab and protein were seen in WBs (Figure 4.3.12). During WB the samples are heated and 
the proteins denatured which would expose the tag and so allow for the protein to be detected.   
The observed lack of interaction between the DM and CRAC channel proteins may also  be caused by the abnormal localisation 
seen in IF or due to the truncation of the protein at amino acid 300, though in published literature the interaction sites of 
CRACR2A with Orai1 and STIM1 appear to be contained in the C terminal region present in this mutant (Srikanth, Ribalet and 
Gwack, 2013). In order to confirm the ability of the DM to bind to Orai1, STIM1 or VAV1 a different pull down method is needed, 





4.5.2.7 Other CRACR2A mutants  
Stable cell lines expressing patient mutations in CRACR2A have not been previously published. As part of this project, other 
CRACR2A mutations were discovered and discussed in Chapter 3. Mutagenesis was performed on the FG11F CRACR2A 
plasmid, but there was not enough time to produce and test the function of these mutants in cell lines.  
An additional plasmid was also made that only contained the short isoform of CRACR2A. This isoform contains the N terminal 
of CRACR2A with the EF hand domains and coiled coil needed for CRAC channel interaction and is 395 amino acids. The 
three mutations investigated in this chapter are located within the short isoform. It is only 95 amino acids longer than the DM 
that had reduced function in IL-2 expression, calcium flux and p-JNK. The aim was to produce a cell line expressing only the 
short form to see how it behaved in comparison to the long isoform and the truncated DM. No data is available in the published 
literature comparing the calcium flux contribution of the short and long isoform, though the short isoform has relatively low 





Chapter 5 CRAC channel related protein mutations  
 
5.1 Introduction 
As described previously the Ca2+-release activated Ca2+ (CRAC) channel contains two main proteins, calcium release-activated 
calcium channel protein 1 (Orai-1) and stromal interaction molecule 1 (STIM1), as well as a regulator protein called calcium 
release activated channel regulator 2A (CRACR2A), which was investigated in Chapters 3 and 4. The CRAC channel allows 
movement of calcium into the endoplasmic reticulum (ER) for storage, where it is used as a secondary massager. It is 
particularly important in the immune system and deficiency of STIM1 or Orai1 results in primary immunodeficiency (PID). Orai1 
proteins form the pore of the channel in the plasma membrane, and STIM1 is located in the endoplasmic reticulum. When the 
intracellular calcium levels are low, STIM1 translocates from the ER and binds to Orai1 to activate the CRAC channel, as 
described in Section 1.3. STIM1 and Orai-1 are the focus of this chapter. 
 
 
5.1.1 STIM1  
The STIM1 protein has both an ER domain and a cytoplasmic domain as shown in Figure 5.1.1. The EF hands, located in the 
ER lumen detect changes in calcium concentration. The EF is structurally a helix-loop-helix motif with negatively charged 
residues (Asp and Glu) which bind calcium at high concentrations in the ER. A conformational change occurs in this region 
when the ER is depleted of calcium, because as the calcium dissociates from STIM1, the auto-inhibitory EF- sterile α motif 
(SAM) structure destabilises. STIM1 undergoes translocation to puncta at ER- plasma membrane (PM) junctions, 
oligomerization and cluster formation and subsequent calcium influx through the CRAC channel (Prakriya, 2009; Jairaman and 







Figure 5.1.1 STIM1 protein functional domains 
Figure compiled from databases (Ensembl, UniProt) and Kozak and Putney 2017. STIM1 is a ubiquitously expressed,  
77 kDa single-pass ER membrane protein as shown by the transmembrane (TM) region.  
The EF-hand domain is a Ca2+ sensor. Sterile α motif (SAM) is a protein interaction domain, During high Ca2+ in the ER it maintains the folded conformation of the protein 
and facilitates oligomerisation during ER store depletion. The coiled-coil (CC) domains are involved in ER retention and stability. The region annotated as CAD (CRAC 
activation domain, p.342–448) is required for the activation of CRAC channels, alternative names include SOAR (STIM1-Orai1 activating region, residues 345–444), or 
Ccb9 (residues 339–446). Mutations in this region inhibit the activation of Orai1, if the SOAR dimer cannot form. In the CC1 regions is an inhibitory helix (p.310-337) 















5.1.1.1 STIM2  
Humans also express STIM2 which has complementary, and nonredundant, functions in Ca2+ signalling (Collins and Meyer, 
2011). STIM1 and STIM2 share many core functional domains shown in Figure 5.1.1, so are likely to use the similar 
mechanisms of sensing and communicating Ca2+ store depletion, such as EF hand domains and translocation to puncta.  
However, there are differences between the two homologs. The N-terminal of STIM2, including the EF hand and SAM domains 
are more structurally stable, which allows for faster reactions to smaller decreases in [Ca2+] ER (Zheng et al., 2011). 
 
5.1.1.2 PID associated with STIM1 
Loss of function or null mutations of STIM1 are known to cause early-onset combined immunodeficiency (CID) disease with 
recurrent and chronic infections, autoimmunity, haemolytic anaemia, ectodermal dysplasia, muscular weakness and myalgia 
(Feske, Picard and Fischer, 2010; Feske, 2011; Jairaman and Prakriya, 2013). STIM1 deficiency is described in more detail in 
Section 1.3.3 and Table 1.3.1. 
STIM1-deficient patients have impaired T cells and natural killer (NK) cell function, a normal distribution of the major immune 
cell types, including T cells, B cells and NK cells and with a T cell repertoire that is normally comparable to healthy individuals 
(Jairaman and Prakriya, 2013). STIM1 deficiency results in no store-operated calcium entry (SOCE) in T cells and as a result 
the patient cells cannot respond appropriately to T cell receptor (TCR) activation or pharmacological agents such as ionomycin, 
thapsigargin, which typically trigger Ca2+ influx (Feske, Picard and Fischer, 2010). 
The CRAC channel is essential for normal T cell function. STIM1 deficient patient T cells lack SOCE and so have impaired 
proliferation and cytokine production such as IL-2, IFNy, and IL-17, regardless of naïve or effector T cells (Oh-hora et al., 2008; 
Beyersdorf et al., 2009; McCarl et al., 2010). However, SOCE is not essential for T cell development, through positive selection 
of TCRαβ+T cells, so patients with STIM1 deficiency often have a normal number of T cells in their peripheral blood (Kozak 





5.1.1.3 CANT1 mutations 
Calcium activated nucleotidase 1 (CANT1) mutation identified in STIM1 P1 has previously been linked to disease. CANT1 
preferentially hydrolyses uridine diphosphate (UDP) followed by guanosine diphosphate (GDP), uridine triphosphate (UTP) and 
adenosine diphosphate (ADP) in the ER and golgi (Furuichi et al., 2011; Nizon et al., 2012; Rice et al., 2019). 
CANT1 gene mutations have been linked to chondrodysplasia, a disease that is related to human stature. Desbuquois dysplasia 
(DBQD) type 1, is a rare autosomal recessive chondrodysplasia, characterized by short stature, joint laxity, short extremities 
and round face; the radiological features include “Swedish key” appearance of the proximal femur, advanced carpal and tarsal 
bone age and progressive scoliosis. Type 1 DBQD differs from type 2 by hand anomalies (extra ossification centre distal to the 
second metacarpal, delta phalanx, bifid distal phalanx of the thumb and phalangeal dislocations) (Furuichi et al., 2011; Paganini 
et al., 2019; Rice et al., 2019). 
 
 
5.1.2 STING  
Stimulator of interferon genes (STING) is involved in the innate immune response, through the production of type I IFNs. STING 
or transmembrane protein 173 (TMEM173), is a 379 amino acid protein, and the functional domains in this protein are shown 
in Figure 5.1.2. Under resting conditions STING is localised in the ER and is expressed mainly in hematopoietic cells 
(macrophages, natural killer cells, and T cells), endothelial and epithelial cells, which are all exposed to the environment and 
thus susceptible to infectious agents (Uhlen et al., 2010; Shang et al., 2012; The Human Protein Atlas, 2020). 
STING is an ER sensor that is activated directly by cyclic dinucleotides (CDNs) which are secreted by intracellular bacteria, 
like Listeria monocytogenes. It is also activated by non-canonical cyclic-GMP-AMP generated by cyclic GMP-AMP synthase 
(cGAS). The cGAS pathway is a viral immune response, which is activated by double stranded DNA in the cytosol. Activation 
of STING leads to a conformational change and triggers the trafficking of STING complexed with TANK-binding kinase 1 (TBK1) 
from the ER to endosomal/lysosomal perinuclear regions. TBK1 phosphorylates transcription factors interferon regulatory factor 




rapidly degraded after activation, to avoid sustained cytokine and autoinflammatory disease (Ishikawa and Barber, 2008; 
Ishikawa, Ma and Barber, 2009; Pokatayev and Yan, 2017; Ahn and Barber, 2019; Zhang et al., 2019). 
The importance of STING function is highlighted by the growing evidence that a variety of microorganisms have attempted to 
evolve strategies to inhibit STING-dependent signalling and autoimmune diseases resulting from STING mutations (Ahn and 
Barber, 2019; Motwani, Pesiridis and Fitzgerald, 2019). 
 
 
Figure 5.1.2 STING protein functional domains 
Image compiled from Xiaomei Wu et al. 2014) and Uniprot.org. Cyclic dinucleotide-binding domain (CBD).  
 
5.1.2.1 Disease association 
Deficiency of STING leads to a type of systemic autoinflammatory disease (SAID), which comprises disorders of the innate 
immune system. This autoinflammatory autosomal dominant condition is called STING-associated vasculopathy with onset in 
infancy (SAVI). This is an autoinflammatory vasculopathy causing severe skin lesions, particularly affecting the face, ears, 
nose, and hands, and resulting in ulceration, eschar formation, necrosis, and, in some cases, amputation. Patients often have 
interstitial lung disease and increased β-interferon signalling (Liu et al., 2014; Kacar, Pathak and Savic, 2019).  
STING-deficient cell lines are defective in IFN-I induction. STING-deficient mice are more sensitive to DNA and RNA viruses 
compared to controls, such as HSV-1, suggesting an important role in maintaining immune homeostasis (Ishikawa, Ma and 
Barber, 2009; Ahn and Barber, 2019). 
  
  












5.1.2.2 Association with STIM1 
STIM1 was found to act as a negative regulator for STING. STIM1 was shown to inhibit STING trafficking by physically 
interacting with STING and retaining it at the ER membrane. This interaction is important in maintaining STING in an inactive 
state. High STING expression results in decreased SOCE, due to the decrease of STIM at puncta sites. In SAVI, the interaction 






5.1.3 Aims  
The work in this chapter focuses on smaller case studies than that shown in Chapters 3 and 4. The three patients discussed 
in this chapter were all identified to have mutations in genes which had previously been linked to disease. This meant less 
evidence was needed to show that the mutations were pathogenic as literature was available on previous cases. However, the 
phenotypes for some of these patients were not in line with current classical symptoms so these new case studies can still add 
to the field of PID.  
All the genes identified containing mutations in this chapter have previously been associated with the CRAC channel and so 
can further our understanding of this pathway.  
 
The aims of the work presented in this chapter were to: 
• Identify CRAC channel related mutations in patients with PID  
• Confirm lack of STIM1 function in primary patient samples  





5.2 Method strategies 
5.2.1 Sequencing strategies 
WES and filtering for the STIM1 P2 and STING patient was done using the same strategy as described in Section 2.2.1.1 and 
2.2.1.2 for the CRACR2A case. For STIM1 P1, STIM1 deficiency was suspected due to their classical phenotype, so a modified 
exome sequencing approach was performed using the Agilent SureSelectXT with All Exon v5 capture library and sequenced 
on Illumina HiSeq 3000 for 2× 150-bp paired-end sequencing. 
 
 
5.2.2 Publications about these specific patients 
In this chapter, two cases of STIM1 deficiency are presented, which have been published. The case study of P1 has been 
published in two articles: Rice et al., 2019 and Srikanth et al., 2019. The case study of P2 has been published in two articles: 
Parry et al., 2016 and Rice et al., 2019. 
 
5.2.2.1 Immunoglobulin gene expression data 
Immunoglobulin related gene expression was measured using the protocol detailed in Section 2.2.1.9.1. This was performed 
on STIM1 P1 and STIM1 P2 and published in Srikanth et al., 2019 and Rice et al., 2019 respectively. The same method was 
performed on the STING 1 patient. 
The data for each experiment was analysed separately. The relative abundance of each transcript was normalized to the 
expression level of HPRT to obtain ΔCT and further normalized to the values obtained for healthy controls to obtain ΔΔCT. To 
compare the data generated for the STIM1 P1 and STING patient, the HC normalised data ΔΔCT was taken. This means the 
patients are normalised to different HCs but any assay variation was accounted for. Prism software was used to determine 






5.3.1  STIM1 patients 
In this section, results from two STIM1 deficient patients are described. Different mutations can present with different 
phenotypes and so the functional and immunological profiles have been compared to try and gain a better understanding of 
the breadth of STIM1 related deficiency with PID.  
 
5.3.1.1 STIM1 mutations 
5.3.1.1.1 Patient 1 
This is a 5-year-old male of consanguineous Pakistani background. For P1, two mutations were identified on the clinical exome, 
described in Section 5.2.1. The clinical exome sequences only genes known to cause disease. For P1 a homozygous mutation 
was identified in the STIM1 gene and another in the CANT1 gene.  
Sanger sequencing confirmed the homozygous deletion in STIM1: c.478del, p.(Ser160ValfsTer15). This was performed as part 
of the clinical diagnosis by the hospital, and so no genomic DNA was available for this project. Parental DNA was sequenced 
in-house by Sanger sequencing to look at the segregation of the of the STIM1 mutation. Both parents were found to have a 
deletion at the same position as the proband, though in a heterozygous form, which confirms the segregation of the mutant 
allele in this family, as can be seen in Figure 5.3.1. The single base deletion in codon 160, occurs in the SAM domain of the 
corresponding polypeptide (Figure 5.1.1). The single base deletion results in a reading frameshift that creates a premature stop 
codon 15 amino acids downstream of the deletion, which will produce a truncated STIM1 protein that lacks essential functional 






Figure 5.3.1 STIM1 Sanger sequencing of P1 family  
STIM1 gene is located at Chromosome 11: 3,854,527-4,093,210, on the forward strand. Genomic DNA isolation from 
patient whole blood, PCR and Sanger sequencing were performed as per Section 2.2.1.4 . Primer pairs Z and A1 were 
used to generate PCR products (Table 2.1.1). The PCR products was amplified in duplicate and run on a 1.5 % agarose 
gel, to confirm the predicted sizes. They were then directly sequenced using both the forward and reverse primers defined 
above.  
The arrow indicates where the deletion of the A base occurred. In the parents, before the deletion a single trace is present, 
meaning the two alleles have the same sequence, after the deletion two traces can be seen, indicating that only one allele 
has the mutation.  
 
The CANT1 homozygous missense mutation c.676 G>A, p.(Val226Met), codon Gtg>Atg was also confirmed as part of the 
clinical diagnosis and segregation was confirmed in parental DNA. The pedigree of the patient containing both mutations is 






Figure 5.3.2 P1 family pedigree.  
Only the genomic DNA from parents and the patient was sequenced. The two siblings are fit and healthy, they were not 
analysed as part of this project and so their genotype is unknown. The double lines indicate a consanguineous union. 
Patient genotype was confirmed by the clinical department and Sanger sequencing of parental genomic DNA performed 
by the author.  
 
5.3.1.1.2 Patient 2 
Patient 2 is a male case aged 17years from a consanguineous family. The STIM1 mutation was identified via WES by Parry et 
al., 2016 and Sanger sequencing confirmed the presence and segregation of the homozygous STIM1 c.221T>C. This mutation 
results in the p.Leu74Pro amino acid change in the EF-hand domain of the protein.  
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STIM1 wt/c.478del STIM1 wt/c.478del 
STIM1 c.478del/c.478del 





5.3.1.2 P1 CANT mutation 
As stated above the CANT1 homozygous missense mutation c.676 G>A, p.Val226Met. Gtg>Atg was confirmed by the hospital 
and segregated by Sanger sequencing of paternal DNA, with primer pair B1 and C1 in Table 2.1.1 using the same method as 
used to confirm the STIM1 mutation. None of the CANT1 sequencing is shown here. The known pathogenic CANT1 mutation 
has previously been described in multiple patients with BKim-variant Desbuquois dysplasia, usually in compound 
heterozygosity with another mutation (Kim et al., 2010; Furuichi et al., 2011).  
The overall small stature observed in P1 was consistent with previous reports regarding the effects of this CANT1 variant. A 
skeletal survey was performed. The skeletal survey showed an abnormal early maturation of carpal bones and a gentle curve 
scoliosis of the cervicothoracic spine, both of which have previously been seen in CANT1-related disorders (Nizon et al., 2012; 
Bui et al., 2014). Though the monkey wrench deformity of the femoral necks, shortened metacarpal bones, and other 
abnormalities was not seen in this patient. Images of this can be seen in Figure 3 of Rice et al., 2019. 
The homozygous mutation of CANT1 c.676G>A has previously been shown to affect the protein function. This missense 
mutation significantly reduces, but does not eliminate, the nucleotidase activity of CANT1 (Furuichi et al., 2011). In patients 
with disease, a second mutation is also normally present which results in a premature stop codon or more significantly reduced 
CANT1 nucleotidase activity. No such second mutation was identified in P1. As such, this single homozygous mutation in 
CANT1 causes a less severe phenotype than the “Kim-variant” Desbuquois dysplasia, which occurs when a more damaging 
mutation is present on the other allele (Balasubramanian et al., 2017; Rice et al., 2019). 
 
5.3.1.3 Patient immunological profiles 
5.3.1.3.1 Patient 1 (P1) 
The patient was suspected of having CRAC channel deficiencies early in life due to their recurrent tooth infections and tooth 
enamel deficiency. A full dental clearance was needed. Other symptoms include; reduced muscle bulk, hypermobile joints, 
proximal weakness, fixed dilated pupils, recurrent sinopulmonary infections, ichthyosis, anhidrosis, severe eczema mainly 




P1 had normal numbers of T, B, and NK cells, which is typical for STIM1 deficiency, as seen in Table 5.3.1. The 
immunoglobulins (IgG, IgA, IgM, and IgG subclasses) were normal with marginally elevated total IgE. The levels of specific 
antibodies to tetanus and Haemophilus influenza type b (Hib) were adequate. The total anti-pneumococcal antibody levels 
were reduced. However, following a challenge vaccination with pneumovax, the levels increased well above the protective titre 
(from 6.2 to 120.7 µg/mL). The T cell proliferation response to PHA was overall comparable to HC, though one measurement 




Table 5.3.1 Lymphocyte and immunoglobulin counts and challenge response of P1 
 
cells/µL 
 May 2017 Nov-2018 Normal range 
Total Lymphocyte 4609 6285 1700 - 6900 
CD3 3581 5329 900 - 4500 
CD19 749 1001 200 - 2100 
CD4 2120 3467 500 - 2400 
CD8 1141 1636 300 - 1600 
NK 273 132 100 - 1000 
Ratio (CD4/CD8) 1.86 2.11 1.07 - 1.87 
g/L 
IgG 8.8 - 4.9 - 16.1 
IgA 1.41 
- 
0.40 - 2.00 
IgM 0.62 
- 
0.50 - 2.00 
IgG1 6.47 
- 
3.62 - 12.28 
IgG2 1.98 
- 
0.57 - 2.90 
IgG3 0.475 
- 
0.129 - 0.789 
IgG4 0.044 
- 
0.013 - 1.446 
Total IgE 60.8 ku/L 
- 
<52 ku/L 
Antibody Response (see normal ranges for units) 
Haemophilus Ab 3.259 5.776 (µg/mL): Inadequate <0.1, Suboptimal 0.1-1, Adequate >1 
Pneumococcal Ab 120.7 6.2 (µg/mL): Inadequate <10, Suboptimal 10-30, Adequate >30 
Tetanus Ab 0.804 1.099 (IU/mL): Inadequate <0.01, Suboptimal 0.01-0.15, Adequate >0.15 
 
Data was generated by Leeds Clinical Department and supplied by Clive Carter (SJUH). Results from patient whole blood. 




Table 5.3.2 T cell proliferation  
 
 11.11.2017 14.05.2018 
PHA at 100 µg/mL Counts per minute (cpm) 
P1 13956 46630 
HC 65335 55285 
PHA at 10 µg/mL Counts per minute (cpm) 
P1 73322 69595 
HC 118453 98104 
 
Data generated by Leeds Clinical Department and supplied by Clive Carter (SJUH). Results below (blue) the HC values 
are colour coded. For PHA the dose was increased and the number of initial cells per condition stayed the same.  
 
5.3.1.3.2 Patient 2 (P2) 
Patient 2 has recurrent infections, mild muscles weakness, normal reflexes, hypermobile, diminished sweating and generalised 
hypomineralised amelogenesis imperfecta (AI) (Parry et al., 2016; Rice et al., 2019). The initial patient tests, in 2011 and 2013, 
showed an immunological profile within normal ranges for bacterial and viral antibodies, lymphocyte counts, T cell proliferation 
and immunoglobulins. The CD4/CD8 ratio was elevated to 1.9 in 2013 (normal 1.07-1.87). In 2018, additional tests showed 
normal cell counts of T cell subsets, B cells and NK cells and normal T cell spectratyping of the β chain of the TCR. The only 





5.3.1.4 STIM1 expression 
5.3.1.4.1 Patient 1 mutation 
The homozygous deletion in STIM1 NM_003156.3:c.478del, p.(Ser160ValfsTer15) creates a frameshift that results in a 
premature stop codon. It is likely that this transcript is sent for nonsense mediated decay. The stop codon occurs in the SAM 
domain and the predicted truncated protein would not contain important functional domains of STIM1, such as the CRAC 
activation domai 
n (CAD p.342-448) needed for Orai1 interaction, as seen in Figure 5.3.3.  
 
Figure 5.3.3 Amino acid sequence of STIM1.  
A) WT STIM1 sequence (Transcript ENST00000616714.4). This shows the amino acid (S) directly affected by the 
deletion as underlined and the grey amino acids are absent in the patient STIM1 polypeptide. B) Predicted patient 





5.3.1.4.2 STIM1 mRNA  
To see if any STIM1 transcripts were present in P1 despite the frameshift pS160fs, qPCR of the patient cDNA was performed. 
The levels of mRNA for STIM1 in the patient PBMCs was comparable to that for HC, as shown in Figure 5.3.4. In order to 
determine if any STIM1 protein was expressed from the mutant transcript, western blots were performed (Section 5.3.1.4.3).  
 
 
Figure 5.3.4 qPCR of STIM1 in Patient 1 
PBMCs and non-monocytes (NM) were isolated by gradient separation and negative selection of monocytes (Sections 
2.2.3.4). RNA was isolated and cDNA produced using high capacity reverse transcription (Section 2.2.1.6). SYBR green 
qPCR was performed (2.2.1.9). The melt curves indicate a single band was produced with both primer pairs.  
qPCR data comparing cDNA for 2 HC with P1. H36B4 was used to normalise each sample, which were run in triplicate. 
2 separate HC were used. There were 2 types of cells for each individual, total PBMCs and non-monocytes (NM). There 
was no significant difference <0.05 using a Two-Tailed unpaired student T test. 
P1 vs HC(pooled) PBMC P=0.6597, P1 vs HC(pooled) non-monocytes P=0.9215 
 
 
5.3.1.4.3 Protein expression in primary patients samples 
To confirm the predicted premature codon in P1 western blots were performed with the patient PBMCs to look for full length 





































Figure 5.3.5  STIM1 WB with P1 sample 
Both western blots were performed using the WB Method A (Section 2.2.6.1) with 20 µg/lane loaded and visualised with 
anti-STIM1 and anti-GAPDH antibodies, for details see Table 2.1.3. A) The lysate was made from P1 and HC PBMC’s 
that had undergone negative T cell selection (Section 2.2.3.3.2), before NP40 lysis. B) The lysate used fresh PBMCs 
including T cells using the same NP40 lysis method as for (A).  
 
The WB in Figure 5.3.5 of patient PBMCs without T cells (A) and fresh PBMCs (B) used the same STIM1 Ab, which was a 
mouse monoclonal, raised against full length STIM1. In both primary patient sample types, no full length STIM1 can be seen 
in the patient. However, the PBMCs without T cell samples did not give an intense band in the HC at the expected size for full 
length STIM1 (84 kDa) that can be seen in Figure 1.3.5 B). Instead, the darkest band can be seen at approximately 60 kDA, 
and a band of this size is also present in the fresh PBMCs but to a lesser extent. This band may be a result of calpain cleavage, 
a Ca2+ -dependent protease (Prins and Michalak, 2015) that results in a 60 kDa product. The lysates in panel A) underwent 
the additional step of negative selection, so they were more heavily manipulated and at room temperature for longer than those 
cells lysed in B), which could have increase the amount of calpain cleaved protein.  
The antibody used in Figure 5.3.5 was a mouse monoclonal, raised against recombinant full length STIM1, with an unspecified 
epitope, which reduces the possibility of detecting truncated forms of STIM1, so a range of STIM1 antibodies were used to try 
and visualise the predicted 20 kDa protein in P1. Figure 5.3.6.A) used a C-terminal specific monoclonal antibody raised against 
a synthetic peptide corresponding to residues surrounding Pro622 of human STIM1 protein. This meant it is unlikely to detect 
the truncated form of STIM1 in P1. Figure 5.3.6.B) used a N-terminal specific antibody raised against amino acid 25-139 of 




no band could be seen. Figure 5.3.6.C) used a rabbit bleed, so contained many possible antibodies raised against STIM1, no 
bands were seen at the predicted size of the truncated protein. 
Three different purified antibodies and an un-purified rabbit bleed where not able to detect any STIM1 protein in the P1 PBMCs 
as shown in Figure 5.3.5 and Figure 5.3.6. This suggests that the patient mutation may result in a transcript that is sent for 
nonsense mediated decay, or produces a very unstable protein. A lack of protein was also seen in P2 which was unexpected 
as the mutation resulted in an amino acid change and not a premature stop codon. When this patient was previously published 
(Parry et al., 2016), no WBs were performed on patient samples and as a result normal protein expression was assumed. In 
this paper, the mutation was expressed in HEK293 cell lines and expression was comparable to WT protein. The discrepancy 
seen between expression of this mutant STIM1 protein in cell lines and patient PBMCs may be due to the vector used for 
lentiviral transduction. The publication used YFP-STIM1 plasmids (Addgene, plasmid 18857) which contains a human 
cytomegalovirus (CMV) immediate-early enhancer, to cause a multiple-log increase in expression (Gruh et al., 2008).  
 
5.3.1.5 STIM2 expression  
STIM2 is a homolog of STIM1, and shares 62.42 % identity at the protein level. STIM2 has been shown to interact with STIM1 
in T cells (Beyersdorf et al., 2009). In some cell types STIM2 has been shown to have a direct effect on SOCE, but its main 
function in T cell is in regulating the resting calcium level in the ER and calcium leakage (Gruszczynska-Biegala et al., 2011).  
Over expression of STIM2 was seen in PBMCs from both patients when compared to HC by WB, though the protein band 
appears darker in P1 (Figure 5.3.7). To quantify expression, the full length protein of STIM2 at 100 kDa and the loading control 
were compared in ImageJ, where the pixel density of the bands was given as an area, the percentage of each band was relative 
to both the loading control and the protein of interest. The relative density was calculated using the relative percentages of 
STIM2 compared to ß actin. For example, when there is no STIM2 band present, the area would be 0 %, and the relative 
density compared to ß actin would be 0. The highest relative density of the full length STIM2 protein band was found in P1, at 





Figure 5.3.6 Range of STIM1 Antibodies with P1 and P2 
All WB seen here were performed using WB Method B (Section 2.2.6.2). Lysate made from frozen PBMCs by sonication. Maximal loading was used of these lysates 
rather than a specific amount of total protein. The blots used different antibodies, more details can be found in Table 2.1.3. A) C-terminal STIM1 D88E10 , B) N-terminal 
specific antibody Anti-GOK/Stim1 and C) used an unpurified rabbit bleed (sera). Full length STIM1 at 84 kDa is indicated by an arrow, the unlabelled arrow indicates 




















































Area of β 
actin 




of β actin 
HC 0.00 0.00 0.00 15564.69 100.00 1.00 
P1 9411.30 35.00 0.54 17499.45 65.00 1.12 
P2 600.51 2.58 0.03 22672.92 97.42 1.46 
 
Figure 5.3.7 STIM2 WB 
WB was run using the same lysate and method as detailed for Figure 5.3.6, with maximal loading and blotted with STIM2 
Ab, full length protein can be seen at 100 kDa. ImageJ was used to calculate the relative density of the ß actin and full 
length STIM2 band using the same protocol (Miller, 2010).  


















5.3.1.6 Calcium flux of patient T cells 
STIM1 deficient T cells, have been shown to have no SOCE when stimulated with TG, TCR activation and Ionomycin. P2 T 
cells and NK cells were previously shown to have no SOCE, though additional samples were not available to reconfirm this 
result using the plate reader method. In Figure 5.3.8, this same lack of response was observed when using T cells from the 
STIM1 patient. (Feske, Picard and Fischer, 2010; Feske, 2011; Jairaman and Prakriya, 2013; Parry et al., 2016) 
 
Figure 5.3.8 Calcium flux of P1 T cells 
Calcium flux was run using the Flex Station protocol described in Section 2.2.7.1.2. For a system check Jurkat cell were 
run on the same day, and on both occurrences the cell line responded as seen previously. Calcium flux of STIM1 patient 
showed no response to either TG or TCR stimulation, each condition was run in duplicate. Patient cells were run on 2 





5.3.1.7 Interferon levels in patients 
In (Srikanth et al., 2019), P1 was shown to have increased expression of type 1 interferons under resting conditions using 
cDNA and increased IFNß cytokine in the serum of the patient compared to HC using an ELISA. The paper also showed an 
increased IFNß protein in STIM1 deficient MEF supernatant.  
The plasma IFN in the two STIM1 patients described in this project could not be compared via protein analysis as no plasma 
sample were available from P2. Therefore, quantitative RT-PCR was used to look at the levels of mRNA of IFN alpha and beta. 
 
 
Figure 5.3.9 qPCR of STIM1 patients basal Interferon levels 
Method described in 2.2.1.9. All samples were run in triplicate and normalised to H36B4 before further processing. The 
data was all normalised to the mean of 2 HC samples, so HC=1. 2 way ANOVA multiple comparisons shows the only 
significant difference (p<0.05) found was between hSTIM1 of P1 and P2 PBMCs (p=0.0076) 
 
The increased IFNß protein previously reported in P1 was not reflected in the mRNA levels of the patient, as shown in Figure 
5.3.9, where no significant difference was seen between the HCs and P1 for IFN α and ß. There was also no difference seen 



















































































































































5.3.2 STING patient 
STIM1 and STING functions were recently found to be linked (Srikanth et al., 2019). and increased IFN protein levels and IFN 
gene transcription was shown in STIM1 deficient human and mice. WES identified a patient with a homozygous STING mutation 
and so functional tests were performed to see if their IFN expression levels were comparable to HC and ultimately to STIM1 
patients detailed in section 1.3.1. The STING patient is a female from Czechoslovakia.  
 
5.3.2.1 Patient Phenotype 
The patient was diagnosed with systemic autoinflammatory diseases (SAID). They had periodic fever and the classical SAVI 
phenotype, recurrent fevers, abdominal pain and arthralgia. The phenotype displayed many characteristics typical of STING 
mutation carriage. Only minimal immunological data was available. They were found to have significantly elevated inflammatory 
markers, inflammation in the gut and active lymph nodes.  
No improvement was seen with anakinra (anti-IL-1 therapy). The patient is currently responding to tocilizulab (anti-IL-6). IL-6 
neutralizing antibodies promote the degradation of STING as part of the downstream molecule of STING along the DNA sensor 
pathway (Liu et al., 2014; Wu et al., 2017). IL-6 serves as a negative feedback mechanism to limit innate immune response 
induced by dsDNA. Another treatment for SAVI is JAK inhibition (Kacar, Pathak and Savic, 2019) . 
 
5.3.2.2 Genetics  
The homozygous missense mutation was identified by WES in the gene TMEM173 which encodes for the protein STING. The 
mutation found was c.992 G>A, p.Arg331Gln in the C-terminal tail (CTT). This change could affect autoinhibitory interaction 
with c-di-GMP-binding domain (CBD), constitutively mimicking activation by cGAMP (Huang et al., 2012; Ouyang et al., 2012; 
Shu et al., 2012).  
This mutation is present in the normal population in heterozygous form with a frequency of 0.0000955 (gnomAD, URL, 
accession date), which makes it a rare mutation and therefore increases the likelihood of the mutation being pathogenic. Arg331 
is a highly conserved amino acid in the STING protein throughout evolution. This Arg131 conservation is seen in 100 




Sanger sequencing was used to confirm the c.992G>A homozygous point mutation, as shown in Figure 5.3.10. Unfortunately 
any family members were not available for DNA sequence analysis and so no pedigree or segregation information could be 
obtained. No history of disease was mentioned in the patient’s family, so the parents could potentially be heterozygous carriers 
as seen in the normal population.   
 
Figure 5.3.10 Sanger sequencing of TMEM173 from patient genomic DNA 
STING gene (TMEM173) is located on Chromosome 5: 139,475,533-139,482,935, reverse strand. Genomic DNA isolation 
was from patient whole blood and PCR and Sanger sequencing were performed as per Section 2.2.1.2. Primer pairs 
D1and E1 were used to generate PCR products (Table 2.1.1). The PCR products were amplified in duplicate and run on 
a 1.5 % agarose gel, to confirm the predicted sizes. They were then directly sequenced using both the forward and reverse 
primers defined above, but only the forward traces are shown here. The box indicates the codon and the arrow shows the 
codon where the point mutation occurs (cGg> cAg). 
 
5.3.2.3 Predicted change in STING protein 
The missense p.Arg331Gln mutation occurs in the C-terminal tail of the protein, as shown in Figure 5.3.11.The amino acid 
change from arginine to glutamine is quite a significant change in the side change, from a large basic charged side chain to a 
smaller polar side group. This change could potentially affect the function of the protein by altering the tertiary structure or its 
interaction with other proteins, especially as it is located on the exterior of the protein.  
Comprehensive prediction software was used to look at the changes in atom potentials and torsion angle potentials. The 
mutation was found to be potentially disabling due to unfavourable torsion angles (Huang et al., 2012; Ouyang et al., 2012). 
The C-terminal tail domain is important due to its autoinhibitory interaction with c-di-GMP-binding domain. This means a 
mutation in this region could result in a constitutive activation of STING by mimicking of cGAMP binding (Huang et al., 2012; 
Ouyang et al., 2012; Shu et al., 2012).  
GG GG GG G G AA A A CC T C AT T AC T C T C T C CC C T A T C T C C C T
1 10 20 30
TG T TCCA G A AC C T G C A G AT G AC A G C A G C T T C T C G C T G T C C
40 50 60 70
C CA G G AG G T T C T C C A G C AC C T G C G G C AG G AG G A A A A G G A
80 90 100 110
AAG A G G T T AC T G T G G G C A G C T T G A A G AC C T C A G C G G T G C C
120 130 140 150
CC A G T A C C T C C A C G A T G T C C C A A G A G C C T G AG C T C C T CA T C
160 170 180 190
LRTMF_G01_MULRAK_070918_2018-09-07.ab1  (483 bases)
Printed from SnapGene® Viewer:  Sep 11, 2018  13:07 Page 1
TA A G G A AA G GG G AA G AT CC T CA T T AC T C T C T C CCC T A T C T C CC T G T T CCA G A AC C T G C
1 10 20 30 40 50
C AG AT G AC A G C A G C T T C T C G C T G T C C CA G G AG G T T C T C C G G C A C T C C AG G A G G
60 70 80 90 100 110
G A A A A G G A A G A G GT T A C T G T G G G C AG C T T G A A G AC C T C A G C G G T G C C C A G T A C C T C C
120 130 140 150 160
C A C G AT G T C C C A A G A G C C T G A G C T C C T C A T C A G T G G A AT G G A A A A G C C C C T C C C T C T
170 180 190 200 210 220
TMF_E07_5_11_TD_2019-11-05.ab1  (617 bases)
Printed from SnapGene® Viewer:  Nov 6, 2019  10:41 Page 1
TC C G C AC G G A T T T C T C T T G A G A C C C A G G G T C A C C A G G C C A G A G C C T C C A G T G G T C T
230 240 250 260 270 280
TC C A A G C C T C T G G A C T G G G G GC T C T CTTAA T G G C T G A A G AC G T C G G T G C G G A
290 300 310 320 330
A G G G G G G AG ACC AC TG G AG G CT C T G CCG G G G G ACCC G G G G T CTCA G GAG A A A TCC TG C G
340 350 360 370 380 390
G AG A G G G G G G G C G T TTC A GTCCC T T AT TT TT TTA T T T T T T TG T G G G AC T C C G G AA G T
400 410 420 430 440
TMF_E07_5_11_TD_2019-11-05.ab1  (617 bases)
Printed from SnapGene® Viewer:  Nov 6, 2019  10:41 Page 2





Figure 5.3.11 Structure of STING and pArg331 
Crystal structure of ligand free human STING (4EMU) (Shu et al., 2012), with amino acid of interest highlighted in purple. 
This figure was produced using https://www.uniprot.org/uniprot/ (accession data 14Sep2018). 
 
5.3.2.4 Interferon levels in STING patient 
STING has an important role in activating innate immune gene transcription and the interferon response. Preliminary IFN 
response experiments were performed using an established TaqMan assay to look at the effect of the STING mutations on 
gene expression profiles. A range of genes well known to be involved in the interferon response were measured (York et al., 
2015; Shrivastava et al., 2016). A brief description of the genes are provided in Table 5.3.3. 
In this experiment, HC and STING patient cells were compared. Three cell types were isolated, monocytes, non-monocytes 
and PBMC, and the IFN gene transcription levels quantified at baseline and after stimulation with IFNα. Of the three cells types 
monocytes had the higher overall ISGs expression and can be seen in Figure 5.3.12. This expression was abolished with IFN 
stimulation, except for in CXCL10, for which levels remained high. 
Overall not much difference was seen between patient and HC for any cell type. In particular no significant trends were seen 
in non-monocytes or PBMCs at baseline or stimulated cells. These cell types are less sensitive to IFNα stimulation and produce 
less IFN than monocytes, and so the result was not unexpected. Therefore, all graphs for these cell types are not shown, but 




Table 5.3.3 Gene panel for TaqMan experiment  
 
Gene Function 
HPRT Name - Hypoxanthine Phosphoribosyltransferase gene 
Transferase enzyme, Housekeeping gene 
IFI44 Name - Interferon Induced Protein 44 
 
Associated with hepatitis C virus (HCV) infection (Power et al., 2015) 
CXCL10 Name - C-X-C Motif Chemokine Ligand 10 
Ligand for the receptor CXCR3. Binding results in pleiotropic effects, including stimulation of monocytes, natural 
killer and T-cell migration, and modulation of adhesion molecule expression. (Vazirinejad et al., 2014) 
IFIT1 Name - Interferon Induced Protein with Tetratricopeptide (IFIT1) 
Inhibiting viral replication and translational initiation. Sensor of viral single-stranded RNAs. Inhibiting expression 
of viral messenger RNAs. (Fensterl and Sen, 2015) 
MX1 Name - MX Dynamin Like GTPase 1 
Encodes for GTP-metabolizing protein that participates in the cellular antiviral response 
OASL Name - 2'-5'-Oligoadenylate Synthetase Like 
Binds double-stranded RNA. Antiviral activity and enhances retinoic acid-inducible gene 1 (RIG-1) signalling to 
activate cellular innate immunity. (J. Zhu et al., 2014)  
IF16 Name - Interferon Gamma Inducible Protein 16 
Antiviral & pathogen detection activity. Encodes for a nuclear protein that functions as a transcriptional repressor 
IF127 Name - Interferon Alpha Inducible Protein 2 
RNA polymerase II activating transcription factor binding and lamin binding. Diseases associated with IFI27 
include Hepatitis C Virus and Hepatitis C. 
ISG15 Name - Interferon-stimulated gene 15 
Ubiquitin-Like Modifier conjugated to intracellular target proteins upon activation. Antiviral activity 
IL6 FAM Name - Interleukin 6 
Cytokine that functions in inflammation and the maturation of B cells 
IFI44L Name - Interferon Induced Protein 44 Like 
Antiviral activity against HCV (Huang et al., 2018) 
PPIA Name - Peptidylprolyl Isomerase A 
Accelerates the folding of proteins. The encoded protein is a cyclosporin binding-protein and may play a role in 
cyclosporin A-mediated immunosuppression. 
m1 RSAD2 Name - Radical S-Adenosyl Methionine Domain Containing 2 






Figure 5.3.12 Interferon related gene expression in monocytes 
TaqMan qPCR protocol described in Section 2.2.1.9.1 was used for this experiment, which was established by Srikanth 
et al., 2019. All expression was normalised to HC which was made as 1. A large standard deviation was seen for each 
gene in both the HC and patient data. For more conclusive data this experiment needed to be repeated, but unfortunately 
no patient sample was available. Multiple T tests used to analyse data. P values : ns P > 0.05 (ns), P ≤ 0.05 (*), P ≤ 0.01 
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Table 5.3.4 Significant results from ISGs experiment of STING patient 
 
Cell type Gene P value Patient Mean SE of difference Adjusted P Value 
PBMC  CXCI10 0.0005 6.8 0.1302 0.0045 
PBMC  m1 RSAD2 0.0047 0.1169 0.06074 0.037 
Stimulated PBMCs IF127 0.0002 8.153 0.09076 0.0019 
Stimulated PBMCs ISG15 0.0015 2 0.03896 0.0165 
Stimulated monocytes IF144 0.0004 0.6313 0.007155 0.0038 
Stimulated monocytes CXCI10 0.0051 42.61 2.974 0.0419 
Stimulated monocytes m1 RSAD2 0.0047 1.335 0.02318 0.0419 
 
This table highlights all statistically significant results (p< 0.05) from qPCR experiment, shown in Figure 5.3.12. Statically 
significance was calculated using multiple T tests. Mean HC for all samples was normalised to 1. SE = Standard Error. 
 
5.3.2.5  Interferon response compared to STIM1 deficient patient 
The interferon response was compared between STIM1 P1 and the STING patient, as seen in Figure 5.3.13, in stimulated 
PBMCs and monocytes. The STIM1 patient had significantly elevated levels of expression compared to the STING patient, in 
both cell types. CXCL10 expression, however, was significantly higher in the STING patient. This gene was comparable to HC 






Figure 5.3.13 IFN response of patient cells 
Stimulated cell data for both patients was normalised to the HC run in the same experiment, as originally reported (Section 
5.3.2.4 and Srikanth et al., 2019). This was done to eliminate differences between the experiments, but could incorporate 
bias as the HC were not the same. The STIM1 P1 data was produced by Dr Yasser M. El-Sherbiny (Srikanth et al., 2019) 
and the raw data provided for analysis. Statically significance was calculated using multiple T tests. P values : ns P > 0.05 




5.4 Key findings 
In this chapter, experiments were performed on primary samples from three patients with PID to further understand the cause 
of their disease. 
• Segregation of the homozygous STIM1 mutation c.478del, p.Ser160ValfsTer15 was confirmed in P1, by Sanger 
sequencing of parental DNA. 
• Mutations c.478del (p.Ser160ValfsTer15) and c.221T>C (p.Leu74Pro) in STIM1 in P1 and P2 respectively, resulted in 
no protein expression of STIM1.  
• STIM1 deficiency and subsequent lack of calcium flux in patient T cells can present with a mild immunological phenotype. 
• Sanger sequencing confirmed the homozygous STING mutation, c.992 G>A, p.Arg331Gln.  








The aims of this chapter were to confirm potential mutations in patients with PID, show the functional effects of STIM1 mutations 
in patient cells and to determine the IGS expression of a patient with a STING mutation. The key findings summarised above 
show that these aims where achieved.  
 
 
5.5.1 STIM1 phenotype  
Two patients with STIM1 mutations were investigated in this chapter. P1 was newly identified and the mutation was confirmed 
(c.478del, p.Ser160ValfsTer15), segregation shown in their pedigree, no protein expression shown in PBMCs and no SOCE 
shown in patient T cells. This patient showed classical STIM1 deficiency traits, such as tooth enamel deficiency, recurrent 
infection and anhidrosis. Outside of the classical phenotype they presented with eczema ichthyosis and a normal T cell 
proliferation and normal cell numbers. The most recent cell numbers were slightly above the normal range for some T cell 
populations but this was not seen in the previous testing so could have been a result of infection (Table 5.3.1). The 
autoinflammatory features of the fever and rash were novel for patients with this deficiency (Picard et al., 2009; Byun et al., 
2010; Wang et al., 2014; Rice et al., 2019).  
P2 had been previously confirmed to have a STIM1 mutation (c.221T>C, p.L74P). In this project, this mutations was shown to 
cause STIM1 deficiency rather than the lack of function previously reported as no protein was detected in patient PBMCs (Parry 
et al., 2016). P2 phenotype also showed mild immunodeficiency, normal cell numbers, enamel deficiency and anhidrosis. This 
patient had not developed any overt immunological problems during their 6 year follow up.  
Both P1 and P2 had significantly increased interferon gene expression after stimulation compared to HC (Rice et al., 2019; 
Srikanth et al., 2019). P2 had a milder increase in gene expression compared to P1. This may offer some protection against 
viral pathogens (Bourdon, Manet and Montagutelli, 2020). Mutations in Orai1 and STIM1 that abolish SOCE were recently 
reported to cause a new form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (Lian et al., 2018). This 




kappa-B kinase regulatory subunit gamma (IKBKG) and nuclear factor kappa-B inhibitor alpha (NFKBIA) genes (Picard, 
Casanova and Puel, 2011; Kawai, Nishikomori and Heike, 2012). It presents with hypotrichosis, hypodontia, hypohidrosis, and 
recurrent bacterial, viral, and fungal infections. These conditions are seen in patients with STIM1 deficiency and share 
overlapping susceptibility to pathogens. Patients with IKBKG mutations have presented with inflammatory bowel disease, 
whereas in STIM1 patients autoimmune presentations are normally thrombocytopenia (Kawai, Nishikomori and Heike, 2012). 
In contrast, P1 presented with the additional phenotype of rashes. The data presented here supports this new form of anhidrotic 
ectodermal dysplasia with immunodeficiency for patients with STIM1 deficiency. However, the immunodeficiency can vary in 
severity, and P2 in particular had very mild immunodeficiency.  
 
 
5.5.2 STIM2 overexpression  
STIM2 has been shown to interact with STIM1 and is thought to play a role in regulating SOCE. In alphaT3 cells STIM2 is 
thought to play a role in translocation of STIM1, Orai1 interaction and SOCE activation (Berna-Erro et al., 2017). However, 
overexpression of STIM2 appeared to inhibit STIM1 function downstream of puncta formation in HEK293, PC12, A7r5 and 
Jurkat T cells (Soboloff et al., 2006).  
The western blot of patient PBMCs (Figure 5.3.7) showed that both patients had an overexpression of STIM2 compared to HC, 
with P1 showing the highest relative density compared to the no visible protein seen in HC. The loading control of P2 showed 
a more intense band , which suggested more protein was loaded for this sample. Potentially, STIM2 expression would have 
been seen in HC if similar amounts of protein were loaded and so this experiment would need to be repeated to confirm the 
overexpression of STIM2 in P2. However, the overexpression of STIM2 in P1 is a valid conclusion from this blot. It is interesting 
to note that this potential compensatory mechanism for STIM1 deficiency (Figure 5.3.6) was not seen in both patients.  
For both compensation mechanisms, STIM2 expression and interferon gene expression, for STIM1 deficiency P1 showed 
significantly more expression than P2. This could potentially be due to the milder immunodeficiency displayed by P2 or the 
younger age of P1. The difference in cytokine and protein expression between children and adults is still not completely 




5.5.3 Measuring IFN levels 
As shown in Section 5.3.1.7, there is a discrepancy between the mRNA and protein levels for IFN expression. The increased 
IFNß protein previously reported in P1 (Srikanth et al., 2019) could not be seen at the mRNA levels in the patient (Figure 5.3.9), 
where no significant difference was seen between the HCs and P1 for IFN alpha and ß.  
This discrepancy between mRNA and protein levels for cytokines is well documented due to regulation at a translational (IL4 
and 10) and post-translational (IL1 and 18) level (Le et al., 1997; Petrilli, Papin and Tschopp, 2005; Scheu et al., 2006; Amsen, 
Visser and Town, 2009). Therefore, where possible it is best to test both the mRNA and protein of cytokines of interest. Data 
at the protein level was not available for STIM1 P2 or the STING patient, which both showed less interferon stimulated gene 
elevation than P1 by qPCR. If time and patient sample was available it would have been beneficial to look at the levels of 




Expression of ISGs are induced by type I interferon via the JAK-STAT signalling pathway. ISGs are involved in a wide spectrum 
of cellular activities including apoptosis, immune modulation, cell migration and adhesion, and antiviral responses. Some ISGs 
have multiple roles in immune regulation (Fensterl and Sen, 2015). 
Interferon stimulated genes were measured in all three patients discussed in this chapter. For the two STIM1 patients the 
results were generated by Dr Yasser El-Sherbiny at the University of Leeds and are now published (Rice et al., 2019; Srikanth 
et al., 2019). 
Both patients with STIM1 deficiency showed significantly elevated ISGs when stimulated IFNα in PBMCs and monocytes 
compared to HC. IGS was measured in these patients due to the recent link between STING and STIM1. STIM1 acts as a 
negative regulator for STING and can inhibit STING trafficking by physically interacting with STING and retaining it at the ER 
membrane. Therefore, retaining STING in an inactive state. STIM1 deficiency causes elevated ISG expression as STING is no 




STIM1 P1 results showed unstimulated PBMCS and monocytes with all ISG genes significantly increased compared to HC 
(Srikanth et al., 2019), except for CXCL10, which showed comparable levels to that seen in HC for both cell types. STIM1 P2 
also showed increased expression of ISG genes in PBMCs and monocytes (baseline data only) (Rice et al., 2019). However, 
P1 showed higher expression than P2. All genes showed increased expression in monocytes, apart from CXCL10 and OAS1 
which were comparable to HC, and MX-1 which was significantly reduced. In P2 PBMCs, all genes showed significant increase 
in expression, apart from CXCL10 which showed a slight decrease in expression and OAS1 which was significantly reduced.  
The same experiment was performed using patient cells with a confirmed STING mutation (c.992 G>A, p.Arg331Gln). This 
mutation occurs in the C-terminal tail domain which has an autoinhibitory function, due to interaction with c-di-GMP-binding 
domain. This means a mutation in this region could result in a constitutively active STING by mimicking of cGAMP binding 
(Huang et al., 2012; Ouyang et al., 2012; Shu et al., 2012). The ISG profile for this patient was comparable to HC for most 
genes and suggests that the patient mutation does not affect the protein function. This would need to be confirmed by more 
vigorous functional testing, such as binding studies, additional ISG experiments with different stimuli and protein modelling.  
A gene of interest, C-X-C Motif Chemokine Ligand 10 (CXCL10), was identified by comparing the gene expression profiles of 
the STING patient to HC and STIM1 P1. This gene was significantly elevated in the STING patient under both baseline and 
stimulated conditions. The expression of this gene was comparable to HC in both STIM1 patients.  
CXCL10 encodes for interferon-γ-inducible protein 10, a chemokine which is induced by IFN-γ and is produced by a wide range 
of cell types, including monocytes and neutrophils. CXCL10 binds to CXCR3. Both CXCL10 and CXCR3 are essential for 
leukocyte trafficking and homing and perpetuation of inflamed tissues. CXCR3 is preferentially expressed on activated Th1 
cells. These proteins have been linked to multiple sclerosis and autoimmune disease (Vazirinejad et al., 2014). In the literature, 
recent studies have shown links between STING and CXCL10 in mice, CXCL10 signalling promotes viral persistence and 
knock outs show a moderate decrease in immune cell numbers (Tao Lin, Tingting Geng, Andrew Harrison, Duomeng Yang, 
Anthony T. Vella, Erol Fikrig, 2021). Due to time limitations no further work was done on these two genes. However, looking at 




The data generated for the STING patient would need to be repeated before additional experiments can be performed. The 
standard deviation showed high variation and some data was missing for multiple genes. Different stimulations, such as cGAS, 




Chapter 6 General discussion 
 




6.1 Aims  
The two overall aims of this project are summarised below.  
 
6.1.1 Confirm potential mutations and their segregation in patients with PID. 
Sanger sequencing was used to confirm the presence of mutations identified by whole exome sequencing (WES) and gene 
panels (Chapter 3 and 5). This is also essential for mutations identified by next generation sequencing (NGS) as all of these 
approaches can result in false mutations due to the large data and filtering approach needed for its analysis. This is highlighted 
by the identification of the dehydrogenase/ reductase 4 (DHRS4) mutation as homozygous rather than heterozygous (Chapter 
3).   
Where possible the segregation of these mutations was found by sequencing of parental DNA or by cloning which isolated the 
patient alleles. This can improve the likelihood of mutations being pathogenic if only the proband has no WT allele due to 
homozygous or compound heterozygous mutations and the rest of the family are carriers or wildtype homozygous (Section 






6.1.2 Use primary samples and in vitro models to determine if mutations identified are pathogenic and 
causing of the patient’s phenotype 
For patients with confirmed STIM1 and calcium release activated channel regulator 2A (CRACR2A) mutations, the protein 
expression in peripheral blood mononuclear cell (PBMC) was examined. This was done to determine if the mutations affected 
the expression of the protein, such as protein deficiency (Chapter 5, STIM1 P1 and P2) or truncated forms (The section on 
‘Protein expression in patient cells’ showed no truncated CRACR2A). 
Functional experiments were developed to look at the overall function of patient primary cells (cytokine expression and 
proliferation) and specific function related to the mutated protein (Calcium flux, Jun N-terminal kinase [JNK] signalling and ISG 
expression). Where further information was required for the effect of mutations cell lines were produced, that had the protein 
knocked-out (KO) and the patient alleles expressed. Functional experiments were then performed on these cell lines.  
STIM1 deficiency was confirmed in two patients (Chapter 5). For STIM1 P2 this contrasted the previously published in vitro 
data (Parry et al., 2016), which had assumed it was a loss of function mutant due to its ability to be expressed in cell lines. The 
main functional experiments performed in this study were for calcium flux. A range of methodologies were used to show the 
effect of confirmed mutations in patient T cells and cell lines by plate reader (Chapter 5, STIM1 P1) and single cell imaging 
(Chapter 3 and 4, CRACR2A). 
The important overall conclusion  from this work is that both primary samples from the patient and cell lines are needed to fully 






6.2 Impact of work  
6.2.1 Effect on patient treatment 
PIDs are rare diseases (O’Shea, 2018). The number of patients being diagnosed with PID is increasing. However, as at 2018 
less than 22 % of patients had a proven genetic defect underlying their PID (Shillitoe et al., 2018). Being able to identify the 
genetic cause of PID disease can improve the diagnosis and treatment options available to the patients. Personalized medicine 
or gene therapies may be available depending on the genetic cause. Furthermore,  family members at risk can also be 
identified.  
Personalised treatments are sometimes available when genes or mutations have already been identified as pathogenic. In this 
project, the confirmation of a stimulator of interferon genes (STING) mutation allowed for patient treatment by tocilizulab 
(Chapter 5), which is an anti-IL-6 neutralizing antibody that promotes the degradation of STING. 
Currently no changes in treatment have been implemented as a result of this case study into the patient with CRACR2A 
mutations. This is because there is no specific CRACR2A drug and the patient’s main phenotype of low immunoglobulins is 
managed by immunoglobulin replacement therapy. Their quality of life is considered good and so no further treatments are 
needed. If over time the phenotype progresses and further treatment is needed, the identification of T cells being the cell type 
affected, rather than B cells, may impact treatment. The identification of patients with CRACR2A mutations with heart conditions 




6.2.2 Primary immunodeficiency field 
This project supports previous studies that highlight the benefits of NGS in identifying pathogenic variants in patients (Y. Yang 
et al., 2013; Rae et al., 2018). It has also led to the identification of a potential novel gene, CRACR2A, causing PID. The case 
study in Chapters 3 and 4 strongly suggest that mutations in this gene could cause PID, though recessive inheritance, such as 
haploinsufficiency or in a compound heterozygous state. This was demonstrate by the lack of maternal allele (R144G, E300*) 
expression in patient T cells (Figure 3.3.8), which had reduced calcium flux, JNK expression and abnormal cytokine profiles 
(Figure 3.3.11, Figure 3.3.12 and Figure 3.3.13). These CRACR2A alleles also showed altered function in cell lines (Figure 
4.3.15, Figure 4.3.16 and Figure 4.3.17), which supported the primary cell data as shown in Table 4.5.1  
The data in Chapter 5 supports the new form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) for patients 
with STIM1 deficiency. Which was previously reported in patients with Orai1 deficiency (Lian et al., 2018).  
 
6.2.3 The pathogenic effect of CRACR2A mutations 
CRACR2A mutations have been identified in only a few patients to date, and these cases have very varied phenotypes, as 
shown in Table 6.2.1. As a result it is hard to determine if the mutations or lack of CRACR2A protein will cause disease. The 
main patient presented in this chapter displayed a T cell specific immunodeficiency, as seen by the reduced calcium flux, 
proliferation and cytokine response. To better understand if the identified mutations were causing the immunological profile in 
the patient in vitro studies will need to be developed in Jurkat cells, which is a human T cell derived line.  
The cardiac related phenotypes observed in the other CRACR2A patients is something not seen in patients with confirmed 
STIM1 or Orai1 deficiency or mutations. It is difficult to determine if this phenotype is related to CRACR2A mutations, especially 
as it is not seen in the main patient presented here, which was the only patient available for further study.  
In vitro studies were started on all other patient mutations in Table 6.2.1, by performing mutagenesis in vectors used to express 
CRACR2A in Jurkat cell lines. Primer information is given Table 2.1.1. However, due to time constraints no cell work was 






Table 6.2.1 CRACR2A Phenotypes 
  CRACR2A cases 
Deficiency Orai1 and STIM1 Leeds Cambridge USA Italy 
Mutation Multiple  









T cell activation defect 
Mitochondria-mediated cell death 
pathways ↓ 






























Respiratory muscle insufficiency 
Atrophy of type II muscle fibres 
Normal -   
Ehlers-Danlos 
syndrome  
-   
Ectodermal 
dysplasia 
Dental enamel defect 
(amelogenesis imperfecta type III) 
Anhidrosis 
Normal -  Bone pain -   
Thrombocyte 
function 
No bleeding diathesis 
Thrombocytopenia (autoimmune) 
Normal -   Anaemia  -  
Cardiac 
function 



















(Barozzi et al., 
2019) 
STIM1 and Orai1 phenotypes were taken from Table 1.3.1. For the CRACR2A cases other than Leeds patient, the clinical 





6.2.4 CRAC channel inhibitors as drug targets 
The CRAC channel as previously discussed has a role in many tissue types as shown by the SCID like disease that deficiency 
of STIM1 or Orai1 can cause. As a result CRAC channel inhibitors have been identified as useful therapeutics for autoimmune, 
inflammatory and other conditions, as shown in Table 6.2.2. As a result the more information that is known about these proteins 
and the effects of STIM1 and Orai1 deficiency and mutations in particular can lead to a better understanding of possible off 
target effects. 
CRAC channel inhibitors stabilise the pulmonary endothelium and block proinflammatory cytokine release, potentially mitigating 
respiratory complications observed in patients with COVID-19. Clinical trials are ongoing (Table 6.2.2) but initial data on the 
safety and efficacy of Auxora was promising and improved the outcome in patients with severe COVID-19 pneumonia (Miller 
et al., 2020). 
Previously CRAC channel inhibitors have been researched as possible therapies in cancer. Calcium signals and CRAC 
channels are known to influence the development, growth, and metastasis of cancer, including cervical, breast, prostate, 
glioblastoma, esophageal cell carcinoma, hepatocellular carcinoma and pancreatic ductal adenocarcinoma (Yang, Zhang and 
Huang, 2009; Flourakis et al., 2010; Chen et al., 2011; Liu et al., 2011; N. Yang et al., 2013; H. Zhu et al., 2014; Khan et al., 
2020). STIM1 and Orai1 have been seen to be overexpressed in cancer cells and so inhibition of the CRAC channel and its 
associated signalling pathways has been used as a potential therapy (Khan et al., 2020).  
CRAC channel mediated SOCE plays a key role in airway smooth muscle cell (ASMC) proliferation and as such, STIM1 or 
Orai1 represent targets that reduce airway remodelling in chronic asthma. Hyperplasia of ASMC is a characteristic of chronic 
asthma patients. SOCE plays an important role in regulating Ca2+ signalling and cellular responses of ASMCs. SOCE is 
upregulated during ASMC proliferation, which results in a mild increase of STIM1 and a significant increase of Orai1 mRNA 
expression, which is partially inhibited by CRAC channel blockers (Zou et al., 2011). 
Different T cell subsets require different levels of SOCE for their function. Th1 and Th17 cell function is inhibited by changes in 




difference between T cell subsets could allow for the suppression of proinflammatory Th1 and Th17 cells, while maintaining 
immune tolerance in other T cell subsets (Vaeth, Kahlfuss and Feske, 2020). 
Inhibition of the main proteins of the CRAC channel, Orai1 and STIM1, may result in off target effects due to their role in enamel, 
heart and muscle tissues (Stauderman, 2018) . CRACR2A has been shown in this project to potentially be more specific to T 






Table 6.2.2 CRAC channel inhibitor or modulator clinical trials 
 







Acute pancreatitis and 
systemic inflammatory 
response syndrome 
Awaiting results, completed April 2019 NCT03401190 None 
Auxora 
CM4620 
CalciMedica 1 COVID-19 Pneumonia 
Initial results promising 
Completion predicted April 2021 
NCT04345614 
















Lower plasma levels of tumour necrosis 
factor-alpha (TNFα) and interleukin-4 
(IL-4) seen. 
Completed Oct 2019. 
NCT02958982 


















1 Plaque Psoriasis 
No results reported 








6.3 Limitations  
The main limitation in this project is the low number of mutations and patients available for study. This means data is potentially 
biased to the single patient and may not be directly applicable to a wider population. This is a recurring issue with rare diseases 
such as PID, which highlights the use of cell lines and mouse models for further study of the protein function and effect of 
mutations.  
Low cell numbers from patient primary samples was a limiting factor in many experiments (Chapter 3 and 5). Alternative 
methodologies were used where possible that required less cells. Expansion of the CRACR2A patient cells was also used, 
though the patient phenotype caused issues because the cells were difficult to expand and had a preference for CD8 T cell 
expansion over CD4, which is the opposite of that seen in healthy controls. The CD8 T cells are also known to be less 
responsive to calcium flux changes, which may be a reason for the reduced response seen when comparing HC to patient in 
the expanded populations. Other limitations of the different calcium flux methods used were discussed in more detail in 





6.4 Future work 
Future work and outstanding experiments are discussed in the results chapters. The main avenues to explore would be: 
1. Identification of more patients with mutations in CRAC channel related proteins 
2. Mouse studies 
o CRACR2A deficiency and mutant expression. These experiments are currently being undertaken by 
collaborators (Gwack lab)  
3. Identification of additional pathways affected by CRACR2A 
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